

a. **Name:** Alfonso Iorio

Home address:

132 Dromore Crescent
Hamilton, ON L8S 4J3

b.

Phone (home) +1 (905) 538 2739
Phone (mobile) +1 (289) 339 3713

c. **Business address:**

CRL-140 - Health Information Research Unit
Clinical Epidemiology & Biostatistics
McMaster University
1280 Main St West, CRL-140
Hamilton, ON L8S 4K1
Phone (office) +1 (905) 525 9140 ext 22421
Fax: +1 905-526-8447
E-mail: iorioa@mcmaster.ca
HIRU Administrative Assistant: Linda Sheridan
E-mail: sheridl@mcmaster.ca

d. **Other Personal Data**

- Date of birth: May 21, 1965. Santarcangelo di Romagna. (FO), Italy
- Nationality: Italian

e. **Educational Background**

▪ Degrees and Diplomas

- 2011 PhD, University of Perugia, Italy
- 1991 MD, University of Perugia, Perugia, Italy

▪ Fellowship Certification

- 2011 FRCPC – Internal Medicine, Canada
- 2006 Internal Medicine, Dept of Medicine, University of Perugia, Perugia, Italy
- 1995 Clinical Chemistry and Biochemistry, Dept of Experimental Medicine, University of Perugia, Perugia, Italy

▪ Continuing Education

- 2014 Faculty Leadership Course – Faculty of Health Science, McMaster University

- 2014 Summer School on Prognostic Research – Keele University & Medical Research Council UK
- 2012 McMaster University, Program for Faculty Development, Fundamentals of Clinical Teaching
- 2011-12 McMaster University, Program for Faculty Development, Mentorship Program (Orientation to Mentorship: Building a Mentoring Relationship-Part 1-4).
- 2011 McMaster University, Program for Faculty Development, Tutoring 101.
- 2011 McMaster University, Program for Faculty Development, Experimental PBL.
- 2009 Workshop: The role for ethical committees in the evaluation of design and meaningfulness of clinical trials. Italian Cochrane Centre, Perugia
- 2009 Bayesian statistics, University of Cambridge and the Royal Statistical Society.
- 2008 X Training Course on “Antithrombotic therapy in cardiology”, held in Florence
- 2007 Cochrane Workshop “Identifying and publishing uncertainties about the effects of treatments in Duets –the Database of Uncertainties about the effects of treatments, held in Milan
- 2007 Cochrane Workshop “Transparency in the production of guidelines and recommendation: the WHO experience”, held in Milan
- 2007 XII annual meeting of the Italian Cochrane Network titled “Transparency of production and dissemination of scientific information”, held in Milan
- 2006 III° WORKSHOP. “Systematic reviews of diagnostic accuracy; advanced course” at the Institute Neurologico C. Besta, Milano
- 2006 XIV Cochrane Colloquium, Dublin-Ireland
- 2005 II° WORKSHOP. “Systematic reviews of diagnostic accuracy” at the Institute Mario Negri, Milano
- 2005 Workshop “Evidence Based Medicine” held by GIMBE in Bologna
- 2004 “Diagnostic Systematic reviews” held by the Italian Cochrane Centre in Florence.
- 2004 “Critical appraisal of the grading system for guidelines” held by the Italian Cochrane Centre in Florence.
- 2002 training course of the Cochrane Collaboration on the Analysis methods, London.
- 2001 “Fifth and sixth European Community Framework Granting Program”, organized in Perugia by the University of Perugia.
- 2000 “Antiphospholipid Antibodies– News and perspectives”, organized by the Instrumentation Laboratory, Milan.
- 2000 “The relationship attitude in the organization of the Clinical Pathology Department of the Azienda Ospedaliera S.Maria Nuova of Reggio Emilia”,

- organized by the ASMN, Reggio Emilia. 1999 Clinical fellow, Laboratories of the Centro Angelo Bianchi-Bonomi (prof Augusto Federici and prof Marco Cattaneo), University of Milan, Milan.
- 1997 Microsoft Access and database planning, Arcispedale S.M.Nuova - Azienda Ospedaliera di Reggio Emilia.
 - 1997 Advanced analytical techniques for environmental, clinical, alimentar and industrial analyses, Dept of Pharmacy, University of Bologna, Bologna.
 - 1995 Basic Pharmacokinetics, University of Manchester, Manchester.
 - 1994 Vascular Medicine, Dept of Internal Medicine, University of Perugia, Perugia.
 - 1993 Clinical Research Methodology. Good Clinical Practice, Smith-Kline Foundation, Perugia.
 - 1993 Pathophysiological and Clinical Research in Thromboembolic Disease. European Thrombosis Research Organization. Bologna.
 - 1992 European Intensive Course on Haematology and Haemostasis, Amsterdam University & Erasmus Program. Amsterdam.
 - 1992 Regression models in epidemiology", The Biometric Society, Italian Reg. Florence.
 - 1991 "Connective Tissue Diseases". University of Perugia, Italian Society of Rheumatology, Italian Society of Immunology and Immunopathology and Italian Society of General Medicine, Perugia
 - 1989 "Advanced course on coagulation and fibrinolysis", organized by the Ortho Technical Center in Milan.
 - 1989 - 1995 Clinical Fellowship of the International Inter-University Centre for Thrombosis and Haemostasis in Perugia, beginning as a research fellow under the tutorship of prof. G. Agnelli
 - 1988 XV course on: "Congenital and acquired alteration in blood coagulation. Study methods.", organized in Milano by the Centro Angelo Bianchi Bonomi, by the Fondazione Internazionale Menarini, by the Centro di Ricerche Mario Negri Sud and sponsored by the Siset and CISMEL.

f. Current Status at McMaster

- 2014-present Associate Professor, CAWAR, Jointly in the Department of Clinical Epidemiology & Biostatistics and Medicine

g. Professional Organizations

- 2013 – present American College of Physicians
- 2013 – present Association of Hemophilia Directors of Canada
- 2012- present American Society of Hematology (ASH)

- 2007– present Prognosis Method Group, The Cochrane Collaboration
- 2002 – present World Federation of Haemophilia (WFH)
- 2001 – present Associazione Italiana dei Centri Emofilia (AICE)
- 1993 – present International Society on Thrombosis and Haemostasis"
- 1992 – present Italian Society for Hemostasis and Thrombosis (elected 2006-8)
- 1992 – 2010 Italian Society for Vascular Pathology.
- 1992 – 2012 The Biometric Society

h. Employment History

- Academic
 - 2014-present Associate Professor, CAWAR, Jointly in the Department of Clinical Epidemiology & Biostatistics and Medicine
 - 2010 – 2014 Associate Professor, Special Appointment, Jointly in the Department of Clinical Epidemiology & Biostatistics and Medicine
 - 2004 –present Aggregate Professor (tenured), Internal Medicine University of Perugia, Perugia
 - 2001 –2004 Assistant Professor, Internal Medicine, University of Perugia, Perugia
- Clinical
 - 2010 - present: clinical service at Hamilton Health Sciences; Hamilton General Hospital, GIM Clinical Teaching Unit Attending Physician; Juravinski Hospital and McMaster Children Hospital Outpatient and Inpatient Thrombosis Service, staff physician; McMaster University Hospital Hamilton and Niagara Region Hemophilia Program, Head Staff Physician
 - 2003 – 2010 Chief of the Program “Health care management network for congenital and acquired bleeding disorders, with particular attention to the haemophilia and oral anticoagulant therapy”
Department of Internal Medicine, Azienda Ospedaliera di Perugia, Perugia (3 positive reviews three yearly reviews and re-appointments)
 - 2001 – 2010 Clinical Teaching Unit, Internal Medicine & Thrombosis and Haemostasis, Department of Internal Medicine, Azienda Ospedaliera & Università di Perugia, Perugia

- 1996 – 2001 Dirigente Medico (tenured), Clinical Chemistry and Biochemistry, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
- 1996 Dirigente Medico, temporary appointment, Clinical Chemistry and Biochemistry, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
- 1996 Emergency Service Physician, Health Care Unit n°3 of the Regione Umbria, Foligno.
- 1996 “Medicina dei Servizi”, Clinical Chemistry Laboratory of the Ospedale Civile, Riccione.
- 1995 Emergency Service Physician , Health Care Unit n°1 of the Regione Umbria, Città di Castello
- Consultant positions
- 2002 - 2010 Program Director of the Remote Oral anticoagulation monitoring Network, Local Health Care Agency n. 2 of the Region Umbria, Perugia
- 2001 –2007 Coagulation Laboratory and Laboratory Information Technology, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
- 1999 Azienda USL of Reggio Emilia (task force for the integration of the information systems of the Reggio Emilia District).
- Other
- 1996 Idoneity assessment as Medical Official for the Italian Army

i. Scholarly and Professional Activities

- Editorial boards
- 2014-present Advisory Board Member, Haemophilia Journal
- 2013-present Associate Editor, Rare Diseases and Orphan Drugs
- 2012-present Deputy Editor, ACP Journal Club
- 2012-present Advisory Board Member, Journal of Thrombosis and Haemostasis
- 2010 Guest editor, with Gualtiero Palareti of the Abstract Book of the XXI National Congress of the SISET, published as *Blood Transfus 2010; 8 (Suppl 4)*
- 2009-present Advisory Board Member, Internal and Emergency Medicine

- 2009-present Associate Editor, Cystic Fibrosis and Genetic Disorders Group, Cochrane Collaboration
- 2004 Advisory Board Member, Journal of Thrombosis and Haemostasis
- Grant & personnel committees
 - 2014-present Chair, HERO Program Research Grants Adjudication Committee
 - 2014 Reviewer, Foundation Grant Program, CIHR
 - 2013-present HAHSO/AFP grant review committee
 - 2013 Reviewer, Peer Review Committee, Internal Grants, Juravinski Cancer Center
 - 2014 Member, Tenure and Promotion Committee, Faculty of Health Science, McMaster University
 - 2014 Member, Continuing Health Sciences Education Committee (CHSE)
 - 2014 Member, CHSE– Research and Innovation Committee
 - 2012-present Member, Academic Tenure and Promotion (ATP) Committee, Department of Clinical Epidemiology and Biostatistics, McMaster University
 - 2012 - present Member, Steering Committee, Department of Clinical Epidemiology and Biostatistics, McMaster University
 - 2012 - present Departmental Education Coordinator, Department of Clinical Epidemiology and Biostatistics, McMaster University
 - 2012 – present Member, Clinical Investigation D Panel Review Grant – Canadian Institute of Health Research
- Executive positions
 - 2015 Guideline Oversight Committee, American Society of Hematology
 - 2014-present Chair, Canadian Bleeding Disorders Registry Committee (CBDR-C) of the Association of Hemophilia Clinic Directors of Canada
 - 2014-present Chair, Data and Demographics Committee, World Federation of Hemophilia (2 year term)
 - 2014-present Member, Medical Advisory Board, World Federation of Hemophilia
 - 2012-2014 Member, Inhibitor Committee of the Association of Hemophilia Clinic Directors of Canada

- 2012-2014 Secretary, CHARMS & CHR Committee of the Association of Hemophilia Clinic Directors of Canada
- 2012-13 Member, Data and Demographics Committee, World Federation of Hemophilia
- 2006 – 2010 Secretary to the Italian Society for Thrombosis and Haemostasis
- 2004-2006 Executive Committee (elected member), Italian Society for Thrombosis and Haemostasis
- 2004 to 2006 Member of the Scientific Board, Fondazione Paracelso, Milan
- 2004 – present Member and Secretary of the Scientific Board, Fondazione Emo ONLUS, Macerata
- 2004 -2010 Steering Committee Member, Guidelines Project of the Italian Society for Thrombosis and Haemostasis (SISET)
- 2002 – 2010 Coordinator of the Congenital Bleeding Disorders National Registry of the Italian Association of Hemophilia Centres (AICE)

▪ Journal Referee

Journal	Since year:	Number
Acta Hematologica	2007	1
American Journal of Hematology	2006	1
Annals of Hematology	2012	1
Asian Journal of Transfusion Science	2010	2
Blood	2009	13
Blood Transfusion	2008	7
BMC Medicine	2007	1
British Medical Journal (BMJ)	2011	7
BMJ Open	2013	2
Circulation	2013	9
Clinical Drug Investigation	2002	2
Cochrane Library	2006	2
Computer programs and methods in biomedicine	2012	1
Diabetes Nutrition and Metabolism	2003	1
Diabetes Research and Clinical Practice	2004	1
European Journal of Internal Medicine	2011	6
Expert Opinion on Pharmacotherapy	2007	2
Haematologica	2014	5
Haemophilia	2008	24
Implementation Science	2014	1
Internal and Emergency Medicine	2008	24
Journal of Clinical Epidemiology	2012	3

Journal of Medical Case Reports	2008	1
Journal of Medicine	2014	1
Journal of Pediatric Hematology and Oncology	2009	1
Journal of the American College of Cardiology	2007	1
Journal of the American Geriatric Society	2011	1
Journal of Thrombosis and Haemostasis	2002	52
Journal of Thrombosis and Thrombolysis	2011	8
Lancet Haematology	2014	1
PlosMedicine	2013	2
PlosOne	2013	9
Stroke	2004	10
Thrombosis and Haemostasis	2005	22
Transfusion Medicine	2009	1
Total		226

▪ External grant reviews

- 2015 REPRISE - Register of Expert Peer Reviewers for Italian Scientific Evaluation, Ministry of Education, University and Research, Italy – Role – Peer Reviewer – Hemophilia and Hematology
- 2013 Reviewer, Peer Review Committee, Internal Grants, University Roma
- 2011 Reviewer, The Netherlands Organization for Health Research and Development
- 2011 Reviewer, France National Granting Agency (Agence Nationale per la Recherche)
- 2008-2011 Reviewer, University of Padua grant review process
- 2005 Member (elected) in the Evaluation Procedures (II session) for Admission to University positions, Padua.
- 2005-2010 Member, Departmental Committee for staff selection, Department of Internal Medicine, University of Perugia.
- 2004-2010 Reviewer, Italian Ministry of Health Grant Peer review Committee (PRIN and FIRB programs), Medicine.

j. Areas of Interest

▪ Research

I have three main research interests

- a) Efficient uptake of new evidence, at the level of researchers (e.g. systematic reviewers and guidelines users), practicing physicians and patients. I am working into connecting knowledge databases (like McMaster Plus) and clinical databases to push new relevant evidence to the point of care
- b) Prognostic research and prediction of response to treatment. I am interested in optimizing the usage of baseline risk information, integration of Clinical Prediction Guides in tailoring treatment to individual patients or at least to patient subgroups. This has been and will be applied to prediction of risk of developing inhibitors in hemophilia.
- c) Eradicating inhibitors and optimizing prophylactic treatment for haemophilia patients.

▪ Consulting

I am acting as a consultant for clinical trial design and analysis for the World Federation of Hemophilia and several drug manufacturers in the field of hemophilia.

k. Honours

- 2003 Awarded the Prize “Unità Malattie Tromboemboliche ed Emorragiche Cattedra di Ematologia dell’Università di Palermo” during the National Siset National Teaching Course, held in Palermo
- 1999 Awarded the “Individual Performance Quality Prize” by the Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, for the fundamental contribution in the development of the information technology system of the Clinical Pathology Department
- 1994 Awarded the “Scientific Research Prize 1994” by the Association Against Thrombosis (ALT)
- 1992 Awarded the "Italian Society for Vascular Pathology Prize" for the best research work submitted to the Annual Meeting of the Tosco-Umbra Section

l. Courses Taught

▪ Undergraduate

- 2005-2008 Bachelor in Health Science (Technician for Health Prevention), Emergency Medicine and first aid, University of Perugia – Full course, 20 hours + test
- 2005-2008 Bachelor in Health Science (Technician for Health Prevention), Integrated Health Care Systems and alternative medicine, University of Perugia - Full course, 20 hours + test

- 2004-2005 Medical Semeiology, Degree in Medicine Surgery, 4th year, University of Perugia, Lecturer – Module, 4 hours
- 2004-2005 Internal Medicine, Degree in Medicine Surgery, University of Perugia, 6th year, Lecturer - Module, 6 hours
- Graduate courses
 - 2014-present Health Research Methodology (HRM) 777 |- Methods for Diagnostic and Prognostic Research – Course Coordinator & Instructor
 - 2014 –present Health Research Methodology (HRM) 743 – Systematic Reviews, Lecturer and Tutor
 - 2011-2014 Health Research Methodology (HRM) 730 - Introduction to Research Methods for Randomized Controlled Trials. Lecturer and Tutor
 - 2011-present Health Research and Methodology (HRM) 721 Fundamentals of Health Research and Evaluation. Lecturer and Tutor
 - 2005-present PhD course “Biosciences, Biotechnologies and Biomaterials in Vascular and Endocrino-Metabolic Diseases”, University of Perugia.
 - 2013-present Health Research Methodology (HRM) PhD Comp Seminar lecturer
- Postgraduate
 - 2013-present Hematology Fellowship Program, session on Hemophilia A inhibitors and vWD
 - 2011- present Hematology and Thrombolism Fellowship Program, McMaster University, 1st Year residents, 8-week Thrombosis rotation. Taught weeks 3 (Thrombophilia, heredity and acquired, diagnosis and clinical aspects) and 8 (Treatment of VTE).
 - 2011- General Internal Medicine Residency Program. Clinical Teaching Unit (5 clerks, 2 PGY1-GIM, 1 PGY1-FM, 1 PGY2-FM, 1 PGY2-GIM), March.
 - 2006 – 2010 Clinical Chemistry and Biochemistry Fellowship program, Physiopathology of Haemostasis, University of Perugia
 - 2005 – 2010 Subspecialty Training Program in Vascular Medicine, University of Perugia
 - 2002 – 2004 Haematology Fellowship Program, Physiopathology and Clinics of Haemostasis, University of Perugia

- 2002– 2008 Fellowship Program in Vascular Surgery Physiopathology and Clinics of Haemostasis, University of Perugia
- 2001 – 2010 Fellowship Program in Clinical Chemistry and Biochemistry, Automation and Information Technology, University of Perugia
- 2001 – 2010 Fellowship Program in Anesthesia and Intensive Care Medicine Clinical Pathology, University of Perugia
- 2001 – 2010 Fellowship Program in Anesthesia and Intensive Care Medicine, Diagnostics in Hematology and haemostasis, University of Perugia
- 1996 – 1997 Fellowship Program in Orthopaedics and Traumatology, Informatics applied to Medicine, University of Perugia
- Other
 - 2015 Improving Patient Care Through Evidence-Based Clinical Practice (EBCP) – The 4th Kuwait EBCP Workshop, December 15-17, 2015 (3 days intensive course for Residents and Fellows – Member of the Faculty team).
 - 2014 Clinical Epidemiology and Evidence Based Medicine, Intensive Course, United Arab Emirates, El Shargia, 2014 (3 days intensive course – course key faculty)
 - 2013 International Summer School “Clinical practice guidelines on rare diseases”. Rome, Italy. Organized by the Istituto Superiore Di Sanita. Course Director, Dr. Domenica Taruscio, lecturer.
 - 2006 to 2010 Congenital and Acquired Bleeding Disorders, Master in Haemostasis and Thrombosis, University of Florence,
 - 2005 to 2010 Hemophilia, Master in Haemostasis and Thrombosis University of Genua, visiting professor
 - 2005 to 2010 Oral anticoagulant management models, Master in Haemostasis and Thrombosis, University of Genua, visiting professor
 - 2004 – 2006 Chair and trainer, courses for patients on oral anticoagulant therapy of the oral management distributed network of the AUSL 2 of the Region Umbria
 - 2002 – 2006 Chair and teacher, national Health Care System accredited courses for Physician and Nurses involved in the oral management network of the AUSL 2 of the Region Umbria.
 - 2000 “The diagnosis of Antiphospholipid antibodies syndrome”. Symposium “Systemic Lupus erythematosus antiphospholipid antibodies syndrome and pregnancy” Azienda Ospedaliera di Reggio Emilia.

- 2000 "Hyperhomocysteinemia and cerebrovascular risk". with Dr Mauro Silingardi. One day study workshop on cerebrovascular pathology organized by the Azienda Ospedaliera Santa Maria Nuova, Reggio Emilia, by the Associazione Dirigenti Internisti dell'Emilia Romagna and by the Società dei Neurologi Ospedalieri.
- 1999 "Management of the oral anticoagulant treated patient". Up-to-date course "Oral anticoagulant therapy and thrombophilic conditions." Azienda Ospedaliera, Azienda USL, Ordine dei Medici di Reggio Emilia, Reggio Emilia.
- 1999 "Evidence Based Medicine in the Clinical Chemistry Laboratory". Training Course for the personnel of the Clinical Chemistry Laboratory, Institutional Training Program, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia
- 1998 "Arterial Thrombosis: laboratory markers of metabolic and cellular risk." Internal Hospital course, Azienda Ospedaliera S. Maria Nuova, Reggio Emilia.
- 1998 "Theoretical and practical course for the coagulation laboratory." Collaboration with the Istituto Galvani per tecnici di laboratorio. Reggio Emilia.
- 1997 – 2000 "Oral anticoagulant therapy monitoring". Patient training courses for the Center for Oral Anticoagulant Therapy Service. Reggio Emilia
- 1997 "Laboratory monitoring of oral anticoagulant therapy." Internal Hospital course on odontostomatologic care during oral anticoagulant and antiplatelet therapy Reggio Emilia.
- 1997 "The diagnosis of antiphospholipid antibodies syndrome." Internal Hospital course. Azienda Ospedaliera S. Maria Nuova. Reggio Emilia.
- 1994 "Quality controls in oral anticoagulant therapy." Meetings of the Società Lazzaro Spallanzani. Reggio Emilia.

m. Contributions to Teaching Practice

- Development of HRM #777 "Diagnosis and Prognosis". This course was newly introduced in the HRM MSc portfolio in response to a growing request for designing and running methodologically sound studies in the specific categories, which in turn is a consequence of the current interest in personalized medicine and evidence based communication to patients and shared decision making. The course was developed over 2013 and 2014 in collaboration with Mark Smeja and Alice Lytwyn, and first delivered during the Academic Year 2014-15, as intensive course in the spring term. My personal contribution was the development of the 5 units on prognosis, revision of the

units on Diagnosis and Guidelines, and co-development of all the ancillary materials. I am currently acting as co-coordinator of the course with dr Lytwyn.

- I have developed a specific self-learning module, delivered as HRM #705, centered on the Analysis of Registry Data. The course covers aspects as prospective registry data structure planning, linking registry data, data validation, longitudinal data analysis, handling of counfounding, foundations of propensity score analysis. The course has been requested by fellows in hematology and transfusion medicine to date.
- As lecturer and tutor of HRM #721 and #730 I have contributed new teaching and tutoring material (particularly for the units on Outcomes and Measurements)
- As a clinical teacher I have completely redesigned the 4 teaching units for Hemophilia, Von Willebrand Disease, Rare Bleeding Disorders and Laboratory Screening and Diagnosis of Bleeding Disorders for the Bleeding Disorders and Transfusion Medicine Rotation of the Fellowship Curriculum in Hematology. Specifically, I have successfully changed the format of the fromtal component of teaching from criticizing a presenation proposed by the learner to the critical appraisal of a set of articles, among which some mandatory readings and some new references to be proposed by the learners. A specific goal obtained with this change is allowing to teach critical appraisal of literature in the field of rare disease.
- I have been acting as a Department Education Coordinator for the last 3 years. In this capacity, and in addition to the usual DEC activity, I have introduced the following innovations:
 - I have designed a standard operating procedure, compelte with the necessary forms, to ensure faculty in CEB smoothly gets all the needed teaching peer-review requested by McMaster to fulfil assessment to the scope of renewal and promotion.
 - I have been instrumental in creating a new “Education Committee” within the Department, chaired by the DEC and composed by all the Program Directors of the 8 Programs homed in the Department. The scope for this committee is to advice the Chair on the needed intervention to harmonize teaching and best use resources to respond to educational needs. As a part of the scope of action of the Committee, we have planned an educational role Departmental Database, contribution to which will be going forward integrated into the recruitment and Career Review process for full and part-time faculties.

n. Supervisorships

- Undergraduate (Thesis)
 - 2012 Bachelor in Biology (Irum Ritzwan)
 - 2012 Bachelor in Health Sciences (Honours) (Mengchen Xi)
 - 2011 Bachelor in Health Sciences (Luxme Mahendira)
 - 2011 Bachelor in Life Sciences (Anand Jacob)
 - 2010 Bachelor in Informatics (Francesco Codini)
 - 2010 Bachelor in Informatics (Emanuele Giordani)
 - 2003 Bachelor in Biology (Ivan Zipancic)
 - 2003 Bachelor in Biology (Ilenio Servettini)
- Master and PhD
 - 2015-18 HRM PhD (Chatree Chai-Adisaksopha)
 - 2015-17 HRM, Masters (Davide Matino)
 - 2014-16 HRM, Masters (Cindy Yeung)
 - 2014-15 eHealth, Masters (Islam Barghlash)
 - 2013-16 HRM PhD (Thuva Vanni) co-supervisor,
 - 2012-14 HRM, Masters (Abha Athale)
 - 2012-14 HRM, Masters (Maura Marcucci)
 - 2012-14 eHealth, Masters (Anand Jacob)
 - 2008-11 PhD (Ivana de Punzio) (Perugia)
- Perugia, Doctoral (MD degree in Italy, equivalent to a doctorate degree)
 - 2010 MD degree (Luciana Mariotti)
 - 2010 MD Degree (Federica Ferro)
 - 2009 MD Degree (Leonidas Petrogiannopoulos)
 - 2009 MD degree (Simona Pindozzi)
 - 2009 MD degree (Daniela Marona)
 - 2009 MD degree (Simona Pindozzi)
 - 2007 MD degree (Gloria Paganelli)
 - 2007 MD degree (Alessandra Rocca)
 - 2007 MD degree (Ana Macura)
 - 2007 MD degree (Donato Ferilli)
 - 2007 MD degree (Giulio Siano)
 - 2006 MD degree (Nguyen Nguyen Hao)
 - 2005 MD degree (Alice Taddei)
 - 2005 MD degree (Emanuela Marchesini)
 - 2005 MD degree (Giorgia Manina)
 - 2005 MD degree (Luca Pio Evoli)
 - 2004 MD degree (Chiara Busti)
 - 2004 MD degree (Marica Rosmini)
 - 2004 MD degree (Palo Nicotera)
 - 2004 MD degree (Luciana Canonico)
 - 2004 MD degree (Agnese Lanuti)

- 2004 MD degree (Elisabetta Mencaroni)
- 2002 MD degree (Silvia Ferialla)
- 2002 MD degree (Benedetta Enrico)
- 2002 MD degree (Marco Evangelisti)

- Perugia, Post-doctoral
 - 2015 Clinical Chemistry and Biochemistry (Davide Matino)
 - 2013 Internal Medicine (Maura Marcucci)
 - 2011 Clinical Chemistry and Biochemistry (Emanuela Marchesini)
 - 2008 Clinical Chemistry and Biochemistry (Chiara Grillo)
 - 2008 Clinical Chemistry and Biochemistry (Stefano Iaboni)
 - 2008 Gastroenterology (Vittorio Giuliano)
 - 2008 Clinical Chemistry and Biochemistry (Abu Soheban Haphez)
 - 2007 Clinical Chemistry and Biochemistry (Simona Pizzinelli)
 - 2007 Internal Medicine (Elisa Pasqualoni)
 - 2007 Internal Medicine (Lorenzo Silivestro)
 - 2005 Internal Medicine (Serenella Conti)
 - 2005 Internal Medicine (Francesco Guercini)
 - 2004 Anaesthesia (Lavinia Ferialla)
 - 2003 Clinical Chemistry and Biochemistry (Francesca Ferrante)
 - 2003 Anaesthesia (Barbara Bifarini)
 - 2003 Internal Medicine (Simona Goracci)
 - 2003 Internal Medicine (Alessandra Minciotti)

- Supervisory committee
 - 2014 HRM Masters, Erika Arsenau
 - 2014 HRM Masters, Sarah Tachak-Lapner
 - 2014 HRM Masters, Maura Marcucci
 - 2010 MD degree committee (3 sessions)
 - 2009 MD degree committee (2 sessions)
 - 2008 MD degree committee (5 sessions)
 - 2007 MD degree committee (2 sessions)
 - 2006 MD degree committee (4 sessions)
 - 2005 MD degree committee (4 sessions)
 - 2004 MD degree committee (4 sessions)
 - 2003 MD degree committee (3 sessions)
 - 2002 – 2010 Member, Committee for admission to the degree course in Medicine, University of Perugia, Perugia.
 - 2002 – 2010 Member, Committee for admission to the degree course in Health Sciences, University of Perugia, Perugia.
 - 2004 – 2010 Member, Committee of the National Board test certification for Medicine, University of Perugia

- Other.

- 2013-15 Academic Advisor, HRM (Christopher Patriquin)
- 2013-15 Academic Advisor, HRM (Chatree Chai-Adisaksopha)
-

o. Lifetime Research Funding

The total amount of lifetime research funding secured as of December 2015 sums up to 10,087,633 CAD\$, of which 5,120,830 CAD\$ are competitive research funds (2,150,544 CAD\$ as principal investigator) and 4,939,971 CAD\$ are from research service agreements, unrestricted educational grants and other sources.

Competitive Research Funding

- 1) Dec 2015: The Canadian Hemophilia Carriers Study. Principal Investigator: Paula James. Co-investigators: **Alfonso Iorio**, Arun Keepanasseril, Shannon Jackson, Michelle Sholzberg, Rochelle Winikoff, Natalia Rydz, Sue Robinson, and Emily Rimmer.
 - (a) Funding Agency: 2015 Baxalta-Canadian Hemophilia Epidemiological Research Program (B-CHERP).
 - (b) Type: Peer reviewed
 - (c) Terms: December 1, 2015 – November 30, 2017.
 - (d) Amount awarded: \$225,000.
- 2) Nov 2015: Determining the half-life of prophylaxis treatment using population pharmacokinetics. Recipient: Chatree Chai-Adisaksopha. Supervisor and **Principal Investigator: Alfonso Iorio**.
 - (a) Funding agency: Mitacs-Accelerate Graduate Research Internship Program. Partner Organization: Novo Nordisk Canada Inc.
 - (b) Type: Peer reviewed
 - (c) Terms: November 1, 2015 – December 31, 2017.
 - (d) Amount awarded: \$90,000.00.
- 3) Oct 2015 Investigating FIX extravascular localization as a potential new strategy for longer protection in hemophilia B. Co-Principal investigators: **Alfonso Iorio**, Anthony Chan. Co-investigator: Davide Matino.
 - (a) Funding Agency: Pfizer Inc
 - (b) Type: Competitive
 - (c) Terms: Jan 2016 - Jan 2017
 - (d) Amount awarded: \$ 133,032
- 4) Sept 2015: CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network.. Principal Investigators: Kahn, Susan, Rebecca, Rodger, Marc Alan. Co-investigators: Afilalo, Marc, Anderson, David Robert, Bates, Shannon Marie, Blostein, Mark Daniel, Carrier, Marc, Castellucci, Lana, Chagnon, Isabelle, Chitsike, Rufaro, Conway, Edward M, Crowther, Mark Andrew, Demers, Christine, Dolan, Sean, Douketis, James

D, Duffett, Lisa, Emed, Jessica D, Fergusson, Dean A, Gandara, Esteban, Geerts, William Henry, Ginsberg, Jeffrey S, Gonsalves, Carol Lucy, Grad, Roland Michael, Gross, Peter Lawrence, Guindon, Godefroy Emmanuel, Haynes, Robert Brian, Hirsch, Andrew Michael, **Iorio, Alfonso (*)**, Kassis, Jeannine, Kearon, Clive, Kovacs, Michael Joseph, Lang, Eddy Samuel, Lazo-Langner, Alejandro, Le Gal, Grégoire, Lee, Agnes Yuet Ying, Levinson, Anthony Julius, Levy, Adrian R, Liaw, Patricia CY, Lim, Wendy, Linkins, Lori-Ann, Louzada, Martha De Lacerda, McLeod, Anne Gregersen, Moodley, Uthaman; Pai, Menaka, Pluye, Pierre, Ramsay, Timothy Owen, Ray, Joel Geoffrey, Roussin, André, Routhier, Nathalie, Schulman, Sam, Selby, Rita, Shivakumar, Sudeep Pappur, Siegal, Deborah Michelle, Smith, Reginald E, Solymoss, Susan, Tagalakakis, Vicky, Takach Lapner, Sarah, Thavorn, Kednapa, Weitz, Jeffrey I, Wells, Philip Stephen, Wu, Cynthia M, Zarychanski, Ryan, de Wit, Kerstin.

(a) Funding agency: Canadian Institutes of Health Research – ICRH
Community Development Program Grants

(b) Type: Peer reviewed

(c) Terms: September 2015-August 2020.

(d) Amount awarded: \$1,500,000.

(*) Lead of the KT platform.

5) June 2015 Shared Decision Making in Hemophilia. Recipient: Abha Athale.

Supervisor and Principal Investigator: **Alfonso Iorio.**

(a) Funding Agency: ASH, Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award

(b) Type: Research Award (peer reviewed)

(c) Terms: June 1, 2015 – December 2016.

(d) Amount Awarded: \$7000.00.

6) May 2015 Installing FVIII-specific tolerance in hemophilia A via the aryl hydrocarbon receptor (AhR) operated by tryptophan catabolites.

Principal investigators: **Alfonso Iorio**

(a) Funding Agency: Bayer

(b) Type: Competitive

(c) Terms: Sept 2015 - Oct 2016

(d) Amount awarded: \$ 117 997

7) March 2015 Improving Chronic Pain Care for all Canadians: A patient engagement project to identify research priorities. Principal Investigators: Chambers, Christine Therese, Poulin, Patricia Anik, Smyth, Catherine Elizabeth,

Stevens, Bonnie J, Stinson, Jennifer Nan. Co-investigators: Busse, Jason Walter, Forgeron, Paula Anne, **Iorio, Alfonso**, Lalloo, Chitra, Lynch, Mary Elizabeth, McCartney, Colin John Lindsay, Visca, Regina.

(a) Funding agency: Canadian Institutes of Health Research.

(b) Type: Peer reviewed

(c) Terms: March 2015 – February 2016.

- (d) Amount awarded: \$45,000.
- 8) Dec 2014 MASCOT - II: Linkage at McMaster Health Sciences of Accesss, Clinical Clustering Information, Oscar and the ad hoc Developed Trust Xt Database. Proof of Concept of a Knowledge Translation Need and Impact Assessment Strategy. Principal Investigator: **Alfonso Iorio**. Co-Investigators: Michelle Zeller, Nancy Heddle, Mark Crowther, Wendy Gerry, Lilian .
(a) Funding Agency: HAHSO/OMOHLTC.
(b) Type: Peer reviewed
(c) Terms: April 2015 to March 2016
(d) Amount awarded: \$197,162.
- 9) Oct 2014 Hemophilia Clinical and Research Fellowship. Awarded to Chatree Chai-Adisaksopha (fellow) and **Alfonso Iorio** (Mentor).
(a) Funding Agency: Baxter Hemophilia Fellowship program (AHCDC)
(b) Type: Peer reviewed
(c) Terms: 2015-2017
(d) Amount Awarded: \$ 160,000
- 10) Oct 2014 Potential determinants of ITI success using immune gene expression profiling. Hemophilia Clinical and Research Fellowship. Awarded to Davide Matino (fellow) and **Alfonso Iorio** (Mentor).
(a) Funding Agency: Bayer Hemophilia Award Program
(b) Type: Peer reviewed
(c) Terms: 2015-2017
(d) Amount Awarded: \$ 181,000
- 11) July 2014 Re-setting tolerance to FVIII via aryl hydrocarbon receptor ligands. Principal Applicant: Francesca Fallarino. Co-applicant: **Alfonso Iorio**.
(a) Funding agency: Bayer Hemophilia Award Program
(b) Type: Peer reviewed
(c) Terms: July 2014 – June 2016
(d) Amount awarded: \$ 181 855.
- 12) May 2014 Re-setting tolerance to FVIII via aryl hydrocarbon receptor ligands. Principal investigators: Davide Matino. CO-investigators: **Alfonso Iorio**, Francesca Fallarino, Paolo Puccetti.
(a) Funding Agency: Italian Ministry of Health
(b) Type: Peer Reviewed
(c) Terms: Nov 2014 – Nov 2017
(d) Amount awarded: \$ 422 277
- 13) May 2013: Assessing differential immunogenicities of factor VII molecules: Do previously treated hemophilia A patients represent a valid model? Principal Investigator: Alfonso Iorio.
(a) Funding Agency. Pfizer.

- (b) Type: competitive
 - (c) Terms: August 2013 to August 2014.
 - (d) Amount awarded: \$38,696.
- 14) Apr 2013 Evaluation of safety, efficacy and immunogenicity of a recombinant FVIII molecule: meta-analysis of the Advate Postauthorization Safety Surveillance studies. Interns: Maura Marcucci and Ji Cheng. Internship Supervisors: Dr. Lehana Thabane and Dr. **Alfonso Iorio**.
- (a) Mitacs-Accelerate Internship Program and Baxter
 - (b) Type: Peer reviewed
 - (c) Terms: May 27, 2013-March 27, 2014.
 - (d) Amount awarded: \$45,000.
- 15) Feb 2013 The Decision-Box and Patient Decision Aids in Hemophilia: Tools to Facilitate Shared Decision Making. Awarded to Abha Athale (recipient) and **Alfonso Iorio** (principal investigator).
- (a) Mitacs-Accelerate Internship Program and Biogen Idec Canada
 - (b) Type: Peer review
 - (c) Terms: April 1, 2013 – July 31, 2013.
 - (d) Amount awarded: \$15,000.
- 16) Feb 2013 Assessing Differential Immunogenicities of Factor VIII Molecules: Do Previously Treated Hemophilia A Patients Represent a Valid Model? A Clinical Epidemiology Investigational Approach. Principal Investigator: Angela M Barbara. Co-applicant: **Alfonso Iorio**
- (a) Funding Agency: Canadian Hemophilia Society, Care until Cure Program.
 - (b) Type: Peer reviewed
 - (c) Terms: April 2013- March 2012
 - (d) Amount Awarded: \$75,000.
- 17) Dec 2012 Cardiovascular disease (CVD) in Canadians with haemophilia: AgeRelated CVD in Haemophilia Epidemiological Research (ARCHER study). Principal investigator: Leonard Minuk. Co-investigators: Alfonso Iorio, Shannon Jackson, Man-Chiu Poon, Robert Card.
- (a) Funding Agency: AHCCDC B-CHERP
 - (b) Type: Peer reviewed
 - (c) Terms: Jan 2013-Dec 2014
 - (d) Amount awarded: \$ 50,000
- 18) Dec 2012 Interventions to enhance patient adherence with prescribed medications: A systematic review and analysis of components of interventions. Co-Principal Investigators: Haynes, R Brian, Hill, Sophie, and Iorio, Alfonso. Co-Investigators: Jack, Susan Michelle, Nieuwlaet, Robby.
- (a) Canadian Institutes of Health Research.
 - (b) Type: Peer reviewed
 - (c) Terms: 2013

(d) Amount awarded: \$99,998.

19) Oct 2012 Installing FVIII-specific tolerance in hemophilia A via the aryl hydrocarbon receptor (AhR) operated by tryptophan catabolites. Principal investigators: Alfonso Iorio. Co-investigator: Francesca Fallarino, Davide Matino.

(a) Funding Agency: Bayer, Grant4Targets

(b) Type: Competitive

(c) Terms: Oct 2012 - Sept 2014

(d) Amount awarded: \$ 45,689 (EUR 30,000)

20) Oct 2012 WAPPS-Hemo (Web Accessible Population Pharmacokinetics Service – Hemophilia). Principal Investigator: Alfonso Iorio. Co-applicants: Lehana Thabane, Ann McKibbin.

(a) Funding Agency: Baxter Canadian Hemophilia Epidemiological Research Program (B-CHERP).

(b) Type: Peer Reviewed

(c) Terms July 2013 - July 2016.

(d) Amount Awarded: \$221,840.

21) Feb 2012 Patient level meta-analysis of prospective / retrospective studies describing case cohorts of hemophilia patients. Hemophilia Clinical Fellowship. Awarded to Maura Marcucci (fellow) and **Alfonso Iorio** (Mentor).

(a) Funding Agency: Bayer Hemophilia Award Program

(b) Type: Peer reviewed

(c) Terms: 2012-2014

(d) Amount Awarded: \$ 141,000

22) Dec 2011 MASCOT: Linkage at McMaster Health Sciences of Accessss, Clinical Clustering Information, Oscar and the ad hoc Developed Trust Xt Database. Proof of Concept of a Knowledge Translation Need and Impact Assessment Strategy. Principal Investigator: **Alfonso Iorio**. Co-Investigators: Nancy Heddle, David Chan, Mark Crowther, Karon Taggart, Brian Haynes.

(a) Funding Agency: HAHSO/OMOHLTC.

(b) Type: Peer reviewed

(c) Terms: April 2012 to March 2014

(d) Amount awarded: \$199,162.

23) Dec 2011 ACCESSSS to Current Best Evidence to Support Health Care Decisions Phase II: Extending coverage to the community and optimizing usefulness. Principal investigator: Brian R Haynes. Co-investigator: **Alfonso Iorio**

(a) Funding Agency: HAHSO/OMOHLTC.

(b) Type: Peer reviewed

(c) Terms: April 2012-March 2014

(d) Amount awarded: \$155,154.

- 24) Dec 2011 Modulating the antibody response to exogenous Factor VIII: the role of tryptophan catabolism. Awarded to Davide Matino (Recipient) and Alfonso Iorio (mentor and supervisor).
(a) Funding Agency: Bayer Early Career Investigator Award.
(b) Type: Peer reviewed
(c) Terms: March 2012- Feb 2014
(d) Amount awarded: \$210,000
- 25) Dec 2011 Working party on the risk factor for inhibitors development. IPD meta-analysis network. Predictors of Inhibitor Development in Hemophilia. Principal Investigator: **Alfonso Iorio** and Ulrike Nowak-Gottl. Co-investigators: Maura Marcucci, Emanuela Marchesini.
(a) Funding Agency: European Association for Hemophilia and Allied Disorders.
(b) Type: competitive
(c) Terms: 2012-2013
(d) Amount awarded: \$13,125.82
- 26) Oct 2011 The Canadian Hemophilia Surveillance System (CHESS). Principal Investigator: **Alfonso Iorio**. Co-investigators: Nancy Heddle, Irwin Walker, Anthony K Chan.
(a) Funding Agency: B-CHERP competition (AHCDC).
(b) Type: Peer Reviewed
(c) Terms: April 2012-March 2015
(d) Amount Awarded: \$150,000.
- 27) Dec 2010 Multicentre Canadian Study of Prophylaxis in Older Adults with Severe Hemophilia. Principal investigator: Shannon Jackson. Co-investigators: Alfonso Iorio, Man-Chiu Poon, Leonard Minuk, Jean StLouis, Michelle Sholzberg, Robert Card,
(a) Funding Agency: AHCDC B-CHERP
(b) Type: Peer reviewed
(c) Terms: Jan 2011-Dec 2012
(d) Amount awarded: \$ 75,000
- 28) Oct 2005 On demand Plus Extended FVIII Replacement and Activity (OPERA), trial, EUDRACT 2006-003679-12. Principal Investigator: **Alfonso Iorio**. Co-investigators: Elena Santagostino, Giuseppe Tagariello, Massimo Morfini
(a) Funding Agency: Pfizer
(b) Type: Competitive
(c) Terms: 2006-11
(d) Amount awarded: \$ 180,000
- 29) Oct 2005 Across factor Eight Switch Pharmacokinetic Evaluation of Recombinant Factor Trial (AESPERT), Multicentre Italian Trial, EUDRACT 2006-004426-88. Principal Investigator: **Alfonso Iorio** Co-investigator: Massimo Morfini.

- (a) Funding Agency: Pfizer
- (b) Type: Competitive
- (c) Terms: 2005-10
- (d) Amount awarded: \$60,000

30) Jan 2004 Carla Silvani, Alfonso Iorio. Ottimizzazione dell'impiego del plasma umano: riduzione delle reazioni avverse evitabili mediante condivisione di linee guida, generazione ed impiego di un sistema di indicatori di efficacia, sicurezza ed appropriatezza terapeutica mediante l'impiego di outcome clinici e gestionali. Principal Investigator: Carla Silvani Co-Investigators: **Alfonso Iorio**, Mauro Marchesi.

- (a) Funding Agency: Regione dell'Umbria, Ricerca Finalizzata Socio Sanitaria
- (b) Type: Peer reviewed
- (c) Terms: 2004-2005
- (d) Amount awarded: \$ 24,000

31) Jan 2003 Percorso assistenziale integrato per il monitoraggio della terapia anticoagulante orale: dal medico di base al centro specialistico attraverso i centri di salute e i laboratori dell'Azienda Sanitaria Locale. Principal Investigator: **Alfonso Iorio**

- (a) Funding Agency: Regione dell'Umbria, Ricerca Finalizzata Socio Sanitaria
- (b) Type: Peer reviewed
- (c) Terms: 2002-2004
- (d) Amount awarded: \$ 37,500

32) Jan 2001 "Percorso di monitoraggio della terapia anticoagulante orale mediante accesso del paziente in centri periferici distribuiti sul territorio per il prelievo e la consegna della proposta di prescrizione terapeutica e valutazione medica centralizzata in tempo reale da parte di personale specializzato del centro per la sorveglianza della terapia anticoagulante orale". Principal Investigator: **Alfonso Iorio**

- (a) Funding Agency: Regione dell'Umbria, Ricerca Finalizzata Socio Sanitaria
- (b) Type: Peer reviewed
- (c) Terms: 2001-2002
- (d) Amount awarded: \$ 37,500

Research service agreements, educational grants, others

37) Dec 2015 Literature and knowledge translation services for the BMJ publishing group. Principal investigators: Brian R Haynes and Alfonso Iorio

- (a) Funding Agency: BMJ publishing group
- (b) Type: Research service agreement
- (c) Terms: 2015-2018

(d) Amount awarded: \$ 493,571

38) Jun 2015 Literature and knowledge translation services for the Canadian Pharmacist Association. Principal investigators: Brian R Haynes and Alfonso Iorio

(a) Funding Agency: Canadian Pharmacist Association

(b) Type: Research service agreement

(c) Terms: 2015-2016

(d) Amount awarded: \$ 13,798

39) May 2015 Literature and knowledge translation services for Teton Data Systems.

Principal investigators: Brian R Haynes and Alfonso Iorio

(a) Funding Agency: Teton Data Systems

(b) Type: Research service agreement

(c) Terms: 2015-2018

(d) Amount awarded: \$ 122,868

40) Dec 2015 Literature and knowledge translation services for the American College of Physician Journal Club (Annals of Internal Medicine) and the ACP Journal Wise service. Principal investigators: Brian R Haynes and Alfonso Iorio.

(a) Funding Agency: American College of Physicians

(b) Type: Research service agreement

(c) Terms: 2016-2018

(d) Amount awarded: \$ 2,413,928

41) Dec 2015 Literature and knowledge translation services for the Evidence Based Medicine Center at Elsevier. Principal investigators: Brian R Haynes and Alfonso Iorio

(a) Funding Agency: Elsevier

(b) Type: Research service agreement

(c) Terms: 2016-2018

(d) Amount awarded: \$ 141,698

42) Dec 2015 Literature and knowledge translation services for McGraw-Hill Clinical Access. Principal investigators: Brian R Haynes and Alfonso Iorio

(a) Funding Agency: McGraw-Hill Global Education Holdings, LLC

(b) Type: Research service agreement

(c) Terms: January 2016- December 2016

(d) Amount awarded: \$ 56,044

33) Dec 2015 The role of chronic pain in hemophilia: diagnostic and management approaches. Principal investigators: Alfonso Iorio

(a) Funding Agency: Pfizer Canada

(b) Type: Unrestricted Educational Grant

(c) Terms: Jan 2016-Dec 2016

(d) Amount awarded: \$ 125,000

- 43) Oct 2015 Literature and knowledge translation services for the Norwegian Electronic Health Library. Principal investigators: Brian R Haynes and Alfonso Iorio
(a) Funding Agency: NEHL
(b) Type: Research service agreement
(c) Terms: October 2015-December 2018
(d) Amount awarded: \$ 71,866
- 44) Oct 2015 Literature and knowledge translation services for McGraw-Hill Harrison's Principles of Internal Medicine. Principal investigators: Brian R Haynes and Alfonso Iorio
(a) Funding Agency: McGraw-Hill Global Education Holdings, LLC
(b) Type: Research service agreement
(c) Terms: 2015- 2018
(d) Amount awarded: \$ 161,110
- 45) Sept 2013 Developing and managing the International HERO grant initiative. Principal investigators: Alfonso Iorio
(a) Funding Agency: NovoNordisk
(b) Type: Research service agreement
(c) Terms: Jan 2014 – Dec 2016
(d) Amount awarded: \$ 18,000
- 46) Jul 2015 Literature and knowledge translation services for ACP Smart Medicine. Principal investigators: Brian R Haynes and Alfonso Iorio
(a) Funding Agency: ACP
(b) Type: Research service agreement
(c) Terms: July to December 2015
(d) Amount awarded: \$ 31,722
- 47) July 2015 Clinical Study Gena 21b. Local principal investigators: Alfonso Iorio
(a) Funding Agency: Octapharma
(b) Type: Research service agreement
(c) Terms: Nov 2015 to Dec 2016
(d) Amount awarded: \$ 21,000
- 48) Apr 2015 Developing a Delphi consensus on treatment threshold for prophylaxis in hemophilia. Principal investigators: Alfonso Iorio
(a) Funding Agency: Baxter
(b) Type: Research service agreement
(c) Terms: May 2015 – May 2016
(d) Amount awarded: \$ 32,758
- 49) Apr 2015 Literature and knowledge translation services for Duodecim. Principal investigators: Brian R Haynes and Alfonso Iorio
(a) Funding Agency: Duodecim
(b) Type: Research service agreement

- (c) Terms: 2015-2016
- (d) Amount awarded: \$ 97,707

50) Feb 2015 Developing a Delphi consensus on research priorities in Hemophilia.

Principal investigators: Alfonso Iorio

- (a) Funding Agency: NovoNordisk
- (b) Type: Research service agreement
- (c) Terms: May 2015 – May 2016
- (d) Amount awarded: \$ 9765

51) Nov 2013 Comparative effectiveness of extended and regular half life factor concentrates for prevention of bleeding in hemophilia. Principal investigators: Alfonso Iorio

- (a) Funding Agency: Biogen Inc
- (b) Type: Research contract agreement
- (c) Terms: Dec 2013-Dec 2015
- (d) Amount awarded: \$ 14,000

34) Dec 2014 Implementing shared decision models in hemophilia . Principal investigators: Alfonso Iorio

- (a) Funding Agency: Pfizer Canada
- (b) Type: Unrestricted educational grant
- (c) Terms: Jan 2015-Dec 2015
- (d) Amount awarded: \$ 120,000

52) June 2014 Literature and knowledge translation services for the National Board of Medical Examiner, US. Principal investigators: Alfonso Iorio

- (a) Funding Agency: NBME
- (b) Type: Research service agreement
- (c) Terms: June 2014 - June 2017
- (d) Amount awarded: \$ 162,300

53) May 2014 Development of Evidence-Based Practice Guidelines for the Management of Hemophilia. Co-Principal Investigators: Alfonso Iorio and Hoyer Schunemann.

- (a) Funding Agency: National Hemophilia Foundation.
- (b) Type: Research contract awarded with a competitive RFP
- (c) Terms: May 2014 – December 15, 2015.
- (d) Amount awarded: \$ 275,000 (US).

54) Dec 2013 Literature and knowledge translation services for the Health Communication Network, NSW, Australia. Principal investigators: Brian R Haynes and Alfonso Iorio

- (a) Funding Agency: Hunter
- (b) Type: Research service agreement
- (c) Terms: April 2014- March 2017
- (d) Amount awarded: \$ 297,872

- 55) Oct 2013 Literature and knowledge translation services for EBSCO Dynamed.
Principal investigators: Brian R Haynes and Alfonso Iorio
(a) Funding Agency: EBSCO
(b) Type: Research service agreement
(c) Terms: 2013-2016
(d) Amount awarded: \$ 52,560
- 56) May 2013 Internal Research Grant: recipient Alfonso Iorio
(a) Funding Agency: Clinical Epidemiology and Biostatistics
(b) Type: Internal
(c) Terms: 2013-2014
(d) Amount awarded: \$19,950
- 57) April 2013 Surveillance of Safety and Efficacy of Wilate I patients with von Willebrand disease. Local principal Investigator: Alfonso Iorio.
(a) Funding Agency: Octapharma.
(b) Type: clinical research agreement
(c) Terms June 2013 to June 2016.
(d) Amount Awarded: \$24,073.
- 58) Feb 2013 Meta-Analysis of prospective surveillance of data on effectiveness and safety of anti-hemophilic factor (recombinant), plasma/albumin free method among patients with low-risk for immunogenicity in routine clinical practice from different countries. Co-Principal Investigators: L. Thabane, **A. Iorio**, Co-investigators: M. Marcucci, G. Foster.
(a) Funding agency: Baxter Health-Care Corporation
(b) Type: Research contract
(c) Terms: February 2013 to December 2014
(d) Amount \$271,564.30.
- 35) Feb 2013 Developing an educational tool to complement the WAPPS website.
Principal Investigator: Alfonso Iorio.
(a) Funding Agency: Novo Nordisk A/S Denmark.
(b) Type: Unrestricted educational grant
(c) Terms: March 2013 – Feb 2014
(d) Amount Awarded: \$53,000.
- 36) Dec 2012 Decision Boxes for Hemophilia. Principal Investigator: Alfonso Iorio.
(a) Funding agency: Biogen Idec MA Inc.
(b) Type: Education unrestricted grant
(c) Terms: 2013
(d) Amount awarded: \$76,510.
- 59) Jan 2012 McMaster Optimal Aging Portal. Principal Investigators: John Lavis, Brian Haynes, Parminder Raina, Maurine Dobbins, Anthony Levinson. Co-investigator at HiRU: **Alfonso Iorio**

- (a) Funding Agency: The Labarge Optimal Aging Opportunities Fund
- (b) Type: Donation
- (c) Terms: 2012-2017
- (d) Amount awarded \$10,000,000 (*)
(*) to HiRU \$ 723,968

60) Dec 2011 European Hemophilia Surveillance System's sponsored Meta-analysis on inhibitor development in Previously Treated Patient. Principal Investigator: **Alfonso Iorio**

- (a) Funding Agency: University of Sheffield..
- (b) Type: Research contract
- (c) Terms: 2012
- (d) Amount awarded: \$19,521.36

61) Nov 2011 Literature and knowledge translation services for McGraw-Hill Clinical Access. Principal investigators: Brian R Haynes and Alfonso Iorio

- (a) Funding Agency: McGraw-Hill Global Education Holdings, LLC
- (b) Type: Research service agreement
- (c) Terms: Nov 2011- December 2015
- (d) Amount awarded: \$ 162,091

62) May 2011 Knowledge translation and medical informatics. Principal Investigator: **Alfonso Iorio.**

- (a) Funding Agency: Hamilton Academic Health Sciences Organization.
- (b) Type: internal
- (c) Terms: 2012
- (d) Amount awarded: \$29,711.

63) June 2011 Strategies to optimize the use of prognostic predictors. Principal Investigator: **Alfonso Iorio**

- (a) Funding Agency: Department of Medicine internal funding.
- (b) Type: internal
- (c) Terms: Jan 2012-Dec 2012
- (d) Amount awarded: \$26,832.

64) May 2011 Haemophilia Experience Results and Opportunities (HERO) initiative. Principal Investigator: **Alfonso Iorio.**

- (a) Funding Agency: NovoNordisk International
- (b) Type: Research Contract
- (c) Terms: 2012
- (d) Amount awarded: \$18,610.

65) Dec 2008 Support for Management of the Italian National Registry of Congenital Coagulopathies.

- (a) Funding Agency: Association of Italian Centers for Hemophilia (AICE)
- (b) Type: research contract
- (c) Terms: Yearly, started in 2008, ongoing

(d) Amount awarded: \$ 18,000 per year (ongoing)

66) Dec 2005 Mangement of the Italian National Registry of Congenital Coagulopaties.

(a) Fuding Agency: Fondazione Paracelso


(b) Type: research grant

(c) Terms: 2005-2008

(d) Amount awarded: \$ 27,000

p. Lifetime Publications*

In brief, the scientific production can summarized as 181 peer reviewed full papers on journals indexed in Medline, of which 97 published from 2011 to 2015 (last five years, while at McMaster University); 307 peer reviewed published abstracts of presentation at meetings and congresses, of which 109 form 2011 and 2015;



Citation indices	All	Since 2011
Citations	4894	3065
h-index	32	28
i10-index	73	58

Peer Reviewed Full Papers

a) Journal Articles

Year 1992 (n=1)

- 1) L. Paglicci Reattelli, L. Lalli, A. Iorio. La valutazione dell'idoneità allo sport agonistico nella casistica dei Servizi di Medicina Sportiva delle U.S.L. e della

Commissione d'Appello della Regione Umbria (1982-1990). Medicina Legale - Quaderni Camerti 1992, XIV(2), 199-213.

Year 1993 (n=1)

- 2) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet rich plasma. *Fibrinolysis* 1993; 7, 379-385. (IF = 0,845)

Year 1994 (n=3)

- 3) A. Iorio, A. Alatri, L. Mazzolai, G. Agnelli. Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications. *Seminars Thrombosis and Haemostasis* 1994, 20(3), 266-73. (IF = 1,577)
- 4) G. Agnelli, A. Iorio, V. De Angelis, G.G. Nenci. Dermatan sulphate in heparin-induced thrombocytopenia. *Lancet* 1994; 344: 1295-96. (IF = 11,793)

Year 1995 (n=3)

- 5) P. Parise, J. Hauert, A. Iorio, P. Callegari, G. Agnelli. Streptokinase and rt-PA activate platelets by different way: implications on the rethrombosis rate after their administration in myocardial infarction. *J Lab Clin Med* 1995; 125: 212-21. (IF = 2,014)
- 6) G. Agnelli, A. Iorio, C. Renga, E. Boschetti, G.G. Nenci, F.A. Ofosu, J. Hirsh. Prolonged anti-thrombin activity of low molecular weight heparins: clinical implications for the treatment of thromboembolic diseases. *Circulation* 1995; 92: 2819-24. (IF = 9,173)
- 7) C. Muscat, A. Bertotto, R. Ercolani, O. Bistoni, E. Agea, M. Cesarotti, G. Fiorucci, F. Spinozzi, R. Gerli. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. *Annals of Rheumatic Diseases* 1995; 54: 382-85. (A. Iorio did statistical analysis, as stated in acknowledgements)

Year 1996 (n=4)

- 8) A. Iorio, A. Alatri, G. Agnelli. Non anticoagulant actions of glycosaminoglycans: protein binding studies. In: *Non anticoagulant actions of glycosaminoglycans*. J. Harenberg, B. Casu, eds. Plenum Press, New York, 1996, 101-12.
- 9) G. Agnelli, A. Iorio, S. Ricotta, P. Parise, G.G. Nenci. Post-discharge deep-vein thrombosis after orthopaedic surgery. *Lancet* 1996; 348: 1179-80 (IF = 11,793)
- 10) M. Berrettini, P. Parise, S. Ricotta, A. Iorio, C. Peirone, G.G. Nenci. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polynsaturated fatty acid supplementation in patients with chronic atherosclerotic disease.

Thrombosis and Haemostasis 1996, 75, 395-400. (IF = 3,723)

- 11) S. Ricotta, A. Iorio, P. Parise, G.G. Nenci, G. Agnelli. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - an overview analysis. *Thromb Haemost* 1996;76:887-92. (IF = 3,723)

Year 1997 (n=4)

- 12) A. Iorio and G. Agnelli. Pharmacokinetic optimisation of the treatment of deep vein thrombosis. *Clin Pharmacokinet* 1997;32:145-72. (IF = 4,438)
- 13) A. Iorio, F. Nucciarelli, C. Renga, G.G. Nenci, F. Gianese, G. Agnelli. Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. *Hemostasis* 1997;27:85-90. (IF = 1,153)
- 14) G. Agnelli, A. Iorio, P. Parise, S.Z. Goldhaber, M.N. Levine and the coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. *Blood Coagulation and Fibrinolysis* 1997;8:216-222. (IF = 1,399)
- 15) R. Mozzi, V. Andreoli, S. Buratta and A. Iorio. Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex. *Molecular and Cellular Biochemistry* 1997; 168:41-49. (IF = 1,273)

Year 1998 (n=5)

- 16) M. D'Inca, A. Ghirarduzzi, I. Iori, A. Iorio, G. Rinaldi, C. Salvarani, M. Silingardi. Syndrome da anticorpi antifosfolipidi. *L'internista ospedaliero* 1998;3:12-22.
- 17) A. Alatri, A. Iorio, G. Agnelli. Choice of end-points in assessing the efficacy of post-discharge prophylaxis for venous thromboembolism. *Thromb Haemost* 1998;79:234. (IF = 3,723)
- 18) G. Agnelli, F. Piovella, P. Buoncristiani, P. Severi, M. Pini, A. D'Angelo, C. Beltrametti, M. Damiani, G.C. Andrioli, R. Pugliese, A. Iorio, G. Brambilla. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Eng J Med* 1998;339:80-85. (IF = 28,660)
- 19) G. Agnelli, A. Iorio. Enoxaparin in Neurosurgical patients. *N Eng J Med* 1998, 339: 1639-40. (IF = 28,660)
- 20) M.L. Cattabiani, A. Dallari, O. Gaddi, F. Giovanardi, A. Troiso, D. Guidetti, A. Iorio, G. Lo', L. Manzini, G. Baldi, G. Parmiggiani, D. Procičchiani, E. Tincani, I. Iori. Indicazioni al trattamento dell'ictus ischemico. *Geriatria* 1998;4(suppl):21-28

Year 1999 (n=1)

- 21) Ascani A., Iorio A., Agnelli G. Withdrawal of Warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. *Blood Coagulation & Fibrinolysis* (0957-5235) 1999, 5 (10): 291-95 (IF = 1,399)

Year 2000 (n=4)

- 22) Buratta S., Andreoli V., Mambrini R., Iorio A., Porcellati S., Mozzi R. Serine base exchange enzymes in porcine lyophilized platelets: enzyme properties and modulation by ALF4- and different types of heparin. *Molecular And Cellular Biochemistry* (0300-8177) 2000, 203: 177-184. (IF = 1,273)
- 23) Silingardi M., Ghirarduzzi A., Tincani E., Iorio A., Iori I. Miconazole oral gel potentiates warfarin anticoagulant activity. *Thrombosis And Haemostasis* (0340-6245) 2000, 83: 794-5. (IF = 3,723)
- 24) Iorio A., Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a metanalysis. *Archives Of Internal Medicine* (0003-9926) 2000, 160, 2327-2332 (IF = 5,385)
- 25) Silingardi M., Ghirarduzzi A., Galimberti D., Iorio A., Iori I. Mesenteric-portal vein thrombosis in a patient with hyperhomocysteinemia and heterozygous for 20210A prothrombin allele. *Thrombosis And Haemostasis* (0340-6245) 2000, 84: 358-9. (IF = 3,723)

Year 2001 (n=3)

- 26) Iorio A., Agnelli G. Heparin reduces venous thromboembolism in neurosurgery but increases the risk of bleeding. (Iorio A, Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a metanalysis. *Arch Intern Med.* 2000;160:2327-2332). *ACP journal club* (1056-8751) 2001: 55
- 27) Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Iorio A., Bazzan M., Moia M., Guazzaloca G., Bertoldi A., Tomasi C., Scannapieco G., Ageno W., Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. *New England Journal Of Medicine* (0028-4793) 2001, 345: 165-69. (IF = 29,065)
- 28) Tripodi A., Chantarangkul V., Lombardi R., Lecchi A., Mannucci P., Cattaneo M., for the ad hoc study group. Multicenter study of Homocysteine Measurement – Performance characteristic of different methods, influence of standards on interlaboratory agreement results. *Thrombosis And Haemostasis* (0340-6245) 2001, 85: 291-5, (Iorio A. listed as author in the ad hoc study group) (IF = 3,723)

Year 2002 (n=3)

- 29) Nicolini A., Ghirarduzzi A., Iorio A., Silingardi M., Malferrari G., Baldi G. Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. *Haematologica* (0390-6078) 2002, 87: 948-56 (IF = 3,226)
- 30) Testa S., Iorio A., Alatri A., Parisoli A., Ghirarduzzi A., Berrettini M., Rinaldi G., per il Gruppo di Studio di Centri aderenti all'FCSA e per il Gruppo di Studio Coagulazione della SIMEL. Gli standard di accreditamento dei centri per la sorveglianza dei pazienti in terapia anticoagulante orale (TAO). *Journal of Laboratory Medicine* 2002 3 (2-s1): 52-56
- 31) Goracci S., Filippucci E., Guercini F., Santucci L., Iorio A. Successful treatment of Dieulafoy's disease in a von Willebrand patient. *Haematologica* (0390-6078) 2002, 87: ECR23 (IF = 3,226)

Year 2003 (n=3)

- 32) Iorio A. Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. *Journal Of Thrombosis And Haemostasis* (1538-7933) 2003, 1: 881-3. (IF = 5,947)
- 33) Iorio A., Guercini F., Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. *Journal Of Thrombosis And Haemostasis* (1538-7933) 2003, 1: 1906-13. (IF = 5,947)
- 34) Conti S., Guercini F., Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. *Pathophysiology of haemostasis and thrombosis* (1424-8832) 2003, 33: 197-201. (IF = 1,129)

Year 2004 (n=2)

- 35) Iorio A. Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. *Journal Of Thrombosis And Haemostasis* (1538-7933) 2004, 2: 1504. (IF = 5,947)
- 36) Silingardi M., Salvarani C., Boiardi L., Accardo P., Iorio A., Olivieri I., Cantini F., Salvi F., La Corte R., Triolo G., Ciccia F., Ghirarduzzi A., Filippini D., Paolazzi G., Iori I. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis. *Arthritis and rheumatism* (0004-3591) 2004, 51: 177-83. (IF = 7,751)

Year 2005 (n=6)

- 37) Stobart K., Iorio A., Wu J. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. *Cochrane*

Database of Systematic Reviews (1469-493X) 2005, 2, CD003429

- 38) Mourvaki E., Ferrante F., Ghirarduzzi A., Brini M., Depunzio I., Iorio A. Performance Comparison of Three Assay Methods Used in Fasting and Postmethionine Load Plasma Homocysteine Determinations From Patients With Vascular Disease. *American Journal Of Clinical Pathology* (0002-9173) 2005, 124: 675-681. (IF = 2,043)
- 39) Iorio A., Guercini F., Ferrante F., Nenci G.G. Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism. *Current Pharmaceutical Design* (1381-6128) 2005, 11: 3893-3918. (IF = 4,870)
- 40) Iorio A., Ferrante F. Gestione ed organizzazione di un centro di sorveglianza della terapia anticoagulante. *Annali della Facoltà di Medicina e Chirurgia della Università di Perugia che pubblicano gli Atti della Accademia Anatomico-Chirurgica* (0365-2270) 2005, vol.96 suppl.1.
- 41) Mantovani L., Monzini M., Mannucci P., Scalone L., Villa M., Gringeri A., for the Conan Study Group. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia* (Oxford. Print) (1351-8216) 2005, 11: 589-597. (Iorio A è elencato tra All contributors participating in patients' enrollment and in collecting data) (IF = 1,947)
- 42) Belvini D., Salviato R., Radossi P., Pierobon F., Mori P., Castaldo G., Tagariello G., AICE HB study group. Molecular genotyping of the Italian cohort of patients with hemophilia B. *Haematologica* (0390-6078) 2005, 90: 635-642. (Iorio A è elencato in Appendice come responsabile del Centro Emofilia di Perugia.) (IF = 1,947)

Year 2006 (n=7)

- 43) Iorio A, Stobart K, Bolton-Maggs P. J Can evidence harm? Certainly not hemophilia treatment and community. *Journ Thromb Haemost.* 2006 4(3): 505-6. (IF = 5,947)
- 44) Iorio A.M., Camilloni B., Basileo M., Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Iorio A. Influenza vaccination in patients on long-term anticoagulant therapy. *Vaccine* 2006; 24: 6624-6628. (IF = 3,337)
- 45) Iorio A., Agnelli G. Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No. *Journ Thromb Haemost* (1538-7933) 2006, 4: 2133-2136. (IF = 5,947)
- 46) Baldi G., Altomonte F., Altomonte M., Ghirarduzzi A., Brusasco C., Parodi R., Ricciardi A., Remollino V., Spinsi V., Saporito A., Caiazza A., Musso G., Cervellin G., Lamberti S., Buzzalino M., De Giorgi F., Del Prato C., Golinelli M., Gai V.,

Monsù R., Giofrè M., Giovanardi D., Cattaneo S., Frumento F., Caporrella A., Re G., De Iaco F., Bologna G., Nocenti F., Lorenzi C., Zoratti R., Sciolla A., Tiscione V., Pastorello M., Vandelli A., Villa A., Zanna M., De Palma A., Iorio A. Intracranial Haemorrhage in Patients on Antithrombotics: Clinical Presentation and Determinants of Outcome in a Prospective Multicentric Study in Italian Emergency Departments. *Cerebrovascular Diseases* (1015-9770) 2006, 22: 286-293. (IF = 2,534)

47) Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM; The Emoclot15 Study Members. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. *Haemophilia* 2006, 12(2):128-32. (Iorio A in the Appendix as Emoclot 15 study member) (IF = 1,947)

48) Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, Colombo M; Hepatitis Study Group of the Association of Italian Hemophilia Centers. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. *Haematologica*. 2006, 91: 1367-1371 (Iorio A in the Appendix as member of the study group) (IF = 5,516)

49) Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., Pengo V., Ghirarduzzi A., Pattacini C., Testa S., Lensing A., Tripodi A., PROLONG Investigators. D-Dimer Testing to Determine the Duration of Anticoagulation Therapy. *New England Journal of Medicine* (0028-4793) 2006, 355: 1780-1789 2006. (IF = 51,296)

Year 2007 (n=3)

50) Iorio A, Vedovati MC, Filippucci E, Agnelli G. Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence. *Intern Emerg Med*. 2007; 2(3): 202-6.

51) Iorio A, Federici MO, Mourvaki E, Ferolla P, Piroddi M, Stabile A, Timi A, Celleno R, Benedetti MM. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. *Thromb Haemost*. 2007, 98(3): 635-41. (IF = 4,950)

52) Palareti G, Cosmi B, Iorio A. D-Dimer and duration of anticoagulation. *New England Journal of Medicine*, 2007; 356 (4): 421-3. (IF = 51,296)

Year 2008 (n=8)

53) Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; for the KOGENATE® Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. *Thromb Haemost*. 2008; 99(1):

52-58. (IF = 4,950)

- 54) Iorio A, Barnes C, Vedovati MC, Favaloro EJ. Thrombophilia and cerebral vein thrombosis. *Front Neurol Neurosci*. 2008; 23: 55-76.
- 55) Iorio A. Iatrogenic causes of an ICH: OAT therapy. *European Journal of Anaesthesiology* 2008; 25 (Suppl 42): 8-11. (IF = 1,435)
- 56) Alfonso Iorio, Lorenzo Moja, Alessandro Liberati, Gian Franco Gensini, Roberto Gusinu, Andrea A. Conti Selecting references that match constructs: the difficult job of citing the parachute hyperbole. *Intern Emerg Med* 2008, 3: 151-154 (DOI 10.1007/s11739-008-0149-8)
- 57) Alfonso Iorio, Michela Basileo, Emanuela Marchesini, Mario Materazzi, Mauro Marchesi, Antonella Esposito, Gian Paolo Palazzesi, Lucio Pellegrini, Barbara Luciani Pasqua, Lauretta Rocchetti, Carla Maria Silvani. The good use of plasma. A critical analysis of five international guidelines. *Blood Transfus* 2008;6:18-24 (DOI 10.2450/2008.0041-07).
- 58) A. Iorio, E. Oliovecchio, M. Morfini and P. M. Mannucci on behalf of the Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. *Haemophilia* 2008;14:444-453. (IF = 1,947)
- 59) Iorio Alfonso, Basileo Michela, Marchesini Emanuela, Palazzesi Gian Paolo, Materazzi Mario, Marchesi Mauro, Esposito Antonella, Pellegrini Lucio, Germani Antonella, Rocchetti Lauretta, Silvani Carla Maria. Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. *Blood Transfus* 2008;6(4):211-9.
- 60) Verso M, Iorio A. Review: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer. *ACP J Club*. 2008 Dec 16;149(6):11.

Year 2009 (n=10)

- 61) A Iorio and M Marcucci. Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends? *Haemophilia* 2009; 15: 900-3 DOI: 10.1111/j.1365-2516.2009.02031.x (IF = 1,947)
- 62) C. Santoro, A. Iorio, F. Ferrante, A. Pallotta, P. Pignoloni, F. Biondo, G. Agnelli and M. G. Mazzucconi Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII) *Haemophilia* 2009, 15: 779-87 DOI: 10.1111/j.1365-2516.2009.01983 (IF = 1,947)
- 63) Giuseppe Tagariello, Alfonso Iorio, Elena Santagostino, Massimo Morfini,

- Ruggero Bisson, Massimo Innocenti; Maria Elisa Mancuso ; Maria Gabriella Mazzucconi, Gian Luigi Pasta, Paolo Radossi, Giuseppina Rodorigo, Cristina Santoro, Roberto Sartori, Antonio Scaraggi, Luigi Pier Solimeno and Pier Mannuccio Mannucci on behalf of the Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders. *Blood* 2009;114:779-84. doi:10.1182/blood-2009-01-195313 (IF = 10,896)
- 64) Lise L. Gluud, Emanuela Marchesini, Alfonso Iorio. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. *Am J Gastroenterol* 2009; 104(9):2335-41 doi: 10.1038/ajg.2009.311 (IF = 6.101)
- 65) Walter Ageno, David Garcia, Maria I. Aguilar, James Douketis, Guido Finazzi, Davide Imberti, Alfonso Iorio, Nigel S. Key, Wendy Lim, Marco Marietta, Domenico Prisco, Ravi Sarode, Sophie Testa, Alberto Tosetto and Mark Crowther. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 2: Treatment. *Am. J. Hematol.* 2009; 84:584–588 (IF = 2,117??)
- 66) G. Tagariello, A. Iorio, P.M. Mannucci. Author Response: Insufficient evidence to suggest less stringent therapy in haemophilia B? *Blood* 2009;114(23):4907. (IF = 10,896)
- 67) A. Iorio. International clinical trials are the best way to improve global haemophilia care? No. *Haemophilia* 2009; 15(Suppl1), 13 (IF = 1,947)
- 68) SM. Siboni, PM Mannucci, A Gringeri, M. Franchini, A. Tagliaferri, M. Ferretti, FC Tradati, E. Santagostino and S. Von Mackensen for the Italian Association of Hemophilia Centres (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. *Journal of Thrombosis and Haemostasis*, 7: 780–786. DOI: 10.1111/j.1538-7836.2009.03318.x (A. Iorio in the Medline published coauthors list) (IF = 5,947)
- 69) A. Coppola, M. Margaglione, E. Santagostino, A. Rocino, E. Grandone, P.M. Mannucci, G. Di Minno for the AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors. Accepted for publication in the *Journal of Thrombosis and Haemostasis* doi: 10.1111/j.1538-7836.2009.03615.x (A. Iorio in the Medline published coauthors list) (IF = 5,947)
- 70) Alfonso Iorio, Walter Ageno, Benilde Cosmi, Davide Imberti, Federico Lussana, Sergio Siragusa, Daniela Tormene, Alberto Tosetto, Marco Cattaneo. Guidelines of the Italian Society for Haemostasis and Thrombosis: Objectives and methodology. *Thromb Res* 2009;124(5):e1-e5.

doi:10.1016/j.thromres.2009.05.014 (IF = 1,577)

Year 2010 (n=18)

- 71) Alfonso Iorio, Gianluigi Fabbriani, Maura Marcucci, Matteo Brozzetti, Paolo Filippini. Bone mineral density in hemophilia patients. A meta-analysis. *Thrombosis and Haemostasis*, 2010, 103(3):596-603. (IF = 3,500)
- 72) Giuliano V, Bassotti G, Mourvaki E, Castellani D, Filippucci E, Sabatino G, Gizzi S, Palmerini F, Galli F, Morelli O, Baldoni M, Morelli A, Iorio A. Small intestinal bacterial overgrowth and warfarin dose requirement variability. *Thromb Res*. 2010 Jul;126(1):12-7. Epub 2010 Jan 3. PubMed PMID: 20051286.(IF = 1,577)
- 73) Benilde Cosmi, Cristina Legnani, Alfonso Iorio, Vittorio Pengo, Angelo Ghirarduzzi, Sophie Testa, Daniela Poli, Armando Tripodi, Gualtiero Palareti. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the PROLONG study. *European Journal of Vascular and Endovascular Surgery*, 2010; 39, 356-365. doi:10.1016/j.ejvs.2009.11.022 (IF = 3,007)
- 74) Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. *Cochrane Database Syst Rev* 2010 Jan 20(1):CD004888 (IF = 5,947)
- 75) Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio AM. No interaction between influenza vaccination and vitamin K antagonist treatment: A placebo controlled, randomized, double-blind, cross-over study. *Archives of Internal Medicine*, 2010, 170(7):609-16 (IF = 9,111)
- 76) Tagliaferri A, Rivolta GF, Iorio A, Olivoecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M; Italian Association of Hemophilia Centers, Ciavarella N, Scaraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenzi D, Serino ML, Linari S, Molinari C, Boeri E, La Pecorella M, Carloni MT, Santagostino E, Di Minno G, Coppola A, Rocino A, Zanon E, Spiezia L, Di Perna C, Marchesini M, Marcucci M, Dragani A, Macchi S, Albertini P, D'Incà, M, Santoro C, Biondo F, Piseddu G, Rossetti G, Barillari G, Gandini G, Giuffrida AC, Castaman G. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. *Haemophilia*. 2010 May;16(3):437-46. Epub 2010 Feb 9. PubMed PMID: 20148978. (IF 1,947)
- 77) Kenet G, Lütkehoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Günther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostásy K, Simioni P, Sträter RD, Young G, Nowak-Göttl U. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and

- meta-analysis of observational studies. *Circulation*. 2010 Apr 27;121(16):1838-47. Epub 2010 Apr 12 Review. PubMed PMID: 20385928. (IF 10,89)
- 78) A Macura, I Abraha, J Kirkham, GF Gensini, L Moja, A Iorio. Selective outcome reporting –Telling and detecting true lies: The state of the science. *Internal and Emergency Medicine*, 2010, 5(2):151-5. (IF = 2,43)
- 79) Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. *J Thromb Haemost*. 2010 Jun;8(6):1256-65. Epub 2010 Mar 17. PubMed PMID: 20345722. (IF 6,09)
- 80) Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med*. 2010 Oct 25;170(19):1710-6. Review. PubMed PMID: 20975016. (IF 9,81)
- 81) Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. *Ann Intern Med*. 2010 Oct 19;153(8):523-31. PubMed PMID: 20956709. (IF 16,2)
- 82) Iorio A. ACP Journal Club. A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. *Ann Intern Med*. 2010 Oct 19;153(8):JC4-13. PubMed PMID: 20956697.
- 83) Malato A, Saccullo G, Iorio A, Ageno W, Siragusa S. Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis. *Curr Pharm Des*. 2010;16(31):3483-3486. (IF = 4.414)
- 84) Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. *J Thromb Haemost*. 2010 Oct;8(10):2313-5. doi:10.1111/j.1538-7836.2010.03991.x. (IF 6,09)
- 85) Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, Palareti G, Poli D, Tait RC, Iorio A. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis. *J Thromb Haemost*. 2010;8(11):2436-42. (IF = 6,09)
- 86) Iorio A, Matino D, D'Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding

episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004449. Review. PubMed PMID: 20687076. (IF=6,26)

87) Marengoni A, Bonometti F, Nobili A, Tettamanti M, Salerno F, Corrao S, Iorio A, Marcucci M, Mannucci PM; Italian Society of Internal Medicine (SIMI) Investigators. In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. *Rejuvenation Res.* 2010 Aug;13(4):469-77. PubMed PMID: 20586646. (IF = 4.138)

88) Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Marengoni A, Salerno F, Corrao S, Mannucci PM; REPOSI Investigators. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. *Eur J Intern Med.* 2010 Dec;21(6):516-23. Epub 2010 Aug 15. PubMed PMID: 21111937.

Year 2011 (n=19)

89) Douketis J, Tosetto A, Marcucci M, Bagli T, Cushman M, Kryle P, Cosmi B, Poli D, Tait RC, Iorio A. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. *BMJ.* 2011 Feb 24;342:d813. doi: 10.1136/bmj.d813. Review. PubMed PMID: 21349898

90) Marengoni A, Corrao S, Nobili A, Tettamanti M, Pasina L, Salerno F, Iorio A, Marcucci M, Bonometti F, Mannucci PM; on behalf of SIMI Investigators. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. *Int J Geriatr Psychiatry.* 2011 Sep;26(9):930-6. doi: 10.1002/gps.2627. Epub 2010 Nov 9. PubMed PMID: 21061413. (IF 1,98)

91) Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, De Vittorio L, Marengoni A, Corrao S, Iorio A, Marcucci M, Mannucci PM; On behalf of SIMI Investigators. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. *Eur J Clin Pharmacol.* 2011 May;67(5):507-519. Epub 2011 Jan 11. PubMed PMID: 21221958.

92) Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM; REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. *Eur J Intern Med.* 2011 Apr;22(2):205-10. Epub 2010 Dec 21. PubMed PMID: 21402255

93) Basileo M, Micheluzzi C, Minozzi M, Lazzaroni L, Iorio A. Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. *Intern Emerg Med.* 2011 Apr 6. [Epub ahead of print] PubMed PMID: 21468696

94) Marchesini, E, Prisco, D, Iorio, A. Recombinant Factor VIIa concentrate versus plasma-derived concentrates for the treatment of acute bleeding episodes in

- persons with haemophilia and inhibitors. *European Oncology and Haematology*. 2011, 7(2):140-142.
- 95) Douketis JD, Iorio A. The association between venous thromboembolism and physical inactivity in everyday life. *BMJ*. 2011 Jul 4;343:d3865.doi: 10.1136/bmj.d3865. No abstract available.
- 96) Iorio, A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. *Cochrane Database Syst Rev*. 2011 Sep 7;9:CD003429.
- 97) Federici, A. B., Bucciarelli, P., Castaman, G., Baronciani, L., Canciani, M. T., Mazzucconi, M. G., Morfini, M., Rocino A, Schiavoni M, Oliovecchio E, Iorio A, Mannucci PM. (2011). Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. *Seminars in thrombosis and hemostasis*, 37(5), 511-21. doi:10.1055/s-0031-1281037.
- 98) Giampaolo A, Abbonizio F, Puopolo M, Arcieri R, Mannucci PM; Italian Association of Haemophilia Centres, Hassan HJ, Accorsi A, Ettorre PC, Schiavoni M, Palareti G, Roderigo G, Valdré L, Amaddii G, Billio A, Notarangelo L, Iannacaro P, Muleo P, Biasioli C, Rossi V, Alatri A, Testa S, Vincenzi D, Scapoli G, Morfini M, Molinari AC, Lapecorella M, Mariani G, Baudo F, Caimi MT, Federici AB, Gringeri A, Mannucci PM, Santagostino E, Marietta M, Coppola A, Di Minno G, Perricone C, Schiavulli M, Miraglia E, Rocino A, Zanon E, Gagliano F, Mancuso G, Siragusa S, Rivolta F, Tagliaferri A, Gamba G, Iorio A, Oliovecchio E, Dragani A, Arbasi MC, Albertini P, Mancino A, Lombardo VT, Latella C, D'Inca M, Landolfi Raffaele, Biondo Francesca, Mazzucconi MG, Santoro Cristina, Mameli AL, Piseddu G, Schinco PC, Messina M, Rossetti G, Barillari G, Feola G, Franchini M, Gandini G, Castaman G, Rodeghiero F. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. *Transfus Med*. 2011 Aug;21(4):280-4. doi: 10.1111/j.1365-3148.2011.01074.x. Epub 2011 Mar 30. PubMed PMID: 21733006.
- 99) Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? *J Thromb Haemost*. 2011 Nov;9(11):2176-9. doi: 10.1111/j.1538-7836.2011.04480.x. PubMed PMID: 21854537.
- 100) Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters, R, Monagle P, van Ommen H, Rafini L, Simoni P, Young G, Nowak-Gottl U. *Semin Thromb Hemost*. Impact of persistent Antiphospholipid antibodies 2011 Oct;37(7):802-9. Epub 2011 Dec 20.
- 101) Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. An Italian ad hoc study group. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. *Blood Transfus*.

- 2011 Jan 9(1):60-9. doi: 10.2450/2010.0011-10. Epub 2010 Apr 30. PubMed PMID: 21084016. Pubmed Central PMCID: PMC3021399.
- 102) Marcucci M, Nobili A, Iorio A. More about optimal choices in cardioembolism prevention. *Eur J Intern Med* 2011;22:e-19
- 103) Iorio A. ACP Journal Club. The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. *Ann Intern Med*. 2011 Jun 21;154(12):JC6-13.
- 104) Siragusa S, Malato A, Saccullo G, Iorio A, Di Ianni M, Caracciolo C, Coco LL, Raso S, Santoro M, Guarneri FP, Tuttolomondo A, Pinto A, Pepe I, Casuccio A, Abbadessa V, Licata G, Battista Rini G, Mariani G, Di Fede G. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. *Am J Hematol*. 2011 Nov;86(11):914-7
- 105) Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, Iorio A, Marcucci M, Corrao S, Licata G, Mannucci PM. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. *Eur J Intern Med*. 2011 Dec;22(6):597-602. Epub 2011 Sept 29.
- 106) Siboni SM, Zanon E, Sottolotta G, Consonni D, Castaman G, Mikovic D, Biondo F, Tagliaferri A, Iorio A, Mannucci PM, Peyvandi F. Central nervous system bleeding in patients with rare bleeding disorders. *Haemophilia*. 2012 Jan 18 (1):34-8. doi:10.1111/j.1365-2516.2011.02545.x. Epub 2011 May 4.
- 107) Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, Coppola A, Castaman G, Mannucci PM; the Italian Association of Hemophilia Centers, Barillari G, Dragani A, Gamba G, Giuffrida A, Lapecorella M, Mancuso G, Lucia L, Mazzucconi MG, Messina M, Musso R, De Martis F, Rossetti G, Schinco P, Spiezia L, Valdre L. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. *Haemophilia*. 2012 Jan 18(1):39-45. 2011 doi: 10.1111/j.1365-2516.2011.02611.x Epub 2011 Jul 14.

Year 2012 (n=8)

- 108) Marengoni, A, Bianchi G, Nobili A, Tettamanti M, Pasina L, Corrao S, Salerno F, Iorio A, Marcucci M, Mannucci PM. Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients. *Int Psychogeriatr*. 2012 Apr;24(4):60613. doi: 10.1017/S1041610211002353. Epub 2011 Dec 8. PMID: 22152153.
- 109) Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism. A proposed prediction score (DASH). *J Thromb Haemost*. 2012 Jun; 10(6): 1019-25. doi:

10.1111/j.15387836.2012.04735.x. PMID: 22489957

- 110) Cassis FR, Querol F, Forsyth A, Iorio A; On behalf of the HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. *Haemophilia*. 2012 May;18(3): e101-e114.
- 111) Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, Pellegrini F, Tengborn L, and Levesque H. On behalf of the EACH2 Registry. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *J Thromb Haemost* 2012; 10: 622-31.
- 112) Marengoni A, Nobili A, Romano V, Tettamanti M, Pasina L, Djade S, Corrao S, Salerno F, Iorio A, Marcucci M, Mannucci PM; SIMI Investigators. Adverse Clinical Events and Mortality During Hospitalization and 3 Months After Discharge in Cognitively Impaired Elderly Patients. *J Gerontol A Biol Sci Med Sci*. 2013 Apr;68(4):41925. doi: 10.1093/gerona/gls181. Epub 2012 Sep 12. PMID: 22972941
- 113) Don-Wauchope AC, Sievenpiper JL, Hill SA, Iorio A. Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. *Clin Chem*. 2012 Oct;58(10):1426-37. Epub 2012 Aug 9. PubMed PMID: 22879395.
- 114) Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. *Blood*. 2012 Jul 26;120(4):720-7. Epub 2012 Jun 12. PubMed PMID: 22692511.
- 115) Uncertainties in baseline risk estimates and confidence in treatment effects. Spencer FA1, Iorio A, You J, Murad MH, Schünemann HJ, Vandvik PO, Crowther MA, Pottie K, Lang ES, Meerpohl JJ, Falck-Ytter Y, Alonso-Coello P, Guyatt GH. *BMJ*. 2012 Nov 14;345:e7401. doi: 10.1136/bmj.e7401.

Year 2013 (n=16)

- 116) Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, Marengoni A, Salerno F, Corrao S, Mannucci PM; REPOSI (Registro Politerapie Societa Italiana di Medicina Interna) Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med*. 2013 Sep;8(6):509-20. doi: 10.1007/s1173901309448. Epub 2013 May 8. PMID: 23653407
- 117) Kessler CM, Iorio A. The Rodin (Research of Determinants of Inhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. *Haemophilia*. 2013 May;19(3):351-4. Doi: 10.1111/hae.12149. Epub 2013 Apr 12. PubMed PMID: 23577743.
- 118) Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe

- hemophilia A. *N. Engl J Med.* 2013 Apr 11;368(15): 1456. Doi: 10.1056/NEJMc1301995#SA1. PubMed PMID: 2374132.
- 119) Santagostino E, Messina M, Tagliaferri A, Iorio A, Morfini M. Haemophilia at various states of life: design of new therapeutic strategies through an interactive course – the Kogeniale project. *Blood Transfus.* 2013 Apr;11(2): 272-80. Doi: 10.2450/2012.0158-12. Epub 2013 Jan 23. PubMed PMID: 23399360; PubMed Central PMCID: PMC3626480.
- 120) Marcucci M, Smith CT, Douketis JD, Tosetto A, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. *J Clin Epidemiol.* 2013 Apr;66(4) : 415-25. Doi: 10.1016/j.jclinepi.2012.08.007. Epub 2013 Feb 8. PubMed PMID: 23395515.
- 121) Marengoni A, Nobili A, Pirali C, Tettamanti M, Pasina L, Salerno F, Corrao S, Iorio A, Marcucci M, Franchi C, Mannucci PM. Comparison of Disease Clusters in two Elderly Populations Hospitalized in 2008 and 2010. *Gerontology.* 2013;59(4):30715. doi: 10.1159/000346353. Epub 2013 Jan 25. PMID: 23364029.
- 122) Marcucci M, Iorio A, Douketis J. Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. *Curr Treat Options Cardiovasc Med.* 2013 Apr;15 (2): 224-39. Doi: 10.1007/s11936-012-0225-2. PubMed PMID: 23344704; PubMed Central PMCID: PMC3608888.
- 123) Pasina L, Djade CD, Lucca U, Nobili A, Tettamanti M, Franchi C, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Violi F, Mannucci PM. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study. *Drugs Aging.* 2013 Feb;30(2):103-12. Doi: 10.1007/s40266-012-0044-x. PubMed PMID: 23239364.
- 124) Tagariello G, Iorio A, Matino D, Belvini D, Salviato R, Sartori R, Radossi P. High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. *J. Hematol Oncol.* 2013 Aug 30;6:63. Doi: 10.1186/1756-8722-6-63. PubMed PMID: 24001010; PubMed Central PMCID: PMC3766100.
- 125) Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, Franchi C, Marengoni A, Salerno F, Corrao S, Violi F, Mannucci PM; REPOSI Investigators. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. *Eur J Intern Med.* 2013 Dec;24 (8): 800-6. Doi: 10.1016/j.ejim.2013.08.697. Epub 2013 Sep 12. PubMed PMID: 24035703.
- 126) Pasina L, Djade CD, Nobili A, Tettamanti M, Franchi C, Salerno F, Corrao S,

- Marengoni A, Iorio A, Marcucci M, Mannucci P. Drug-drug interactions in a cohort of hospitalized elderly patients. *Pharmacoepidemiol Drug Saf.* 2013 Oct;22(10):1054-60. doi: 10.1002/pds.3510. Epub. 2013 Aug 30. PubMed PMID:24038765.
- 127) Halimeh S, Bidlingmaier C, Heller C, Gutsche S, Holzhauer S, Kenet G, Kurnik K, Manner D, Iorio A, Nowak-Gottl U. Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study. *Biomed Res Int.* 2013;2013:901975. Doi: 10.1155/2013/901975. Epub 2013 Oct 2. Pubmed PMID: 24199202; Pubmed Central PMCID: PMC3807559.
- 128) Cohen AM, Demner-Fushman D, Iorio A, Sim I, Smalheiser NR. Tools for Identifying Reliable Evidence and implementing it in everyday clinical care. *AMIA Summits Transl Sci Proc.* 2013 Mar 18;2013:42-4. eCollection 2013. PubMed PMID: 24303233; PubMed Central PMCID: PMC3845785.
- 129) Franchi C, Nobili A, Mari D, Tettamanti M, Djade CD, Pasina L, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM; REPOSI Investigators. Risk factors for hospital readmission of elderly patients. *Eur J Intern Med.* 2013 Jan;24(1):4551. doi: 10.1016/j.ejim.2012.10.005. Epub 2012 Nov 8. PMID: 23142413
- 130) Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Sun X, Johnston BC, Briel M, Busse JW, Glujovsky D, Granados CE, Iorio A, Irfan A, Garcia LM, Mustafa RA, Ramirez-Morera A, Sola I, Tikkinen KA, Ebrahim S, Vandvik PO, Zhang Y, Selva A, Sanabria AJ, Zazueta OE, Vernooij RW, Schunemann HJ, Guyatt GH. A methodological survey of the analysis, reporting and interpretation of Absolute Risk Reduction in systematic reviews (ARROW): a study protocol. *Syst Rev.* 2013 Dec 13;2:113. Doi: 10.1186/2046-4053-2-113. PubMed PMID: 24330779; PubMed Central PMCID: PMC3867670.
- 131) Xi M, Makris M, Marcucci M, Santagostino E, Mannucci PM, Iorio A. Inhibitor development in previously treated hemophilia A patients: a systematic review, metaanalysis, and metaregression. *J Thromb Haemost.* 2013 Sep;11(9):1655-62. doi: 10.1111/jth.12335. Review. PMID: 23802542

Year 2014 (n=21)

- 132) Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. *Thromb Haemost.* 2014 Jan;111(1):172-9. doi: 10.1160/TH13-04-0336. Epub 2013 Oct 24. PubMed PMID: 24154729.
- 133) Iorio A, Douketis JD. Ruling out DVT using the Wells rule and a D-dimer test.

- BMJ. 2014. Mar 10;348:g1637. doi: 10.1136/bmj.g1637. No abstract available. PMID: 24615174.
- 134) Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. *Cochrane Database Syst Rev*. 2014 Apr 24;4:CD010561. doi: 10.1002/14651858.CD010561.pub2. Review. PMID: 24763974
- 135) Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. *Am J Med*. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003. Epub 2014 May 13. PMID: 24838192.
- 136) Akl EA, Kahale LA, Agarwal A, Al-Matari N, Ebrahim S, Alexander PE, Briel M, Brignardello-Petersen R, Busse JW, Diab B, Iorio A, Kwong J, Li L, Lopes LC, Mustafa R, Neumann I, Tikkinen KA, Vandvik PO, Zhang Y, Alonso-Coello P, Guyatt G. Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. *Syst Rev*. 2014 Nov 26;3(1):137. doi: 10.1186/2046-4053-3-137. PubMed PMID: 25423894.
- 137) Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014 Nov 20;11:CD000011. doi: 10.1002/14651858.CD000011.pub4. PubMed PMID: 25412402.
- 138) Moja L, Kwag KH, Lytras T, Bertizzolo L, Brandt L, Pecoraro V, Rigon G, Vaona A, Ruggiero F, Mangia M, Iorio A, Kunnamo I, Bonovas S. Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. *Am J Public Health*. 2014 Dec;104(12):e12-22. doi: 10.2105/AJPH.2014.302164. Epub 2014 Oct 16. PubMed PMID: 25322302; PubMed Central PMCID: PMC4232126.
- 139) Athale A, Giguere A, Barbara A, Krassova S, Iorio A. Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients. *Haemophilia*. 2014 Nov;20(6):800-6. doi: 10.1111/hae.12495. Epub 2014 Oct 2. PubMed PMID: 25273544.
- 140) Agoritsas T, Iserman E, Hobson N, Cohen N, Cohen A, Roshanov PS, Perez M, Cotoi C, Parrish R, Pullenayegum E, Wilczynski NL, Iorio A, Haynes R. Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. *Implement Sci*. 2014 Sep 20;9(1):125. [Epub ahead of print] PubMed PMID: 25239537; PubMed Central

PMCID: PMC4177052.

- 141) Matino D, Iorio A. Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. *Haemophilia*. 2014 Sep;20(5):604-6. doi: 10.1111/hae.12511. Epub 2014 Aug 25. PubMed PMID: 25154445.
- 142) Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. *Haemophilia*. 2014 Nov;20(6):777-83. doi: 10.1111/hae.12480. Epub 2014 Jul 17. PubMed PMID: 25039809.
- 143) Traore AN, Chan AK, Webert KE, Heddle N, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A, Walker I. First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. *Haemophilia*. 2014 Jul;20(4):e251-9. doi: 10.1111/hae.12477. PubMed PMID: 24948405; PubMed Central PMCID: PMC4140609.
- 144) Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Biciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazia MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. *Nature*. 2014 Jul 10;511(7508):184-90. doi: 10.1038/nature13323. PubMed PMID: 24930766; PubMed Central PMCID: PMC4098076.
- 145) Matino D, Teitel J, Page D, Keepanasseril A, Iorio A, Walker I. The haemophilia certification system in Canada. *Blood Transfus*. 2014 Apr;12 Suppl 3:e531-41. doi: 10.2450/2014.0032-14s. PubMed PMID: 24922284; PubMed Central PMCID: PMC4044813.
- 146) Cassis FR, Buzzi A, Forsyth A, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. *Haemophilia*. 2014 Jul;20(4):e287-95. doi: 10.1111/hae.12454. Epub 2014 May 7. PubMed PMID: 24800872.
- 147) Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Joint WFH-ISTH session: issues in clinical trial design. *Haemophilia*. 2014 May;20 Suppl 4:137-44. doi: 10.1111/hae.12415. PubMed PMID: 24762289.
- 148) Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Evaluation of an automated method for measuring von Willebrand factor

- activity in clinical samples without ristocetin. *Int J Lab Hematol*. 2014 Jun;36(3):341-51. doi: 10.1111/ijlh.12218. PubMed PMID: 24750681.
- 149) Jacskon SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. *Haemophilia*. 2014 May;20(3):e199-204. doi: 10.1111/hae.12391. Epub 2014 Mar 3. PubMed PMID: 24589126.
- 150) Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. *Haemophilia*. 2014 Mar;20(2):200-6. doi: 10.1111/hae.12283. Epub 2013 Oct 29. PubMed PMID: 24533949.
- 151) Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. *Haemophilia*. 2014 Jul;20(4):527-34. doi: 10.1111/hae.12371. Epub 2014 Jan 29. PubMed PMID: 24471912.
- 152) Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. *Haemophilia*. 2014 Jan;20(1):44-51. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PubMed PMID: 23902228.

Year 2015 (n=29)

- 153) Rizwan I, Minuk L, Jackson S, Iorio A. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. *Haemophilia*. 2015 May;21(3):e15666. doi: 10.1111/hae.12596. Epub 2014 Nov 24 PMID: 25420604
- 154) McCarthy A, Moore A, Redhead L, McLaughlin P, Iorio A, Chowdary P. Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. *Haemophilia*. 2015 Jan;21(1):11623. doi: 10.1111/hae.12500. Epub 2014 Nov 24. PMID: 25421726
- 155) Nugent D, Kalnins W, Querol F, Gregory M, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. *Haemophilia*. 2015 Jan;21(1):e26-38. doi: 10.1111/hae.12545. Epub 2014 Nov 7. PMID: 25377442.
- 156) Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. *Haemophilia*. 2015 Mar;21(2):2049. doi:

- 10.1111/hae.12550. Epub 2014 Oct 2. PMID: 25274155.
- 157) Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA. J Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. *Thromb Haemost*. 2015 May;13(5):775-81. doi: 10.1111/jth.12871. Epub 2015 Mar 12. PMID: 25660555
- 158) Lawrence Mbuagbaw, MD, Bhairavi Sivaramalingam, MD, Tamara Navarro, Nicholas Hobson, Arun Keepanasseril, MD, Nancy J. Wilczynski, R. Brian Haynes, MD, and the Patient Adherence Review (PAR) Team. Interventions for Enhancing Adherence to Antiretroviral Therapy (ART): A Systematic Review of High Quality Studies. *AIDS Patient Care and SDIs*. 2015 29(5):248-266. (Iorio A listed in the PAR team members)
- 159) Alfonso Iorio, Frederick A Spencer, Maicon Falavigna, Carolina Alba, Eddie Lang, Bernard Burnand, Tom McGinn, Jill Hayden, Katrina Williams, Beverly Shea, Robert Wolff, Ton Kuipers, Pablo Perel, Per Olav Vandvik, Paul Glasziou, Holger Schunemann, Gordon Guyatt. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015;350:h870. doi: 10.1136/bmj.h870. No abstract available. PMID: 25775931
- 160) S. Corrao, C. Argano, A. Nobili, M. Marcucci, C.D. Djade, M. Tettamanti, L. Pasina, C. Franchi, A. Marengoni, F. Salerno, F. Violi, P.M. Mannucci, F. Perticone, on behalf of REPOSI Investigators. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. *European Journal of Internal Medicine* 26 (2015) 243-249. (Iorio A listed in the REPOSI team members)
- 161) Marengoni A, Nobili A, Corli O, Djade CD, Bertoni D, Tettamanti M, Pasina L, Corrao S, Salerno F, Marcucci M, Mannucci PM; REPOSI investigators. The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. *Intern Emerg Med*. 2015 Apr;10(3):305-13. doi: 10.1007/s11739-014-1131-2. Epub 2014 Sep 24. PubMed PMID: 25248643. (Iorio A in the REPOSI team author list)
- 162) Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. *Eur J Intern Med*. 2015 May;26(4):243-9. doi: 10.1016/j.ejim.2015.02.018. Epub 2015 Mar 5. PubMed PMID: 25749554. (Iorio A in the REPOSI team author list)
- 163) Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F, Biganzoli EM, Nobili A, Mannucci PM; REPOSI Investigators. Adherence to antibiotic treatment guidelines and

- outcomes in the hospitalized elderly with different types of pneumonia. *Eur J Intern Med.* 2015 Jun;26(5):330-7. doi: 10.1016/j.ejim.2015.04.002. Epub 2015 Apr 18. PubMed PMID: 25898778. (Iorio A in the REPOSI team author list)
- 164) Santalucia P, Franchi C, Djade CD, Tettamanti M, Pasina L, Corrao S, Salerno F, Marengoni A, Marcucci M, Nobili A, Mannucci PM; REPOSI Investigators. Gender difference in drug use in hospitalized elderly patients. *Eur J Intern Med.* 2015 Sep;26(7):483-90. doi: 10.1016/j.ejim.2015.07.006. Epub 2015 Jul 22. PubMed PMID: 26209883. (Iorio A in the REPOSI team author list)
- 165) Bellelli G, Nobili A, Annoni G, Morandi A, Djade CD, Meagher DJ, MacLulich AM, Davis D, Mazzone A, Tettamanti M, Mannucci PM; REPOSI (REgistro POLiterapie SIMI) Investigators. Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. *Eur J Intern Med.* 2015 Nov;26(9):696-704. doi: 10.1016/j.ejim.2015.08.006. Epub 2015 Aug 31. PubMed PMID: 26333532. (Iorio A in the REPOSI team author list)
- 166) Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM; REPOSI Investigators. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. *Drugs Aging.* 2015 Dec 22. [Epub ahead of print] PubMed PMID: 26693921. (Iorio A in the REPOSI team author list)
- 167) Shannon C Jackson, Ming Yang, Leonard Minuk, Michelle Scholzberg, Jean St-Louis, Alfonso Iorio, Robert Card and Man-Chiu Poon. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. *BMC Hematology* (2015) 15:4. DOI 10.1186/s12878-015-0022-8. PMID: 25692030
- 168) Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escurlola Ettingshausen C, Iorio A, Nowak-Gottl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. *Thrombosis and Haemostasis.* 2015: 113/5 (May) 958-967. doi: 10.1160/TH14070621. Epub 2015 Jan 29. PMID: 25631402
- 169) Fisher K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M on behalf of EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European Haemophilia Safety Surveillance (EUHASS) project. *Thrombosis and Haemostasis.* 2015: 113/5 (May) 968-975. doi: 10.1160/TH14100826. Epub 2015 Jan 8. PMID: 25567324
- 170) Individualizing Factor Replacement Therapy in Severe Hemophilia. Carcao MD, Iorio A. *Semin Thromb Hemost.* 2015 Nov;41(8):864-71. doi: 10.1055/s00351552563. Epub 2015 Aug 13. PMID: 26270111
- 171) Mortality outcomes in patients receiving direct oral anticoagulants: a

- systematic review and meta-analysis of randomized controlled trials. Chai-Adisaksopa C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. *J J Thromb Haemost.* 2015 Nov;13(11):201220. doi: 10.1111/jth.13139. Epub 2015 Oct 5. PMID: 26356595
- 172) Marcucci M, Skjøth F, Lip GY, Iorio A, Larsen TB. A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in real-world population with atrial fibrillation. *Int J Cardiol.* 2015 Nov 6;203:785-790. Doi: 10.1016/j.ijcard.2015.11.035 PMID: 26595784
- 173) Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. *Cochrane Database Syst Rev.* 2015 Dec 16;12:CD004449. [Epub ahead of print] Review. PMID: 26677005
- 174) Palareti L, Poti S, Cassis F, Emiliani F, Matino D, Iorio A. Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study. *Int J Qual Stud health Well-being.* 2015 Nov 16;10:28915. Doi: 10.3402/qhw.v10.28915. eCollection 2015. PMID: 2657860 [PubMed – in process].
- 175) Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Vernooij RW, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martinez Garcia L, Mustafa RA, Ramirez-Morera A, Selva A, Sola I, Sanabria AJ, Tikkinen KA, Vandvik PO, Zazueta OE, Zhou Q, Schunemann H, Guyatt GH. Systematic reviews suffer from major limitations in reporting absolute effects. *J Clin Epidemiol.* 2015 Nov 8. Pii: S0895-4356(15)00505-3. Doi: 10.1016/j.jclinepi.2015.11.002. [Epub ahead of print] PMID: 26560992.
- 176) Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. *J Clin Invest.* 2015 Oct 1;125(10):376681. doi: 10.1172/JCI81859. Epub 2015 Aug 31. PMID: 26426076
- 177) Akl EA, CarrascoLabra A, BrignardelloPetersen R, Neumann I, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martínez García L, Mustafa RA, RamírezMorera A, Selva A, Solà I, Sanabria AJ, Tikkinen KA, Vandvik PO, Vernooij RW, Zazueta OE, Zhou Q, Guyatt GH, AlonsoCoello P. Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. *BMJ Open.* 2015 Sep 30;5(9):e009368. doi: 10.1136/bmjopen2015009368. PMID:

26423858 Free PMC Article

- 178) Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS Participants. Inhibitor development in nonsevere haemophilia across Europe. *Thromb Haemost*. 2015 Oct;114(4):6705. doi: 10.1160/TH14121044. Epub 2015 Aug 13. PMID: 26293381
- 179) Minuk L, Jackson S, Iorio A, Poon MC, Dilworth E, Brose K, Card R, Rizwan I, ChinYee B, Louzada M. Cardiovascular disease (CVD) in Canadians with haemophilia: Age Related CVD in Haemophilia Epidemiological Research (ARCHER study). *Haemophilia*. 2015 Nov;21(6):73641. doi: 10.1111/hae.12768. Epub 2015 Jul 29. PMID: 26222883
- 180) Strike KL, Iorio A, Jackson S, Lawson W, Scott L, Squire S, Chan AK. Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. *Haemophilia*. 2015 Nov;21(6):82831. doi: 10.1111/hae.12767. Epub 2015 Jul 24. No abstract available. PMID: 26208178
- 181) Fischer K, Iorio A, Hollingsworth R, Makris M; all EUHASS collaborators. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. *Haemophilia*. 2015 Jul 24. doi: 10.1111/hae.12764. [Epub ahead of print] No abstract available. PMID: 26208036
- 182) Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. *Haemophilia*. 2015 Nov;21(6):7315. doi: 10.1111/hae.12750. Epub 2015 Jul 14. PMID: 26179330
- 183) Berntorp E, Iorio A. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. *Blood*. 2015 Jun 11;125(24):38167. doi: 10.1182/blood201410608471. PMID: 26069334
- 184) Romanov V, Marcucci M, Cheng J, Thabane L, Iorio A. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post Authorization Safety Studies. *Thromb Haemost*. 2015 Jul;114(1):5664. doi: 10.1160/TH14100882. Epub 2015 May 28. PMID: 26017627

Peer reviewed abstracts published on scientific journals

- 1) Agnelli G, Iorio A, Alatri A, Boschetti E, Mazzolai L, Nenci GG, Ofosu F, Hirsh J. Plasma half-life of the anti-IIa activity of low molecular weight heparins assessed with a sensitive test (PTNA). *Thrombosis and Haemostasis*. 1993 69(6), 768.

- 2) Iorio A, Agnelli G, Leone M, Boschetti E, Nenci GG, Hirsh J. Enoxaparine shows a prolonged plasma half-life of its anti-IIa activity assessed with PTNA. *Annals of Haematology* 1993 66 (suppl 1) A24.
- 3) Iorio A, Agnelli G, Alatri A, Boschetti E, Nenci GG, Hirsh J: Prolonged plasma half-life of the anti-IIa activity of Enoxaparine assessed with a sensitive test (PTNA). *Thrombosis Research* 1993 70(suppl 1) S14.
- 4) A. Iorio, G. Agnelli, G.G. Nenci, A. Mele, R. Bürgi, J. Heim: Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). *Thrombosis Research* 1993, 70(suppl 1), S91.
- 5) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators: role of fibrinogen degradation products. *Thrombosis and Haemostasis* 1993, 69(6), 1337.
- 6) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators: role of fibrinogen degradation products. *Annals of Haematology* 1993; 66 (suppl 1): A31.
- 7) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG: Fibrinogen degradation products (FgDP) generation is the major determinant of platelet inhibition induced by plasminogen activators (PA). *Thrombosis Research* 1993, 70(suppl 1), S112.
- 8) G Agnelli, C Renga, M Leone, P Melelli, P Parise, A. Iorio, GG Nenci. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin twice a day. *Thrombosis and Haemostasis* 1993, 69(6), 857.
- 9) Iorio A, Agnelli G, Renga C, Leone M, Melelli P, Parise P, Nenci GG. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin b.i.d. *Annals of Haematology* 1993; 66 (suppl 1): A25.
- 10) G Agnelli, M Leone, P Melelli, C Renga, A. Iorio, GG Nenci Inhibition of fluid phase and clot-bound thrombin: effects of heparin, hirudin and a thrombin-inhibiting decapeptide (LU 58463). *Thrombosis and Haemostasis* 1993, 69(6), 1301.
- 11) Iorio A, Agnelli G, Leone M, Melelli P, Renga C, Nenci GG. Hirudin and PEG-Hirudin inhibit clot-bound thrombin more efficiently than heparin. *Annals of Haematology* 1993; 66 (suppl 1) A19
- 12) G. Agnelli, A. Iorio, E. Boschetti, G.G. Nenci, F. Ofosu, J. Hirsh. Low molecular weight heparins show prolonged anti-IIa plasma half-life. *Circulation* 1993; 88,4(2), 1200.

- 13) Iorio, F. Nucciarelli, M. Leone, G. Agnelli. Effects of dermatan sulfate on activated partial thromboplastin time determined with five different reagents. *Thromb Haemostas* 1995; 73: 1353.
- 14) Mozzi R, Andreoli V, Buratta S, Iorio A, Horrocks LA. Regulation of phosphatidylserine synthesis in rat cerebral cortex. *J Neurochem* 1994; 63(1): S23B.
- 15) A Iorio, G. Agnelli, S. Goldhaber, M. Levine. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. *Cardiologia* 1994; 39(2): 51.
- 16) G. Agnelli, C. Pascucci, A.M. Mezzasoma, A. Iorio. The displacement of non-specifically bound unfractionated heparin from plasma proteins produces an antithrombotic effect. *Thromb Haemostas* 1995; 73: 963.
- 17) S. Ricotta, A. Iorio, P. Parise, G. Agnelli. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Thromb Haemostas* 1995; 73: 1095.
- 18) S. Buratta, S. Porcellati, A. Iorio and R. Mozzi. Base exchange enzyme activity in porcine lyophilized platelets and the effect of heparin on PS synthesis by base exchange. *Italian Biochemical Society Transactions (IBST)* 1994; 5: 182.
- 19) Iorio, S. Ricotta, P. Parise, G. Agnelli. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Inter Angio* 1996; 15: 30.
- 20) Iorio, P. Parise, S.Z. Goldhaber, G. Agnelli for the BAPE Investigators. Fibrinogenolysis and thrombin activation after accelerated weight adjusted or conventional administration of rt-PA for pulmonary embolism. *Inter Angio* 1996; 15: 31.
- 21) Iorio, A. Alatri, V. Ranucci, S. Falconi, V. Pasqualucci, G. Agnelli. Prophylaxis for venous thromboembolism and spinal anaesthesia: results of a national survey. *Inter Angio* 1996; 15: 32.
- 22) G. Agnelli, A. Iorio, F. Abbadesse, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with AMI treated with a double rt-PA bolus and randomised to two different heparin regimens. *Haemostasis* 1996; 26(Suppl 3): 39A.
- 23) Ascani, A. Iorio, A.M. Stabile, G. Agnelli. Withdrawal of warfarin therapy after deep vein thrombosis: a randomized study on the effects of a very low fixed dose regimen. *Thromb Haemost* 1997; 78(Suppl 1): 335A.
- 24) G. Agnelli, F. Piovella, P. Buon cristiani, P. Severi, M. Pini, L. Crippa, G. Brambilla, M. Damiani, G. Andrioli, E. Giugni, S. Pasetti, G. Ghetti, C. Beltrametti, R.

- Pugliese, A. Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: a randomised double blind venography study. *Thromb Haemost* 1997;78(Suppl 1):1576A.
- 25)G. Agnelli, A. Iorio, F. Abbadesse, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Haemost* 1997;78(Suppl 1):2050A.
- 26)G. Agnelli, A. Iorio, F. Abbadesse, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Res* 1998;91(Suppl 1):89A
- 27)G. Agnelli, F. Piovello, P. Buoncristiani, P. Severi, M. Pini, L. Crippa, G. Brambilla, M. Damiani, G. Andrioli, E. Giugni, S. Pasetti, G. Ghetti, C. Beltrametti, R. Pugliese, A. Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: a randomised double blind venography study. *Thromb Res* 1998;91(Suppl 1):106A
- 28)M. Berrettini, G. Tagariello, G. Castaman, F.A. Scaraggi, A. Tagliaferri, M.G. Mazzucconi, F. Baudó, V. Trapani Lombardo, A. Iorio, G. Lucarelli, A. Sergi. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. *Thromb Res* 1998;91(Suppl 1):107A
- 29)D. Guidetti, E. Bellesia, G. Rinaldi, A. Iorio, A. Pilia, M. Brini. Hemocoagulative and molecular biology parameters in 100 cerebrovascular patients. *Thromb Res* 1998;91(Suppl 1):129A
- 30)Iorio, A. Pilia, G. Rinaldi, M. Silingardi, A. Ghirarduzzi, I. Iori, M. Brini. Antiphospholipid antibodies: economic evaluation of an automated screening protocol. *Thromb Res* 1998;91(Suppl 1):131A
- 31)G. Rinaldi, E. Bellesia, A. Iorio, A. Pilia, A. Ghirarduzzi, M. Silingardi, C.A. Zotti, A. Fanti. Factor V Leiden in young patients with retinal vein occlusion. *Thromb Res* 1998;91(Suppl 1):132A
- 32)G. Rinaldi, E. Bellesia, A. Iorio, A. Pilia, A. Ghirarduzzi. Factor V Leiden and G26210A variation of the prothrombin gene identification by the use of one-step multiplex PCR mediated site-directed mutagenesis. *Thromb Res* 1998;91(Suppl 1):133A
- 33)Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Ascani A., Bazzan M., Alatri A., Guazzaloca G., Bertoldi A., Tomasi C., Scannapieco G., Ageno W., Iorio A. 1999 Three months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the warfarin optimal duration

- italian trial (WODIT). Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2164
- 34) Iorio A., Agnelli G. 1999 Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery: a metanalysis. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2059
- 35) Buratta S., Iorio A., Andreoli V., Mambrini R., Porcellati S., Mozzi R. 1999 Serine base-exchange enzyme in commercially available porcine lyophilized platelets: different effect of unfractionated and low molecular weight heparin. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2137
- 36) Schiatti C., Iorio A., Rinaldi G., Silingardi M., Ghirarduzzi A., Guidetti D., Iori I., Brini M. 1999 Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2440
- 37) Silingardi M., Salvarani C., Rinaldi G., Ghirarduzzi A., Boiardi L., Iorio A., D'Inca M., Cantini F., Govoni M., Salvi F. 1999 Prothrombin 202120A mutation in Behcet's disease. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2112
- 38) Ghirarduzzi A., Iorio A., Silingardi M., D'Inca M., Rinaldi G., Iori I. 1999 Different management of oral anticoagulant therapy in patients with mechanical prosthetic heart valves: prospective cohort study. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2147
- 39) Ghirarduzzi A., Iorio A., Silingardi M., D'Inca M., Tincani E., Galimberti D., Rinaldi G., Iori I. 1999 Elderly patients treated with oral anticoagulant: a prospective cohort study. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 2148
- 40) Berrettini M., Bura A., Lucarelli G., Tagariello G., Castaman G., Scaraggi F., Tagliaferri A., Mazzucconi M., Baudo F., Trapani Lombardo V., Iorio A. 1999 . The role of thrombophilic states in the bleeding tendency of patients with hemophilia. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 1544
- 41) Agnelli G., Airolidi G., Brambilla G., Buoncristiani P., Severi P., Pasetti S., Giugni E., Iorio A. 1999 Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. Thrombosis And Haemostasis (0340-6245), Supplemento 1, 81, 16
- 42) Iorio A., Silingardi M., Tascadda T., Ghirarduzzi A., Guidetti D., Iori I., Brini M. 2000 Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients. Haematologica (0390-6078), Supplemento 5, 85, 57, PO-126

- 43) Silingardi M., Iorio A., Ghirarduzzi A., D'Inca M., Galimberti D., Tincani E., Iori I. 2000 Hyperhomocysteinemia and retinal vein occlusion. *Haematologica* (0390-6078), Supplemento 5, 85, 58, PO-127
- 44) Agnelli G., Airolidi G., Brambilla G., Buoncristiani P., Severi P., Pasetti S., Giugni E., Iorio A. 2000 Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. *Haematologica* (0390-6078), Supplemento 5, 85, 88, CO-194
- 45) M. Silingardi, A. Ghirarduzzi, A. Iorio, G. Rinaldi, C.A. Zotti, A. Fanti. Central retinal vein occlusion in homozygous factor V Leiden. *Thromb Res* 1998;91(Suppl 1):134°
- 46) Ghirarduzzi, A. Iorio, M. Silingardi, G. Rinaldi, D. Galimberti, I. Iori. Different management of oral anticoagulant therapy: a prospective cohort study. *Thromb Res* 1998;91(Suppl 1):135A
- 47) Iorio A., Agnelli G. 2000 Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Haematologica* (0390-6078), Supplemento 5, 85, 128, PO-286
- 48) Filippucci E., Agnelli G., Leone M., Iorio A., Nenci G.G. 2000 Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor. *Haematologica* (0390-6078), Supplemento 5, 85, 139 PO-309
- 49) Buratta S., Iorio A., Tascetta T., Andreoli V., Mambrini R., Porcellati S., Mozzi R. 2000 Serine base exchange enzyme in commercially available porcine lyophilised platelets: different effect of unfractionated and low molecular weight heparins. *Haematologica* (0390-6078), suppl. 5, 85, 120, PO-267
- 50) Ghirarduzzi A., Tascetta T., Silingardi M., Galimberti D., D'Inca M., Nicolini A., Cattabiani L., Brini M., Iorio A. 2001 Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P2944
- 51) Tascetta T., Silingardi M., Ghirarduzzi A., Iori I., Brini M., Iorio A. 2001 APTT evaluation in the presurgery screening: survey of 5000 patients. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, CD3324
- 52) Silingardi M., Ghirarduzzi A., Iori I., Salvarani C., Boiardi L., Bellesia E., Tascetta T., Morini L., Galimberti D., Cantini F., Govoni M., Salvi F., Iorio A. 2001 Factor V Leiden and G20210A prothrombin allele are not associated with thrombosis in Behcet's disease. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P2519
- 53) Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Farnetti E., Bellesia E., Tascetta

- T., Silingardi M., Morini L., Guiducci U., Iori I. 2001 Genima study: genetic polymorphisms and myocardial infarction among italian young adults. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P1571
- 54)Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Tascetta T., Silingardi M., Guiducci U., Iori I. 2001 Studio GEMINA: ruolo dei polimorfismi genetici e dell'omocisteinemia nell'infarto del miocardico in giovani-adulti italiani. *Italian Heart Journal* (1129-471X), suppl.6, 2, 67
- 55)Iorio A., Guercini F., Pini M. 2002 Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparison with oral anticoagulant. *Haematologica* (0390-6078), suppl.5, 87, 31
- 56)Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Bellesia E., Silingardi M., Nicolini A., Guiducci U., Iori I. 2002 Gemina study:genetic polymorphisms and myocardial infarction among italian young adults. *Haematologica* (0390-6078), suppl.5, 87, 69
- 57)Iorio A., Accardo P., Bellesia E., Tascetta T., Tonelli L., Brini M. 2002 Feasibility of the use of filtered plasma in the automated screening test for activated protein C resistance. *Haematologica* (0390-6078), suppl.5, 87, 93
- 58)Ghirarduzzi A., Silingardi M., Cattabiani L., Nicolini A., Tonelli L., Iorio A. 2002 Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Haematologica* (0390-6078), suppl.5, 87, 94
- 59)Guercini F., Pini M., Iorio A. 2002 Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months. *Haematologica* (0390-6078), suppl.5, 87, 127
- 60)Nicolini A., Ghirarduzzi A., Silingardi M., Iorio A., Baldi G. 2002 Intracranial bleeding in Reggio Emilia: epidemiology and relationships with antithrombotic treatment. *Haematologica* (0390-6078), suppl.5, 87, 128
- 61)Conti S., Guercini F., Pini M., Iorio A. 2002 Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature. *Pathophysiology Of Haemostasis And Thrombosis* (1424-8832), suppl.2, 32, 51
- 62)Iorio A., Guercini F., Pini M. 2002 Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulant. *Pathophysiology Of Haemostasis And Thrombosis* (1424-8832), suppl.2, 32, 71
- 63)Massi Benedetti M., Brunetti P., Iorio A., Ferolla P., Stabile A., Akwe J., Canonico V., Celleno R., Timi A. 2003 Acute ketoacidosis in continuous subcutaneous

- insulin infusion treated Type 1 diabetics impairs the fibrinolytic capacity. *Diabetes & Metabolism* (1262-3636), 29, 4S361 (2738)
- 64)Ghirarduzzi A., Iorio A., Nicolini A., Silingardi M., Cattabiani L., Belloni L., Iori I. 2003 1286 Prospective consecutive cases of venous thromboembolic diseases at the single Venous thromboembolic Unit of Reggio Emilia. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, 1286a, P1444
- 65)Iorio A., Testa S., Parisoli A., Alatri A., Franzoni M., Trottini S., Cinotti R., Rinaldi G., Ghirarduzzi A. 2003 Clinical quality assessment program for the oral anticoagulant clinic. Preliminary report of a multicentric italian exercise. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1965
- 66)Paccamiccio E., Trottini S., Rosafalco M., Filippucci E., Duca E., Vecchioli M., Nenci G.G., Iorio A. 2003 Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS). *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1956
- 67)Accardo P., Ghirarduzzi A., Silingardi M., Franzoni M., Iorio A. 2003 Clinical and laboratoristic performance evaluation of three point-of-care devices for INR determination (Coagucheck, ProTime, Harmony). *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1966
- 68)Iorio A., Guercini F., Conti S., Pini M. 2003 Low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism: metanalysis of the randomized comparisons with oral anticoagulants. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1873
- 69)Silingardi M., Fornaciari G., Beltrami M., Iorio A., Ghirarduzzi A., D'Incà M., Negri E., Nicolini A., Morini L., Iori I. 2003 Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0463
- 70)Iorio A., Ferolla P., Orsini Federici M., Celleno R., Stabile A., Canonico V., Massi Benedetti M. 2003 Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0957
- 71)Mancuso M., Santagostino E., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolini R., Rumi M., De Filippi F., Colombo M., Mannucci P. 2004 Sustained suppression of hepatitis C by pegylated Interferon (PEG-INF) and Ribavirin in hemophilic patients. *Haematologica* (0390-6078), September, 89, 30
- 72)Iorio A., Ferrante F., Conti S., Nenci G.G. 2004 LMWH or Ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials. *Haematologica* (0390-6078), 89, 37

- 73) Castori L., Depunzio I., Servettini I., Ferrante F., Carloni D., Iorio A. 2004 Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications. *Haematologica* (0390-6078), September, 8, 89, 58
- 74) Ghirarduzzi A., Nicolini A., Iotti M., Iorio A., Baldi G. 2004 Intracranial bleeding: relationship with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. *Haematologica* (0390-6078), September, 8, 89, 61
- 75) Ferrante F., Ghirarduzzi A., Silingardi M., Franzoni C., Iorio A. 2004 Clinical and laboratory performance evaluation of three point-of-care devices for INR determination (Coagucheck, Prottime, Harmony). *Haematologica* (0390-6078), September, 8, 89, 62
- 76) Iorio A., Minciotti A., Ferrante F., Nenci G.G. 2004 Pharmacoeconomic evaluation of the management of oral anticoagulant treatment with point-of-care devices in the Italian national health care system. *Haematologica* (0390-6078), 89, 63,
- 77) Ferrante F., Bifarini B., Tesoro S., Peduto F., Iorio A. 2004 Coagulation screening for otorhinolaryngoiatric surgery: a pharmacoeconomic appraisal in the setting of the Italian national health system. *Haematologica* (0390-6078), September, 8, 89, 81
- 78) Iorio A., Orsini Federici M., Ferrante F., Stabile A., Galli F., Massi Benedetti M. 2004 Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients. *Haematologica* (0390-6078), September, 8, 89, 119
- 79) Guercini F., Conti S., Iorio A. 2004 Low-molecular-weight heparin and cancer survival: pooled analysis of 1726 patients treated for three months. *Haematologica* (0390-6078), September, 8, 89, 133
- 80) Altomonte F., Altomonte M., Iorio A., Ghirarduzzi A., Ricciardi A., Remollino V., Spinsi L., Saporito A., Caiazza A., Musso G., Cervellin G., Lamberti S., Buzzalino M., De Giorgi F., Del Prato C., Golinelli M., Gai V., Monsù R., Giofrè M., Giovanari D., Cattaneo S., Frumento F., Caporrella A., Re G., De Iaco F., Bologna G., Nocenti F., Lorenzi C., Zoratti R., Sciolla A., Tiscione V., Pastorello M., Vandelli A., Villa A., Zanna M., De Palma A. 2004 Ecaps study: multicentric evaluation of cerebral hemorrhage in anticoagulated/antiaggregated patients in the Italian emergency rooms. *Haematologica* (0390-6078), September, 8, 89, 152
- 81) Ghirarduzzi A., Iotti M., Cattabiani L., Ieran M., Iorio A., Silingardi M., Iori I. 2004 Venous thromboembolic disease: clinical features of 1282 prospective consecutive cases at angiology unit of Reggio Emilia. *Haematologica* (0390-6078), September, 8, 89, 161
- 82) Paccamiccio E., Ferrante F., Trottini S., Rosafalco M., Duca E., Vecchioli M., Nenci G.G., Iorio A. 2004 OAT with POC devices and remote computer monitoring in

- the setting of the Italian NHS: a controlled clinical trial. *Haematologica* (0390-6078), 89, 180-1
- 83) Ferrante F., Paccamiccio E., Servettini I., Iorio A. 2004 Quality control programs for POC devices to measure INR. Results of a pilot exercise. *Haematologica* (0390-6078), September, 8, 89, 181
- 84) Mackensen S., Gringeri A., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A., Molinari C. 2004 Development of disease-specific quality of life questionnaire for adult patients with hemophilia (HAEM-A-QOL). *Haematologica* (0390-6078), September, 8, 89, 186
- 85) Mackensen S., Gringeri A., Mantovani I., Skovlund S., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A. 2004 Development and validation of the first treatment satisfaction scale for adult hemophiliacs (HEMO-SAT). *Haematologica* (0390-6078), September, 8, 89, 191
- 86) Iorio A., La Torre D., Conti S., Gambelunghe G. 2004 Successful treatment of spontaneous intracerebral haemorrhage in a patient with prosthetic mechanical heart valves. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 9
- 87) Iorio A., Chantarangkul V., Ferrante F., Tripodi A. 2004 Hemo Web, a web-based tool to handle the external quality control program for the hemophilia center coagulation laboratory. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 17
- 88) Mancuso M., Santagostino E., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolini R., Rumi M., De Filippi F., Colombo M., Mannucci P. 2004 Sustained suppression of hepatitis C by pegylated interferon (pegINF) and ribavirin in hemophilic patients. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 48
- 89) Von Mackensen S., Gringeri A., Mantovani L., Skovlund S., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A. 2004 Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo0-SatA). *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 126
- 90) Baudo F., Gaidano G., Carloni M., Coppola A., Iorio A., Marietta M., Marongiu F., Mazzucconi M., Miraglia E., Schiavoni M., Schinco P., Fariciotti A. 2004 Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0596
- 91) Stobart K., Iorio A. Systematic Review of Randomized Controlled trials of prophylactic clotting factor concentrate in Hemophilia. *Blood* 2005, November 16, issue 11, 106, abstract 3114, Session Type: Poster Session 365-III

- 92) Mancuso M., Santagostino E., Rumi M., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolin R., Colombo M., Mannucci P. High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. *Blood* 2005, November 16, issue 11, 106, abstract 3219
- 93) Giuliano V., Castellani D., Clerici C., Morelli O., Iorio A., Sabatino G., Baldoni M., Palmerini F., Ascitti S., Morelli A. Oral Anticoagulants and small intestinal bacterial overgrowth. *Canadian journal of gastroenterology* 2005, September, Suppl B, 19
- 94) Baldi G., Altomonte F., Altomonte M., Ghirarduzzi A., Brusasco C., Parodi R., Conti S., Iorio A. 2005 Determinants of Mortality in Cerebral Hemorrhage Patients on Antithrombotic Treatment: Prospective Evaluation in the Italian Emergency Departments of a Multicentric Cohort of 1071 Patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), August , suppl 1, 3, P0257
- 95) Iorio A., Guercini F., Ferrante F., Nenci G.G. 2005 Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism. *Journal Of Thrombosis And Haemostasis* (1538-7933), August , Suppl 1, 3, P1613
- 96) Ferrante F., Fattorini L., Bifarini B., Tesoro S., Depunzio I., Peduto V., Iorio A. 2005 Coagulation Screening for Otorhinolaryngoiatric Surgery: A Pharmacoeconomic Appraisal in the Setting of the Italian National Health System. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P0249
- 97) Ferrante F., Paccamiccio E., Iaboni S., Iorio A. 2005 Validation of Laboratory Reference Standard for Clinical Use of INR-POC Devices: A Randomized Multicentre Exercise. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P1733
- 98) Giuliano V., Iorio A., Castellani D., Gizzi S., Palmerini F., Sabatino G., Morelli O., Clerici C., Filippucci E., Baldoni M., Nenci G.G., Morelli A. 2005 Host-Drug Interaction: The Influence of Small Intestinal Bacterial Overgrowth on Oral Anticoagulant Dose Requirement. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl 1, 3, P2219
- 99) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A., Iorio A. 2005 Absence of Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P1027
- 100) Mancuso M., Santagostino E., Rumi M., De Filippi F., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolin R., Colombo M., Mannucci P. 2005 Pegylated Interferon and Ribavirin Anti-hepatitis C Therapy

- in Patients with Hemophilia Is as Effective and Safe as in Non-hemophilic Patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P0218
- 101) Palareti G., Tosetto A., Cosmi B., Legnani C., Brusi C., Pengo V., Ghirarduzzi A., Pattacini A., Testa S., Iorio A., Tripodi A. 2005 The D-dimer (DD) Test to Establish the Duration of Anticoagulation after a First Unprovoked Episode of Venous Thromboembolism (VTE); the Prospective Randomized 'Prolong' Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, H02
- 102) Mantovani L., Monzini M., Mannucci P., Scalone L., Villa M., Gringeri A., for the Conan Study Group -. 2005 Differences between patients', physicians' and pharmacists 'preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia* (Oxford. Print) (1351-8216), 11, 589-597, Iorio A è elencato tra All contributors participating in patients' enrollment and in collecting data
- 103) Belvini D., Salviato R., Radossi P., Pierobon F., Mori P., Castaldo G., Tagariello G., AICE HB study group -. 2005 Molecular genotyping of the Italian cohort of patients with hemophilia B. *Haematologica* (0390-6078), 90, 635-642, Iorio A è elencato in Appendice come responsabile del Centro Emofilia di Perugia
- 104) v Mackensen S., Gringeri A., Ravera S., the HAEM-A-QoL G., 2005 Validation of the Haemophilia-specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL). 10th Anniversary Congress of the European Hematology Association (EHA), Stockholm, Sweden, June 2-5, Iorio A. è elencato come membro del HAEM-A-QoL Group
- 105) v Mackensen S., Gringeri A., the HAEM-A-QoL Group -. 2005 Health-related Quality of Life in Adult Patients with Haemophilia-Assessment with a New Disease-specific Questionnaire (Haem-A-QoL). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl.1, vol.3, P0813, Iorio A. è elencato come membro del Ham-A-QoL Study Group
- 106) V Mackensen S., Gringeri A., Skovlund S., Hemo-Sat Study Group -, 2005 Assessment of Treatment Satisfaction in Patients with Haemophilia-Development and Validation of the First Disease-Specific Questionnaire (Hemo-SatA). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl.1, vol.3, P1999, Iorio A. è elencato come membro del Hemo -Sat Study Group
- 107) Iorio A., Camilloni B., Basileo M., Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Iorio A. 2005 Influenza vaccination in patients on long-term anticoagulant therapy. The Second European Influenza Conference, Malta, 11-14 september
- 108) Camilloni B., Iorio A.M., Neri M., Lepri E., Ferrante F., Guercini F., Iaboni S.,

- Paccamiccio E., Iorio A. 6th National Congress of the Italian Society of Virology a joint meeting with the Virus Group of the Society for General Microbiology (UK). Orvieto (TR), 18-20 september 2006, 79 tris; 78 2006
- 109) Iorio A., Giuliano V., Bassotti G., Castellani D., Filippucci E., Palmerini F., Morelli O., Clerici C., Baldoni M., Gizzi S., Agnelli G., Morelli A. Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica* (0390-6078), September, suppl 2, 91, (C036) 11 2006
- 110) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A.M., Iorio A. The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica* (0390-6078), September, suppl 2, 91, (C038) 11 2006
- 111) Iorio A., Gringeri A., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica* (0390-6078), September, suppl 2, 91, (C074) 22 2006
- 112) Iorio A., Stobart K. Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica* (0390-6078), September, suppl 2, 91, (C075) 23 2006
- 113) Guercini F., Ferrante F., Nenci G.G., Iorio A. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica* (0390-6078), September, suppl 2, 91, (P041) 56 2006
- 114) Iorio A., Giuliano V., Bassotti G., Castellani D., Filippucci E., Palmerini F., Morelli O., Clerici C., Baldoni M., Gizzi S., Agnelli G., Morelli A. 2006 Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica* (0390-6078), September, suppl 2, 91, September, (C036) 11
- 115) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A.M., Iorio A. 2006 The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica* (0390-6078), September, suppl 2, 91, (C038) 11
- 116) Iorio A., Gringeri A., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. 2006 The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica* (0390-6078), September, suppl 2, 91, (C074) 22
- 117) Iorio A., Stobart K. 2006 Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica* (0390-

- 6078), September, suppl 2, 91, (C075) 23
- 118)Guercini F., Ferrante F., Nenci G.G., Iorio A. 2006 Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica* (0390-6078), September, suppl 2, 91, (P041) 56
- 119)Iorio A. [Correspondent Author], Gringeri A., Iannaccaro P., Morfini M., Scaraggi A., Schiavoni M. 2006 The Haemophilia Registry of the Italian association of haemophilia centres: methodology and preliminary analysis. *Haemophilia* (1351-8216), (suppl 2), 12, 33
- 120)Dragani A., Marchesini E., Carloni M., Oliovecchio E., Ferrante F., Iuliani O., Agnelli G., Iorio A. 2007 HAEMOPHILIA MANAGEMENT THROUGH AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12, M-127
- 121)Iorio A. [Correspondent Author], Stobart K. 2007 SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS OF PROPHYLACTIC CLOTTING FACTOR CONCENTRATE IN HEMOPHILIA. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva , 2007, July 6–12 , P-M-128
- 122)Iorio A.[Correspondent Author], Gringeri A., Hassan J., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. 2007 THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva , 2007, July 6–12 , P-M-129
- 123)Iorio A.[Correspondent Author], Marchesini E., Agnelli G. 2007 ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-M-147
- 124)Iorio A.[Correspondent Author], Marchesini E., Falco A., Caso M., Pastorello M., Tiscione V., Ballarino P., Altomonte F., Baldi G., Agnelli G., Toni D. 2007 RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-T-162
- 125)Santagostino E., Coppola A., Tagliaferri A., Mancuso M., Scaraggi F., Biasoli C., Schinco P., Iorio A., Latella C., Di Minno G. 2007 IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS: THE

ITALIAN RETROSPECTIVE-PROSPECTIVE REGISTRY - THE PROFIT STUDY. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-W-128

- 126) Santoro C., Iorio A., Pignoloni P., Rago A., Biondo F., Ferrante F., Agnelli G., Mazzucconi M. 2007 OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII (BDD-RFVIII) CONCENTRATE USING CHROMOGENIC AND ONE-STAGE ASSAYS WITH POOLED NORMAL PLASMA (PNP) AND REFAC TO LABORATORY STANDARD (RLS). Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva , 2007, July 6–12 , P-W-129
- 127) A Iorio, J. Douketis, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto D-DIMER TO PREDICT THROMBOSIS RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: EFFECT OF PATIENT- AND D-DIMER-RELATED FACTORS ON RECURRENCE PREDICTION. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1 OC-TH-002
- 128) Tosetto, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, J. Douketis CLINICAL PREDICTION GUIDE TO PREDICT THROMBOSIS RECURRENCE AFTER A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. OC-TH-004
- 129) Iorio, C. Kearon, E. Filippucci, M. Marcucci, V. Pengo, G. Agnelli, G. Palareti VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-MO-282
- 130). Douketis, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto DOES THE CLINICAL PRESENTATION OF VENOUS THROMBOEMBOLISM PREDICT THE RISK FOR AND TYPE OF THROMBOSIS RECURRENCE? Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-WE-286
- 131). Douketis, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto DOES PATIENT SEX AND PRIOR HORMONAL THERAPY PREDICT RISK FOR THROMBOSIS RECURRENCE AFTER A FIRST VENOUS THROMBOEMBOLISM? Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. AS-TH-005
- 132) M. Marcucci, A. Iorio, J. Douketis, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto D-DIMER TO PREDICT THROMBOSIS RECURRENCE: COMPARISON OF AGGREGATE DATA AND INDIVIDUAL PATIENT DATA META-ANALYSES. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-TH-412

- 133) M. Basileo, E. Filippucci, S. Iaboni, P. Grilli, M. Vecchioli, G. Agnelli, A. Iorio COMPUTER ASSISTED VKA MONITORING WITH POINT OF CARE DEVICE BY GENERAL PRACTITIONERS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-MO-457
- 134) Iorio, E. Filippucci, M. Basileo, S. Iaboni, E. Paccamiccio, M. Vecchioli, G. Agnelli PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-MO-458
- 135) Zanon, L. Spiezia, E. Santagostino, A. Coppola, A. Tagliaferri, G. Rossetti, A. Iorio, R. Santoro, A. Dragani, A. Giuffrida, R. Musso, G. Mancuso, G. Castaman, G. Gamba, G. Mazzucconi, M. Lapecorella INTRACRANIAL HAEMORRHAGE IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. AS-TU-032
- 136) Iorio, M. Marcucci, E. Marchesini, P. Mannucci PLASMA DERIVED (PD) AND RECOMBINANT (R) FACTOR VIII (FVIII) CONCENTRATES INDUCE A DIFFERENT RATE OF INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS. A SYSTEMATIC REVIEW OF THE LITERATURE. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. OC-MO-035
- 137) G. Tagariello, A. Iorio, E. Santagostino, M. Morfini, R. Bisson, M. Innocenti, M. Mancuso, M. Mazzucconi, G. Pasta, P. Radossi, G. Rodorigo, C. Santoro, R. Sartori, A. Scaraggi, L. Solimeno, P. Mannucci COMPARISON OF THE RATES OF JOINT ARTHROPLASTY IN PATIENTS WITH SEVERE FACTOR VIII AND IX DEFICIENCY: AN INDEX OF DIFFERENT CLINICAL SEVERITY OF THE TWO COAGULATION DISORDERS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-MO-542
- 138) M. Marcucci, G. Fabbriani, M. Brozzetti, A. Iorio BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSIS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-WE-529
- 139) Coppola, M. Margaglione, E. Santagostino, A. Rocino, F. Scaraggi, A. Tagliaferri, G. Castaman, M. Messina, M. E. Mancuso, A. Iorio, P. Schinco, E. Zanon, R. Musso, G. Mancuso, G. Di Minno, P. Mannucci FACTOR VIII GENE (F8) MUTATIONS AS A PREDICTOR OF OUTCOME IN IMMUNE TOLERANCE INDUCTION (ITI) IN HEMOPHILIA A PATIENTS WITH HIGH-RESPONDING INHIBITORS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. OC-TU-075
- 140) S. M. Siboni, E. Zanon, G. Sottilotto, D. Mikovic, A. Iorio, G. Castaman, M. Mazzucconi, P. M. Mannucci, F. Peyvandi CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PATIENTS WITH RARE BLEEDING DISORDERS (RBDS) . *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. AS-TU-033
- 141) Iorio, A. Rocca, S. Pizzinelli MULTICENTRIC EVALUATION OF CURRENT

- DOSING PRACTICE OF RECOMBINANT FIX IN ITALY. *Journal of Thrombosis and Haemostasis*, 2007; 9: Suppl 1. PP-TH-654
- 142) M. Basileo, M. Marchesi, E. Marchesini, M. Materazzi, A. Germani, L. Rocchetti, C. Silvani, A. Iorio AUDIT OF THE CLINICAL USE OF FRESH-FROZEN PLASMA IN UMBRIA: STUDY DESIGN AND RESULTS. *Journal of Thrombosis and Haemostasis*, 2007; 9: Suppl 1. PP-WE-688
- 143) Santoro, F. Ferrante, A. Iorio, F. Biondo, P. Pignoloni and M. Mazzucconi. Pharmacokinetics of reformulated B-domain deleted recombinant factor VIII (BDD-rFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (03 PO 08)
- 144) Iorio, S. Pizzinelli and F. Ferrante. Replacement therapy with recombinant FIX – multicentre evaluation of current dosing practice in Italy. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (03 PO 26)
- 145) Iorio, E. Oliovecchio,* E. Zanon, M. Mazzucconi, A. Accorsi and M. Luciani. The haemophilia registry of the Italian Association of Haemophilia Centres. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (03 PO 26)
- 146) E. Zanon, A. Coppola, A. Tagliaferri, G. Rossetti, M. Lapecorella, A. Dragani, F. Peyvandii, E. Santagostino, A. Iorio and R. Santoro. Haemophilia A and B and other rare bleeding disorders: an Italian retrospective survey on the intracranial haemorrhagic episodes. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (05 PO 16)
- 147) Iorio, E. Marchesini, F. Ferrante, E. Oliovecchio and L. Lotte Gluud. Antiviral therapy for chronic hepatitis C in haemophilia patients with human immunodeficiency virus. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (07 PO 08)
- 148) F. Ferrante, A. Iorio, B. Camilloni, M. Basileo, G. Tagariello and A. Iorio. Inhibitor development in mild/moderate haemophilia: could influenza vaccination have been the trigger? *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (08 PO 17)
- 149) G. Tagariello, E. Santagostino, M. Morfini, A. Iorio, M. Innocenti, M. Mancuso, G. Pasta, P. Radossi, G. Rodrigo, C. Santoro, R. Sartori, A. Scaraggi and L. Solimeno. Lower than expected frequency of prosthetic surgery in patients with haemophilia B and chronic arthropathy: data from the Italian registry for surgery in haemophilia. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (12 PO 89)
- 150) Iorio, M. Basileo, E. Marchesini, L. Rocchetti, M. Marchesi and C. Silvani. Critical appraisal of five international guidelines on fresh frozen plasma clinical use. *Haemophilia* (2008), 14 (Suppl. 2), 1–120 (13 PO 25)
- 151) Iorio A. THE ITALIAN REGISTRY OF HEMOPHILIA AND ALLIED DISORDERS: A TOOL TO HELP HEALTH CARE PLANNING FOR A RARE DISEASE. 13^o Triennial

Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008 (1) s3

- 152) Tagliaferri A., Franchini M., Rivolta G.F., Iorio A., Mannucci P.M., AICE. FINAL RESULTS FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTERS (AICE) SURVEY ON THE CAUSES OF DEATH AMONG ITALIAN HEMOPHILIACS. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO023
- 153) Tagariello G., Iorio A., Santagostino E., Morfini M., Innocenti M., Mancuso M.E., Pasta P.L., Radossi P., Rodorigo G., Santoro C., Sartori R., Scaraggi A., Solimeno L.P. HEMOPHILIA B PATIENTS HAVE A LOWER RISK TO UNDERGO ORTHOPAEDIC SURGERY THAN HEMOPHILIA A PATIENTS: RESULTS FROM AN ITALIAN COHORT STUDY AND REVIEW OF THE LITERATURE. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO032
- 154) Zanon E., Spiezia L., Santagostino E., Peyvandi F., Coppola A., Tagliaferri A., Rossetti G., Iorio A., Santoro R., Lapecorella M., Mazzucconi G., Dragani A., Giuffrida A., Gamba G., Giancarlo C. INTRACRANIAL HAEMORRHAGE IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO120
- 155) Basileo M., Camilloni B., Ferrante F., Iorio A.M., Tagariello G., Agnelli G., Iorio A. INHIBITOR DEVELOPMENT IN MILD HAEMOPHILIA A: COULD INFLUENZA VACCINATION HAVE BEEN THE TRIGGER? 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO003
- 156) Siboni S.M., Zanon E., Mikovic D., Iorio A., Castaman G., Mazzucconi M.G., Peyvandi F. CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PATIENTS WITH RARE BLEEDING DISORDERS (RBDS). 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO005
- 157) Iorio A., Marchesini E., Ferrante F., Agnelli G. ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008 PO007
- 158) Iorio A., Biasoli C., Coppola A., D'Inca M., Federici A., Ferrante F., Girotto M., Landolfi R., Mancuso G., Musso R. 2007 ANNUAL UPDATE OF THE HAEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HAEMOPHILIA CENTRES. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November

2008. P0008

- 159) Santoro C., Iorio A., Ferrante F., Marchesini E., Pignoloni P., Rago A., Biondo F., Agnelli G., Mazzucconi M.G. PHARMACOKINETICS EVALUATION OF THE RECALIBRATED REFACTO LABORATORY STANDARD IN THE ASSESSMENT OF POST-INFUSION PLASMA LEVELS OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII CONCENTRATE. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0009
- 160) Oliovecchio E., Ferrante F., Marchesini E., Carloni M.T., Dragani A., Iuliani O., Agnelli G., Iorio A. WEB BASED SUPPORT FOR HAEMOPHILIA MANAGEMENT: AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0010
- 161) Basileo M., Iorio A., Ferrante F., Marchesini E., Materazzi M., Marchesi M., Esposito A., Pellegrini L., Rocchetti L., Agnelli G., Silvani C.M. INTERNATIONAL GUIDELINES ABOUT CLINICAL USE OF FRESH FROZEN PLASMA: A CRITICAL APPRAISAL. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0011
- 162) Basileo M., Iorio A., Marchesini E., Iaboni S., Palazzesi G., Marchesi M., Esposito A., Pellegrini L., Rocchetti L., Agnelli G., Silvani C.M. CLINICAL AUDIT OF THE USE OF FRESH FROZEN PLASMA IN UMBRIA. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0012
- 163) Iorio A., Ferrante F., Rocca A., Accorsi A., Barillari G., Biasoli C., Carloni M.T., Castaman G., Ciavarella N., Contino L., D'Incà M., Coppola A., Dragani A., Grandini G., Luciani M., Mariani G., Mazzucconi M.G., Molinari C., Morfini M., Muleo G., Rocino A., Rodorigo G., Rossetti G., Santagostino E., Schiavulli M., Schinco P.C., Scaraggi F., Siboni S., Tagariello G., Tagliaferri A.R., Targhetta R., Zanon E. REPLACEMENT THERAPY WITH RECOMBINANT FIX. MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE IN ITALY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0013
- 164) Coppola A., Biasoli C., Iorio A., Castaman G., Messina M., Mansueto F., Feola G., Santoro R., Sartori R., Schinco P., Santagostino E. MANAGING INCOMPLETE OR LACK OF RESPONSE TO THE FIRST IMMUNE TOLERANCE INDUCTION (ITI) COURSE: STRATEGIES FROM THE ITALIAN ITI REGISTRY (THE PROFIT STUDY). 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. P0064
- 165) Iorio A., Marchesini E., Falcou A., Caso V., Pastorello M., Tiscione V., Ballarino P.,

- Altomonte F., Baldi G., Agnelli G., Toni D. RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO070
- 166) Alfonso Iorio, Esmeralda Filippucci, Maura Marcucci, Clive Kearon, and Gualtiero Palareti. Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3029.
- 167) An Iorio. International clinical trials are the best way to improve global haemophilia care? No. Haemophilia 2009; 15: 22. DOI: 10.1111/j.1365-2516.2009.1979.x
- 168) M Marcucci, A Iorio, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci a nome dei partecipanti al progetto Registro Politerapie SIMI. Somministrazione di FANS in pazienti in trattamento anticoagulante orale ed eventi emorragici correlati in una cohorte di anziani ricoverati in reparti di medicina interna. Internal and Emergency Medicine, 2009; 4: S11
- 169) A Iorio, M Marcucci, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci a nome dei partecipanti al progetto Registro Politerapie SIMI. Terapia antitrombotica combinata e correlati eventi emorragici e tromboembolici in una coorte di anziani ricoverati in reparti di Medicina Interna. Internal and Emergency Medicine, 2009; 4: S14
- 170) A Iorio, PM Mannucci, L Pasina, M Marcucci, J Bonazzi, G Agnelli, F Salerno, S Corrao, A Nobili, a nome dei partecipanti al progetto Registro Politerapie SIMI. La profilassi antitrombotica in pazienti con fibrillazione o flutter atriale (FFA) preesistente ricoverati in reparti di Medicina Interna: adesione alle linee guida. Internal and Emergency Medicine, 2009; 4: S26
- 171) Lisa K Lütkehoff, Manuela Albisetti, Timothy J. Bernard, Mariana Bonduel, Leonardo R. Brandao, Stephane Chabrier, Anthony Chan, Barbara Fiedler, Heather J. Fullerton, Vijeja Ganesan, Neil A Goldenberg, Meredith Golomb, Eric F. Grabowski, Christine Heller, Susanne Holzhauer, Alfonso Iorio, Janna Journeycake, Gili Kenet, Fenella J Kirkham, Karin Kurnik, John K Lynch, Christoph Male, Marilyn J. Manco-Johnson, Rolf Mesters, Paul Monagle, Heleen C van Ommen, Leslie Raffini, Paolo Simioni, Ronald Straeter, Guy Young, and Ulrike Nowak-Gottl. Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3993.

- 172) Alfonso Iorio, Susan Halimeh, Christoph Bidlingmaier, Leonardo R. Brandao, Carmen Escuriola-Ettingshausen, Neil A Goldenberg, Alessandro Gringeri, Susanne Holzhauer, Gili Kenet, Ralf Knoefler, Wolfhart Kreuz, Karin Kurnik, Daniela Manner, Emanuela Marchesini, Maura Marcucci, Elena Santagostino, Guy Young, Pier Mannucci, and Ulrike Nowak-Gottl. Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3154.
- 173) Augusto B. Federici, Paolo Bucciarelli, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, and Pier M. Mannucci. Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 3494
- 174) Martino D, Makris M, D'Amico R; Iorio A. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Haemophilia (2010), 16 (Suppl. 4), 1–158, 06P24
- 175) Morfini M, Iorio A; Mazzucconi M, Cinotti S, Zanon E; Paladino E. Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. Haemophilia (2010), 16 (Suppl. 4), 1–158, 08P28
- 176) Iorio A, Halimeh S, Goldenberg N, Kenet G, Young G, Brandao L. Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review. Haemophilia (2010), 16 (Suppl. 4), 1–158, 17P40
- 177) Marcucci M, Fabbriani G, Brozzetti M, Luciani M, Iorio A. Bone mineral density in hemophilia patients: a meta-analysis. Haemophilia (2010), 16 (Suppl. 4), 1–158, 22FP09
- 178) Iorio A, Marchesini E, Marcucci M, Stobart K. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Haemophilia (2010), 16 (Suppl. 4), 1–158, 29P15
- 179) Oliovecchio E, Marchesini E, Martino D, Contino L, Alatri A, Carloni M. Transition to a web-based architecture of the Italian hemophilia registry network. Haemophilia (2010), 16 (Suppl. 4), 1–158, 10F15
- 180) Federici A.B.), Bucciarelli P., Iorio A., Castaman G., Mazzucconi M.G., Morfini M., Rocino A., Schiavoni M., Rodeghiero F., Mannucci P.M. PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS. Blood Transfus 2010; 8 (Suppl 4) OC007
- 181) Iorio A., Douketis J., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosi A. D-DIMER TO DETERMINE RISK FOR DISEASE

- RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: ADDRESSING UNANSWERED QUESTIONS WITH A LARGE INDIVIDUAL PATIENT META-ANALYSIS. Blood Transfus 2010; 8 (Suppl 4) OC025
- 182) Marcucci M., Tosetto A., Douketis J., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Iorio A. ARE MEN AT HIGHER RISK FOR DISEASE RECURRENCE THAN WOMEN? Blood Transfus 2010; 8 (Suppl 4) OC033
- 183) Morfini M., Iorio A., Mazzucconi M.G., Cinotti S., Zanon E., Paladino E., Marchesini E. BIOEQUIVALENCE OF B-DOMAIN DELETED AND PLASMA DERIVED FVIII CONCENTRATES Blood Transfus 2010; 8 (Suppl 4) OC046
- 184) Iorio A., Halimeh S., Goldenberg N., Kenet G., Young G., Brandao L.R., Marchesini E., Marcucci M., Mannucci P.M., Nowak-Gottl U. EFFECT OF PLASMA-DERIVED OR RECOMBINANT FACTOR VIII ON INHIBITOR DEVELOPMENT. A SYSTEMATIC REVIEW Blood Transfus 2010; 8 (Suppl 4) OC047
- 185) Zanon E., Santagostino E., Rocino A., Mazzucconi M.G., Messina M., Tagliaferri A., Giuffrida A.C., Coppola A., Santoro R., Iorio A., Valdrè L., Musso R. INTRACRANIAL HAEMORRHAGE (ICH) IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY Blood Transfus 2010; 8 (Suppl 4) OC104
- 186) Tosetto A., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait R.C., Douketis J. CLINICAL PREDICTION OF VTE RECURRENCE IN PATIENTS WITH PREVIOUS UNPROVOKED VENOUS THROMBOEMBOLISM. RESULTS FROM AN INDIVIDUAL-LEVEL META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) OC114
- 187) Filippucci E., Kearon C., Marcucci M., Pengo V., Siragusa S., Palareti G., Iorio A. VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE Blood Transfus 2010; 8 (Suppl 4) OC115
- 188) Iorio A., Marcucci M., Pasina L., Marengoni A., Salerno F., Corrao S., Nobili A., Mannucci P.M on behalf of the REPOSI investigators. ANTITHROMBOTIC PROPHYLAXIS IN ELDERLY PATIENTS ATRIAL FIBRILLATION ADMITTED TO INTERNAL MEDICINE WARDS IN ITALY: ADHERENCE TO GUIDELINES Blood Transfus 2010; 8 (Suppl 4) P021
- 189) Marcucci M., Tosetto A., Baglin T., Douketis J., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Iorio A. DOES THE CLINICAL PRESENTATION AND EXTENT OF VENOUS THROMBOSIS PREDICT LIKELIHOOD AND TYPE OF RECURRENCE? A PATIENT LEVEL META-ANALYSIS OF 2,554 UNSELECTED PATIENTS AFTER A FIRST THROMBOSIS Blood Transfus 2010; 8 (Suppl 4) P043
- 190) Marcucci M., Douketis J., Tosetto A., Baglin T., Cushman M., Eichinger S., Palareti

- G., Poli D., Tait C.(9), Iorio A., D-DIMER TO PREDICT RECURRENCE AFTER A FIRST EPISODE OF UNPROVOKED VENOUS THROMBOEMBOLISM: COMPARISON OF AGGREGATE AND INDIVIDUAL PATIENT DATA META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) P046
- 191) Marchesini E., Marcucci M., Stobart K., Chan A., Iorio A. CLOTTING FACTOR CONCENTRATES GIVEN TO PREVENT BLEEDING AND BLEEDING-RELATED COMPLICATIONS IN PEOPLE WITH HAEMOPHILIA A OR B Blood Transfus 2010; 8 (Suppl 4) P052
- 192) Marcucci M., Marchesini E., Fabbriani G.L., Brozzetti B., Luciani M., Iorio A. BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) P057
- 193) Martino D., Makris M., D'Amico R., Iorio A. RECOMBINANT FACTOR VIIA CONCENTRATE VERSUS PLASMA DERIVED CONCENTRATES FOR THE TREATMENT OF ACUTE BLEEDING EPISODES IN PEOPLE WITH HAEMOPHILIA AND INHIBITORS. Blood Transfus 2010; 8 (Suppl 4) P061
- 194) Olivovichio E., Marchesini E., Rodorigo G., Marietta M., Di Minno G., Perricone C., Macchi S., Castaman G., Morfini M., Iorio A. TRANSITION TO A WEB-BASED ARCHITECTURE OF THE ITALIAN HEMOPHILIA REGISTRY NETWORK Blood Transfus 2010; 8 (Suppl 4) P065
- 195) Alessandra Rocca, Davide Martino, Ana Macura, Alfonso Iorio. Systematic reviews in the prognosis field: a critical appraisal of six core clinical journals Cochrane Database Syst Rev Suppl 1-166 (2010) Published by John Wiley & Sons, Ltd. DOI:10.1002/14651858.CD000002. P51:
- 196) Augusto B. Federici, Alfonso Iorio, and Giancarlo Castaman. Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 238
- 197) Gili Kenet, Mariana Bonduel, Anthony Chan, Neil Goldenberg, Suzzane Holtzhauer, Alfonso Iorio, Janna M. Journeycake, Ralf Junker, Christoph Male, Mary Patricia Massicotte, Rolf M. Mesters, Paul Monagle, Heleen Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young, and Ulrike Nowak-Gottl. Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies] Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 3169
- 198) Susanne Holzhauser, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Susan Halimeh, Alfonso Iorio, Gili Kenet, Brigitte Pautard, and Ulrike Nowak-Gottl. A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter

- Cohort Study. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 710.
- 199)Federici AB, Bucciarelli P, Iorio A, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Mannucci, PM. Clinical Laboratory and Molecular Markers of Von Willebrand Disease Type 3 (VWD3): Results from the Retro/Prospective Studies on 105/52 Italian Patients. Blood Transfus 2011; 9 (Suppl 3) P0006
- 200)Oliovecchio E, Morfini M, Iorio A. EMOCARD Diventa Emoweb: L'evoluzione del registro delle coagulopatie congenite. Blood Transfus 2011; 9 (Suppl 6) RE01
- 201)Iorio A, Marchesini E, Marcucci M, Stobart K, Chan A.K.C. I Concentrati dei fattori della coagulazione nella prevenzione delle emorragie e delle loro complicanze nei pazienti con emofilia A E B. Blood Transfus 2011; 9 (Suppl 6) RE05
- 202)Zanon E, Iorio A, Rocino A, Artoni A, Santoro A, Tagliaferri A, Coppola A, Castaman G, Mannucci P.M. L'Emorragia cerebrale nella popolazione degli emofilici Italiani con o senza inibitore. Blood Transfus 2011; 9 (Suppl 6) C004
- 203)Matino D, Iorio A, Gargaro M, Luciani M, Tagariello G, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleamina 2,3 diossigenasi e tolleranza al fattore VIII in pazienti affetti da emofilia a grave. Blood Transfus 2011; 9 (Suppl 6) C007
- 204)Coppola A, Santagostino E, Rocino A, Scaraggi F.A., Tagliaferri A, Biasoli C, Zanon E, Iorio A, Schiavulli M, Schinco P, Santacroce R, Mancuso M.E., Morfini M, Margaglione M. Fattori prognostici di successo nell 'Induzione di immunotolleranza (ITI) negli emofilici a con inibitore high-responding (HR). Uno score predittivo dal registro Italiano. Blood Transfus 2011; 9 (Suppl 6) C012
- 205)Morfini M, Scaraggi F.A., Musso R, Molinari A.C., Mannucci P.M, Gringeri A, Santagostino E, Rocino A, Coppola A, Zanon E, Gagliano F, Tagliaferri A, Iorio A, Mazzucconi M.G., Piseddu G, Schinco P, Castaman G. Consensus Conference sulla profilassi peri-operatoria in pazienti emofilici. Blood Transfus 2011; 9 (Suppl 6) C015
- 206)Marchesini E, Fierro T, Mosca M, Becattini C, Iorio A, Gresele P. Case Report: Sequestro polmonare in un paziente con emofilia a grave HIV positivo. Blood Transfus 2011; 9 (Suppl 6) P081
- 207)Marchesini E, Mancini G, Fierro T, Manganelli I, Matino D, Iorio A, Gresele P. Case Report: Infiltrazione di gel piastrinico autologo nel trattamento di un caso di artropatia emofilica del gomito. Blood Transfus 2011; 9 (Suppl 6) P082
- 208)U Nowak-Gotti, G Kenet, M Bonduel, A Chan, N Goldenberg, S Holzhauer, A

- Iorio, J Journeykake, R Junker, C Male, P Masicotte, P Monagle, H Van Ommen, L Raffini, P Simioni, G Young. Impact of Persistent Antiphospholipid antibodies on symptomatic thromboembolism in children: A systematic review & meta-analysis (observational studies). *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) (O-WE-032).
- 209)A Federici, P Bucciarelli, G Castaman, E Olivoecchio, A Iorio, P Mannucci. Heterogeneity of the clinical, laboratory and molecular markers of VWD Type 3: Results from the retrospective/prospective studies on 122/52 Italian patients. *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) (P-WE-461)
- 210)A Iorio, F Querol, A Forsyth, F Cassis. HERO, An international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries. *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) 2011. (P-WE-491)
- 211)A Iorio, F Cassis, F Querol, A Forsyth. HERO – An International initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in 7 countries. *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) 2011. (P-WE-492)
- 212)A Iorio, A Forsyth, F Cassis, F Querol. Psychological Aspects of Living with Haemophilia: The HERO project and narrative review of the published literature. *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) 2011. (P-WE-493)
- 213)M Morfini, A Iorio, M Gabriella Mazzucconi, S Cinotti, E Zanon, E Paladino, E Marchesini, C Santoro. Bioequivalence of a B-Domain deleted and plasma derived FVIII concentrates. *Journal of Thrombosis and Haemostasis* 2011;9(suppl 2) 2011. (P-WE-515)
- 214)Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Irfan A, Solà I, Dahm P, Glujovsky D, Johnston B, Martinez L, Ramirez-Morera A, Sun X, Vandvik PO, Akl E, Tikkinen KA, Iorio A, Santesso N, Brozek J, Schünemann H, Guyatt. Risk difference estimation and reporting in systematic reviews. *Cochrane Database Syst Rev Suppl* 3–233 (2011) Published by John Wiley & Sons, Ltd. DOI:10.1002/14651858.CD000003. P2A158
- 215)Catrin Tudur-Smith, James Oyee, Maura Marcucci, Maroeska Rovers, Alfonso Iorio, Richard Riley, Paula Williamson, Mike Clarke. Individual participant data meta-analyses compared with meta-analyses based on aggregate data. *Cochrane Database Syst Rev Suppl* 3–233 (2011) Published by John Wiley & Sons, Ltd. DOI:10.1002/14651858.CD000003. P3B364
- 216)Tosetto A, Iorio, A, Marcucci M, Baglin T, Cushman M, Sabine E, Palareti G, Poli D, Tait CR, Douketis, JD. Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score.

- Blood, 2011 (ASH Annual Meeting Abstracts), 118;21.
- 217)Matino D, Iorio A, Gargaro M, Tagariello G, Luciani M, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor XIII: A Multi-Centre Pilot Study. Blood, 2011, (ASH Annual Meeting Abstracts), 118;21.
- 218)Iorio A. IPD meta-analysis to investigate the risk factor for inhibitor development. Hemophilia. (2012), 18 (Suppl. 1), 1-10.
- 219)Iorio A. The use of the clinical trial design in hemophilia: methodological considerations. Hemophilia. (2012), 18 (Suppl. 1), 1-10.
- 220)M. Marcucci, G. Kenet, S. Holzhauser, C. Bidlin gmaier, C. Escuriola Ettin gshausen, A. Iorio, U. Nowa k-Gottl. Concentrate type and dose in hemophilia A patients: is there an independent effect on risk of inhibitor formation? Oral communication. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1 Haemophilia 2012, 18 (Suppl. 1), 11-51
- 221)W. KALNINS, F. QUEROL, M. GREGORY and A. IORIO. Clinical presentation and management of adult patients responding to the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-MO-04.4-1. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 222)W. KALNINS, F. QUEROL, K. HALTER and A. IORIO. Clinical presentation and management of pediatric hemophilia patients as reported by parents surveyed in the Haemophilia Experiences Results Opportunities (HERO) survey. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-022. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 223)C. BOS , A. CHAN, S . ATKINSON, K. BANDOSZ, K. NAGEL, K. STRIKE, C. WEBBER, K. WEBERT, A. IORIO and I . WALKER. Nutritional intake and bone mineral density in boys with severe hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-047. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 224)C. BOS, A. CHAN, C. WEBBER, A. IORIO, K. NAGEL,I WALKER and K. WEBERT. Low bone mineral density and increased fat mass in boys with severe Hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-048. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 225)A STAIN,* E. SANDOVAL, K. HALTER, and A. IORIO. Hemophilia knowledge and frequently used and valued information sources: Patient/parent perceptions from the Hero study. Abstracts of the XXX International Congress

- of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-088. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 226) F. CASSIS, A. BUZZI, A. FORSYTH, M. GREGORY and A. IORIO. Impact of hemophilia on relationships with partners, family, and friends: Assessment of adult patient respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-087. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 227) D. NUGENT, C. GARRIDO, K. HALTER, A. BUZZI and A. IORIO. Impact of hemophilia on interpersonal relationships: Assessment of parent/caregiver respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-2. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 228) A. COPPOLA, M. MARGAGLIONE, E. SANTAGOSTINO, A. ROCINO, A. TAGLIAFERRI, M. MESSINA, E. ZANON, S. LINARI, A. IORIO, L. VALDRE, M. MANCUSO and G. DI MINNO. Predictors of success of immune tolerance induction in hemophilia A patients with high-responding inhibitors: A score from the Italian registry. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 229) M. MARCUCCI, G. KENET, S. HOLZHAUER, C. BIDLINGMAIER, C. ESCURIOLA ETTINGSHAUSEN, A. IORIO and U. NOWAK-GOTTL. Assessment of treatment-related risk factors for inhibitor development in previously untreated hemophilia A patients: Different statistical approaches. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-3. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 230) K. STRIKE, A. CHAN, K. ROSS, C. BOS, T. ALMONTE, K. DECKER, R. GOLDSMITH, A. IORIO, I. WALKER, K. WEBERT and L. WATERHOUSE. Osteochondral Lesions of the Ankle Joint in Patients with Hemophilia A: A Retrospective Case Series. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-212. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 231) F. CASSIS, A. FORSYTH, M. GREGORY and A. IORIO. Qualitative and quantitative assessment of sexual intimacy in adult patients in the hemophilia experiences results opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-148. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 232) A. FORSYTH, M. GREGORY and A. IORIO. Demographic characteristics of adult patient respondents in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World

- Federation of Hemophilia, July 8-12, Paris, France PO-MO-199. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 233) D. NUGENT, C. GARRIDO, K. HALTER and A. IORIO. Demographic characteristics of parents of children/adolescents with hemophilia responding in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-200. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 234) C. GARRIDO, S. RAMIREZ, A. FORSYTH and A. IORIO. Quality of life (QOL) and well-being of hemophilia patients and parents managing hemophilia: Hero study analysis. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-218. Haemophilia 2012, 18 (Suppl. 3), 1-208.
- 235) Guyatt G, Spencer F, Iorio A, Vandvik P, You J. Uncertainty in baseline risk can reduce confidence in estimates of effect. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 236) Sun X, Brignardello-Petersen R, Carrasco-Labra A, Neumann I, Alonso-Coello P, Akl E, Johnston B, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Subgroup analyses in systematic reviews: a survey of Cochrane and non-Cochrane reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 237) Johnston B, Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Sun X, Akl E, Briel M, Busse J, Dahm P, Glujovsky D, Granados C, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Reporting of absolute estimates of effect of patient important benefits and harms in abstract of systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 238) Akl E, Alonso-Coello P, Neumann I, Brignardello-Petersen R, Carrasco-Labra A, Johnston B, Sun X, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. reporting, handling and judging risk of bias associated with missing participant data in systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 239) Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl E, Sun X, Johnston B, Busse J, Dahm P, Glujovsky D, Iorio A, Irfan A, Martinez L, , Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Briel M, Granados C, Mustafa R, Guyatt G. Risk difference estimation and reporting in

- systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 240) Irwin Walker, Aicha N Traore, Alfonso Iorio, Bruce Ritchie, Nancy Heddle, Kathryn E Webert, Jean St. Louis, David Lillicrap, Jerome M. Teitel, and Anthony K.C. Chan. Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood 2012 (ASH Annual Meeting Abstracts):120 (21)
- 241) Diane J Nugent, Chris Guelcher, Angela Forsyth, Neil Frick, Michelle Rice, Alfonso Iorio, Tami Wisniewski, and David L. Cooper. Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life. Blood 2012 (ASH Annual Meeting Abstracts):120 (21)
- 242) E. Santagostino, S. Lentz, A. Iorio, A. K. Busk, L. Adab-Franch, J. Meunier, A. Regnault. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: results from two clinical trials Haemophilia (2013), 19 (Suppl. 2), 10–82 PO024
- 243) Alfonso Iorio, Frederica Cassis, Felipe Querol, Trine Pilgaard. Demographic Characteristics of European Respondents in the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10–82 PO030
- 244) Alfonso Iorio, Frederica Cassis, Felipe Querol, Werner Kalnins, Trine Pilgaard. Effects of Haemophilia on Relationships, Intimacy and Family: European Results From the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10–82 PO031
- 245) Alfonso Iorio, Felipe Querol, Werner Kalnins, Trine Pilgaard. Access to Haemophilia Treatment Centres, Treatment and Information Sources: European Results From the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10–82 PO044
- 246) Alfonso Iorio, Felipe Querol, Trine Pilgaard. Quality of Life in Adults With Haemophilia: European Results From the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10–82 PO043
- 247) Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A and Nowak-Gottl U. Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: first results of an individual patient data meta-analytic project. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933. AS 22.2
- 248) Martino D, Iorio A, Gargaro M, Santagostino E, Santoro C, Di Minno G, Morfini M, Puccetti P and Fallarino F. Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. Journal of

- Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933. AS 22.3
- 249) Federici AB, Castaman G, Iorio A, Bonduel M, D'Amico EA, Oliovecchio E, Santoro C, Siboni SM, Zieger B and Mannucci PM. Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PA 2.08-1
- 250) Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilisation: an analysis of adults with haemophilia in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PB 3.36-6
- 251) Marcucci M, Eichinger S, Iorio A, Douketis JD, Tosetto A, Baglin TPT, Cushman M, Palareti G, Poli D, Campbell TR and Kyrle PA. External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PB 3.70-3
- 252) Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia treatment centre and provider utilisation: An analysis of parents of children with haemophilia in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 122
- 253) Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships with haemophilia centre/ provider utilisation: An analysis of parents of children with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 123
- 254) Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships and haemophilia treatment centre/provider utilisation: an analysis of adults with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 124
- 255) Iorio A, Forsyth A, Guelcher C, Buzzi A, Wisniewski T and Cooper D. Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate and haemophilia treatment centre/provider utilisation: results from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11

(Suppl 2) Jul ISSN 1538–7933. PO 125

- 256) Iorio A, Forsyth A, Querol F, Stain AM, Pericleous L and Cooper D. Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 126
- 257) Iorio A, Forsyth A, Querol F, Stain AM, Pericleous L and Cooper D. Do bleed rates and haemophilia treatment centre/ provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 127
- 258) Iorio A and Buzzi A. Association of treatment regimen and location with bleed frequency, quality of life and comorbidities in adults and children with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 128
- 259) Iorio A, Buzzi A, Benchikh El Fegoun S and Cooper D. Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 129
- 260) Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L and Iorio A. Meta-analysis of Post Authorization Safety Studies: worldwide postmarketing surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 148
- 261) Sun J, Yang R, Zhao Y, Wang X, Wu J, Zhang X, Guan T and Iorio A. Quality of life and well-being of haemophilia patients and parents in China: subgroup analysis of the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 166
- 262) Abha Athale, Anik Giguere, Angela Barbara, Emma Iserman, and Alfonso Iorio. Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients. *Blood* 2013 (ASH Annual Meeting Abstracts), 122 (21)
- 263) Athale A, Iorio A. Investigating the use of the McMaster Premium Literature Service (PLUS) as a method to efficiently update systematic reviews. *Cochrane Database Syst Rev Suppl* 213–222 (2013) DOI:10.1002/14651858.CD201300
- 264) Pardo J, Lawson J, Rader T, Parrish R, Cotoi C, Tugwell P, Haynes B, Iorio A. Improving the efficiency of updating Cochrane Reviews: a joint pilot project of

the McMaster PLUS database team and the musculoskeletal review group.
Cochrane Database Syst Rev Suppl 213–222 (2013)
DOI:10.1002/14651858.CD201300

- 265) Akl EA, Johnston B, Carrasco A, Brignardello Petersen R, Neumann I, Sun X, Briel M, Busse J, Granados C, Iorio A, Irfan A, Martinez L, Mustafa RA, Ramirez A, Sola I, Martinez Garcia L, Selva A, Sanabria AJ, Zazueta OE, Vernooij R, Tikkinen KA, Ebrahim S, Vandvik PO, Guyatt GH, Alonso Coello P. Reporting, dealing with, and judging risk of bias associated with missing participant data in systematic reviews: a methodological survey. *Cochrane Database Syst Rev Suppl* 213–222 (2013) DOI:10.1002/14651858.CD201300
- 266) D Nugent, AM Stain, M Gregory, L Pericleous, DL Cooper, A Iorio. Associations Between Inhibitors, Treatment Regimen, Bleed Frequency and Healthcare Practitioner Utilisation in the Haemophilia Treatment Centre: Global Results From the HERO Study. *VALUE IN HEALTH* 16 (2013) A1-A298. PSY86
- 267) F Cassis, M Gregory, W Kalnins, T Wisniewski, DL Cooper, A Iorio. Associations Between Negative Impact on Employment or Relationships and Haemophilia Treatment Centre and Healthcare Practitioner Utilisation: Global Results From the HERO Study. *VALUE IN HEALTH* 16 (2013) A1-A298. PSY87
- 268) Barbara AMG, Aledort LM, Mathew P, Mauser-Bunschoten E, Rivolta GF, Romanov V, Tagliaferri A, Roussel-Robert V, Windyga J and Iorio A. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. Abstracts of the 60th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis June 23-26, 2014. *Journal of Thrombosis and Haemostasis* 2014; 12 (Suppl. 1) 1–106
- 269) Marcucci M, Fisher K, Kenet G, Young G, Walker I, Thabane L. Risk of inhibitor development in previously treated patients with positive inhibitor history or low titer of inhibitor at baseline: results of a survey of hemophilia experts. Abstracts of the 60th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis June 23-26, 2014. *Journal of Thrombosis and Haemostasis* 2014; 12 (Suppl. 1) 1–106
- 270) A. IORIO, A. M. G. BARBARA, P. MATHEW, G. F. RIVOLTA, V. V. ROMANOV, V. ROUSSEL- ROBERT5, A. TAGLIAFERRI, J. WINDYGA. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. *Haemophilia* (2014), 20 (Suppl. 2), 18—91. PO037
- 271) M. MARCUCCI, J. CHENG, V. ROMANOV, L. THABANE, A. IORIO. The use of FVIII concentrate in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: a meta-analysis of advance post-authorization safety studies in different countries. *Haemophilia* (2014), 20 (Suppl. 2), 18—91.

PO044

- 272)A. IORIO. Does product type influence the development on inhibitor in PTPs and PUPs? *Haemophilia* (2014), 20 (Suppl. 2), 18—91. PO121
- 273)LEONARD MINUK, ERINNE DILWORTH, SHANNON JACKSON, ALFONSO IORIO, MAN-CHIU POON, ROBERT CARD, IRUM RIZWAN and MARTHA LOUZADA. Cardiac risk factors in older patients with hemophilia: Report of the age related cardiovascular disease in hemophilia epidemiologic research (ARCHER) study. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 274)MAURA MARCUCCI, JI CHENG, VADIM ROMANOV, LEHANA THABANE and ALFONSO IORIO. Safety of antihemophilic factor recombinant plasma/albumin-free method [rAHF-PFM] in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: A meta-analysis of ADVATE Post- Authorization Safety Studies data. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 275)SHANNON JACKSON, MING YANG, LEN MINUK, JEAN ST-LOUIS, MICHELLE SHOLZBERG, ROBERT CARD, ALFONSO IORIO and MAN-CHIU POON. An evaluation of whether the ankle is now the dominant site of chronic hemophilic arthropathy in young adults with severe hemophilia. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 276)AICHA TRAORE, ANTHONY CHAN, MARGARET WARNER, ALFONSO IORIO, JOHN WU, JAYSON STOFFMAN, ALAN TINMOUTH, JERRY TEITEL, NANCY HEDDLE1 and IRWIN WALKER. Factor VII deficiency patients: 5 years factors concentrates utilization trend based on the Canadian Hemophilia Assessment and Resource Management System (CHARMS). *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 277)ALFONSO IORIO, SANGEETA KRISHNAN, LYNN HUYNH, PAUL KARNER, MEI SHENG DUH and SANDER YERMAKOV. An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 278)ALFONSO IORIO, SANGEETA KRISHNAN, LYNN HUYNH, PAUL KARNER, MEI SHENG DUH and SANDER YERMAKOV. An indirect comparison of the efficacy of prophylactic use of rFVIII Fc and other rFVIII products and model of the effect of compliance. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 279)KAREN STRIKE, FRANK SMITH, ANTHONY CHAN, THERESA ALMONTE, CHRISTINE CHASTON, KAY DECKER, REBECCA GOLDSMITH, NAOMI MATSUI, KIM NAGEL, CHRISTA ORSCHEL, IRWIN WALKER, LINDA WATERHOUSE and ALFONSO IORIO. Assessment of patient preferences and perceived value of the comprehensive interdisciplinary combined hemophilia and orthopedic clinic using a validated questionnaire. *Haemophilia* (2014), 20 (Suppl. 3), 1—

186

- 280) G. BLAMEY and A. IORIO. Investigating Attitudes and Practices of Canadian Physiotherapists on Sexual Health: A Comparison to the HERO Dataset. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 281) KAREN STRIKE, SANDRA SQUIRE, DR. ALFONSO IORIO, DR. SHANNON JACKSON, WENDY LAWSON, KIM NAGEL, LISA SCOTT and DR. ANTHONY CHAN. Physiotherapy and point of care ultrasonography in the management of hemophilia: Training phase. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 282) FREDERICA R.M. Y CASSIS, CHRISTINE GEULCHER, MATT GREGORY and ALFONSO IORIO. Fathers' and Mothers' Perceptions and Communication on Carrier Status and Diagnosis of Congenital Haemophilia: Global Results from the Haemophilia Experiences, Results and Opportunities (HERO) Study. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 283) JING SUN, RENCHI YANG, YONGQIANG ZHAO, XUEFENG WANG, JINGSHENG WU, XINSHENG ZHANG, BIN TENG, TAO GUAN, KUIXING LI and ALFONSO IORIO. Factors influencing quality of life in Chinese adults with hemophilia: Results from the HERO study. *Haemophilia* (2014), 20 (Suppl. 3), 1—186
- 284) Chatree Chai-Adisaksopha, Christopher M. Hillis, Lehana Thabane, Alfonso Iorio. A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia. *Blood* 2014 (ASH Annual Abstracts) 124 (21) 2821;
- 285) Menchen Xi, Tamara Navarro-Ruan, Sunil Mammen, Victor S. Blanchette, Cedric R. Hermans, Massimo Morfini, Peter W. Collins, Kathelijn Fischer, Ellis J. Neufeld, Guy Young, Kaan Kavakli, Paolo Radossi, Amy Dunn, Lehana Thabane, Alfonso Iorio. Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. *Blood* 2014 (ASH Annual Abstracts) 124 (21)
- 286) Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S. Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis: modeling the effect of compliance. *Value in Health* 2014, 17: A1-A295. PSY40
- 287) Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S. Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: simulating the effect of compliance on real-world effectiveness. *Value in Health* 2014, 17: A1-A295. PSY41
- 288) Iorio, A. & Hermans, C. Population pharmacokinetics for busy clinicians and active patients: how to get the most out of it? *Haemophilia*, 2015; 21, 13.
- 289) Iorio A, Blanchette V, Blatny J, Collins P, Croteau S, Dunn A, Fischer K, Hermans C, Kavakli K, Jackson S, James P, Mammen S, Morfini M,

- Navarro-Ruan T, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz-Saez A, Teitel J, Thabane L, Young G and Xi M. A population approach to hemophilia pharmacokinetics. Wapps: a web-service for bayesian post hoc estimation. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. AS122
- 290) Iorio A, Barbara A, Castaman G, Fischer K, Gilman E, Goudemand J, Kavakli K, Kubicek-Hofmann C, Lambert T, Lissitchkov T, Makris M, Matthew P, Castelano MEM, Ozdemir N, Parra R, Peerlinck K, Rivolta G, Romanov V, Roussel-Robert V, Tagliaferri A, Windyga J and Zanon E. Determinants of inhibitor development in previously treated hemophilia A patients. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. OR144
- 291) Iorio A, Krishnan S, Myren K-J, Lethagen S, McCormick N and Karner P. Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products. 2015 International Society on Thrombosis and Haemostasis 2015, 13 (Suppl. 2); 1–997. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO170-MON.
- 292) Iorio A, Krishnan S, Myren K-J, Lethagen S, McCormick N and Karner P. Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO171-Mon.
- 293) Iorio A, Cheng J, Marcucci M, Romanov V and Thabane L. Bayesian approach to the assessment of the population specific risk of inhibitors. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO261-MON.
- 294) Xi M, Blanchette V, Blatny J, Collins P, Dunn A, Fischer K, Hermans C, Navarro-Ruan T, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Neufeld E, Ozelo M, Radossi P, Rangarajan S, Ruiz-Saez A, Teitel J, Thabane L, Young G, Iorio A and on behalf of the WAPPS Investigators. Pharmacokinetic characteristics of factor VIII and IX concentrates – a systematic review. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO262-MON
- 295) Traore A, Chan A, Iorio A, Heddle N, Walker I and on behalf of Association of Hemophilia Clinic Directors of Canada. Utilization of anti-inhibitors products and inhibitors status of severe hemophilia patients: 5 years national data from the Canadian hemophilia assessment and resource management system. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO276-MON
- 296) Khair K, Cruz MS, Werner S, Knaub S, Iorio A and on behalf of Wil-20

- working group. Surveillance study of safety and efficacy of aVWF/ FVIII concentrate in patients with von willebrand disease (WIL-20) – a planned interim analysis. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO662-MON.
- 297) Iorio A, Rentz A, Balantac Z and Hoxer CS. Assessing the indication and success of treatment for haemophilia patients: results from a Delphi panel. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO138-TUE
- 298) Matino D, Gargaro M, Santoro C, Castaman G, Fallarino F and Iorio A. Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO162-TUE
- 299) Chatree Chai-Adisaksopha, Matthew Cheah, Said Y. AlKindi, Alfonso Iorio, Mark A. Crowther, and Lori Ann Linkins. Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis. *Blood* 2015; 126 (23). Abs 1120
- 300) Chatree Chai-Adisaksopha, Said Y. AlKindi, Matthew Cheah, Alfonso Iorio, Mark A. Crowther, and Lori Ann Linkins. Outcomes of Low-Molecular-Weight Heparin treatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors. *Blood* 2015; 126 (23). Abs 428 (oral)
- 301) Augusto Bramante Federici, Giancarlo Castaman, Alfonso Iorio, Emily Oliovecchio and Prodeswil Investigators. Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study. *Blood* 2015; 126 (23). Abs 759 (oral)
- 302) Chatree Chai-Adisaksopha, Alfonso Iorio, Mark A. Crowther, Javier de Miguel, Estuardo Salgado, Marija Zdraveska, and Manuel Monreal. Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis. Clinically Relevant Abstract. *Blood* 2015; 126 (23). Abs 430 (oral)
- 303) Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII. *Value Health*. 2015 Nov;18(7):A660. doi: 10.1016/j.jval.2015.09.2393. Epub 2015 Oct 20. PMID: 26533703.
- 304) Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Factor consumption for prophylaxis and treatment of bleeding: recombinant factor IX Fc fusion compared with conventional recombinant Factor IX. *Value Health*. 2015 Nov;18(7):A660. doi: 10.1016/j.jval.2015.09.2396. Epub 2015 Oct 20.

PMID: 26533702.

- 305) Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Modeling the impact of potential differences in real-world adherence with extended-half-life conventional factor VII and IX on bleeding. *Value Health*. 2015 Nov;18(7):A660-1. Doi: 10.1016/j.val.2015.09.2397. Epub 2015 Oct 20. PMID: 26533698.
- 306) Kahale LA, Diab B, Brignardello-Petersen R, Mustafa R, Busse JW, Agarwal A, Kwong J, Li L, Neumann I, Lopes LC, Olav Vandvik P, Briel M, Iorio A, Guyatt GH, Akl E. Extent and handling of missing dichotomous outcome data in 100 Cochrane and non-Cochrane systematic reviews. *Cochrane Database Syst Rev Suppl* 1-327 (2015). O 9.1
- 307) Iorio A, Matovinovic E, Hayden J. Systematic reviews of prognostic studies 5: using GRADE in systematic reviews of studies on overall prognosis. *Cochrane Database Syst Rev Suppl* 1-327 (2015). W91

Other abstract, not published as journal abstracts (Meetign proceedings)

1. R.Mozzi, V.Andreoli, A.Iorio, F.Pierini. Phosphatidylserine (PS) synthesis by base exchange is inhibited by GTP and activated by heparin in rat brain membranes. Abstract at the 2nd International Union of Biochemistry and Molecular Biology Conference: Biochemistry of Cell Membranes.
2. Iorio A, Hauert J, Agnelli G, Parise P. Streptochinasi ed rt-P attivano le piastrine con meccanismi diversi: implicazioni sull'incidenza di retrombosi dopo terapia trombolitica nell'infarto del miocardio. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A35.
3. Iorio A, Agnelli G, Alatri A, Melelli P, Boschetti E, Nenci GG. Cinetica dell'attività anti-IIa della nadroparina in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A117.
4. Iorio A, Renga C, Leone M, Melelli P, Parise P and Agnelli G per il gruppo BAPE. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A316.
5. Renga C, Agnelli G, Iorio A, Nenci GG, Young E, Hirsh J. Legame non specifico alle proteine plasmatiche dell'eparina non frazionata e delle eparine a basso peso molecolare dopo somministrazione in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A118.
6. Agnelli G, Renga C, Iorio A, Melelli P, Leone M, Lormeau JC. Correlazione tra la lunghezza delle catene saccaridiche e l'attività anti-IIa di frazioni epariniche

- valutata con il plasma thrombin neutralization assay. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A339.
7. Leone M, Melelli P, Renga C, Iorio A, Nenci GG, Agnelli G. Inibizione della trombina libera e legata alla fibrina: confronto tra eprina e LU 58463, un inibitore puro della trombina. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A340.
 8. Renga C, Nucciarelli F, Leone M, Iorio A, Agnelli G. Effetti del dermatan solfato sul tempo di tromboplastina parziale attivato determinato con cinque diversi reagenti. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A342.
 9. S.Buratta, A.Iorio, S.Porcellati, V.Andreoli, R.Mozzi. Effect of heparin on phosphatidylserine synthesis in rat cerebral cortex and porcine platelets. Proceedings of the 35th International Conference on the Biochemistry of Lipids. IV, P24.
 10. Ascani, A. Iorio, A.M. Stabile, G. Agnelli. Sospensione della terapia anticoagulante orale in pazienti con trombosi con trombosi venosa profonda: effetti di una bassa dose fissa di warfarin sui parametri emocoagulativi. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 88.
 11. M.R. Taliani, A. Iorio, F. Gianese, G.G. Nenci, G. Agnelli. Impiego compassionevole del dermatan solfato in pazienti con controindicazioni all'impiego di eparina. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 98.
 12. Alatri, A. Iorio, F. Gianese, G. Agnelli. Lo "spiazzamento" dell'eparina non frazionata dal legame non specifico con le proteine plasmatiche determina un incremento del suo effetto antitrombotico. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 103.
 13. Iorio, S. Ricotta, P. Parise, G. Agnelli. Bassa incidenza del tromboembolismo venoso sintomatico in pazienti sottoposti ad intervento di chirurgia ortopedica con venografia negativa alla dimissione. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 344.
 14. M. Silingardi, M. D'Inca, M. Ghirarduzzi, A. Iorio, G. Rinaldi, M. Brini, I. Iori. Positività per anticorpi antifosfolipidi (aPL) e prevalenza della sindrome da anticorpi antifosfolipidi (APS) primaria in soggetti con piastrinopenia, aborti ripetuti, trombosi venose o arteriose: analisi di 36 casi. Atti del 7° Convegno Nawioanle della FCSA, Bologna, 20-21 febbraio 1997.
 15. Ghirarduzzi, M. D'Incà, M. Silingardi, F. Mazzali, A. Iorio, G. Rinaldi, I. Iori. Sindrome da anticorpi antifosfolipidi e autoanticorpi anti fattore VIII in corso di

leucemia linfatica cronica. Atti del XCVIII Congresso Nazionale della Società italiana di Medicina Interna. Roma, 27-31 ottobre 1997.

16. M. Silingardi, A. Ghirarduzzi, C. Salvarani, G. Rinaldi, A. Iorio, D. Galimberti, M. Brini, I. Iori. Morbo di Behcet: sindrome “catastrofica” vasculitica associata a mutazione 20210A della protrombina. Atti del XCIX Congresso Nazionale della Società Italiana di Medicina Interna. Bari, 10-14 novembre 1998.
17. D. Guidetti, E. Bellesia, G. Rinaldi, A. Iorio. Ischemic stroke in young patients: hemocoagulative and molecular biology study. Atti dell'International Workshop “Stroke in the young”. Genova, 11-12 dicembre 1998.
18. M. Berrettini, A. Iorio et al. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. Hemophilia 1998;vol:pag (Atti del XXIII International Congress of the World Federation of Hemophilia)
19. Ghirarduzzi A., Iorio A., D'Inca M., Silingardi M., Morini L., Salvarani C., Cerioli G., Iori I. 2000 Sindrome da anticorpi fosfolipidi. Descrizione di un caso clinico con trombosi atriale dx e revisione della casistica di Reggio Emilia. Atti del 101° Congresso Nazionale della Società Italiana di Medicina Interna, Torino, 18-22 novembre 2000, 431, abs310
20. Massi Benedetti M., Brunetti P., Iorio A., Ferolla P., Stabile A., Akwe J., Celleno R., Canonico V., Timi A. 2003 Alterazione della fibrinolisi durante chetoacidosi diabetica nel corso di sospensione di terapia insulinica infusoriale continua sottocutanea (CSII) in diabetici di tipo 1. XIV Congresso Nazionale, Catania (Italia)
21. Iaboni S, Filippucci E, Ferrante F, Grilli P, Vecchioli M, Agnelli G, Iorio A. ANTICOAGULATION MANAGEMENT BY POINT OF CARE DEVICES AND COMPUTER MONITORING BY GENERAL PRACTITIONERS. XX Siset National Meeting, Florence, September 25-28, 2008 C076
22. Marchesini E, Ferrante F, Filippucci E, Iaboni S, Agnelli G, Iorio A. ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS IN PATIENTS HIV-INFECTED. XX Siset National Meeting, Florence, September 25-28, 2008 P177
23. Basileo M, Iorio A, Marchesini E, Iaboni S, Palazzesi GP, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. CLINICAL AUDIT OF THE USE OF FRESH FROZEN PLASMA IN UMBRIA: STUDY DESIGN AND RESULTS OF THE PILOT PHASE. XX Siset National Meeting, Florence, September 25-28, 2008 P182
24. Cosmi B, Legnani C, Tositto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Alatri A, Guazzaloca G, Palareti G for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). D-DIMER TO DETERMINE DURATION OF ANTICOAGULATION AFTER A FIRST EPISODE OF IDIOPATHIC VENOUS THROMBOEMBOLISM: EXTENDED FOLLOW-UP OF THE PROLONG

STUDY. XX Siset National Meeting, Florence, September 25-28, 2008 C066

25. Ferrante F, Camilloni B, Iorio AM, Tagariello G, Agnelli G, Iorio A. INHIBITOR DEVELOPMENT IN MILD HAEMOPHILIA A: COULD INFLUENZA VACCINATION HAVE BEEN THE TRIGGER? XX Siset National Meeting, Florence, September 25-28, 2008 P196
26. Ferrante F, Carloni M, Marchesini E, Dragani A, Olivoecchio E, Iuliani O, Agnelli G, Iorio A. MANAGEMENT OF PATIENTS WITH HEMOPHILIA IN AN INTER-REGIONAL NETWORK IN CENTRAL ITALY. XX Siset National Meeting, Florence, September 25-28, 2008 P193
27. Ghirarduzzi A, Landini F, Pengo V, Corradini S, Iorio A, Prandoni P. NEW ONSET OF CANCER AND RECURRENT VENOUS THROMBOEMBOLISM AFTER DISCONTINUING ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLIC EVENT. A PROSPECTIVE COHORT STUDY IN 1,919 PATIENTS. XX Siset National Meeting, Florence, September 25-28, 2008 C053
28. Santoro C, Iorio A, Ferrante F, Marchesini E, Pignoloni P, Rago A, Biondo F, Agnelli G, Mazzucconi M. PHARMACOKINETICS OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII CONCENTRATE USING CHROMOGENIC AND ONE-STAGE CLOTTING ASSAYS WITH POOLED NORMAL PLASMA AND REFAC TO LABORATORY STANDARD. XX Siset National Meeting, Florence, September 25-28, 2008 P190
29. Filippucci E, Iaboni S, Ferrante F, Paccamiccio E, Vecchioli M, Agnelli G, Iorio A. PROSPECTIVE EVALUATION OF THE CLINICAL QUALITY OF ORAL ANTICOAGULANT TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL. XX Siset National Meeting, Florence, September 25-28, 2008 C077
30. Ferrante F, Iaboni S, Filippucci E, Marchesini E, Vecchioli M, Agnelli G, Iorio A. QUALITY ASSURANCE SCHEME BASED ON LEVEY JENNINGS ANALYSIS AND WESTGARD RULES APPLICATION FOR POC-INR MONITORING. XX Siset National Meeting, Florence, September 25-28, 2008 P124
31. Iorio A, Marchesini E, Falcou A, Caso V, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. XX Siset National Meeting, Florence, September 25-28, 2008 P174
32. Iorio A, Ferrante F, Pizzinelli S on behalf of the Italian ad hoc study group. REPLACEMENT THERAPY WITH RECOMBINANT FIX. MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE IN ITALY. XX Siset National

Meeting, Florence, September 25-28, 2008 P192

33. Filippucci E, Vedovati MC, Iorio A, Agnelli G. SAFETY OF R-HIRUDIN USE FOR HEPARIN-INDUCED THROMBOCYTOPENIA TREATMENT IN A CEREBRAL VEIN THROMBOSIS PATIENT: A CASE REPORT. XX Siset National Meeting, Florence, September 25-28, 2008 P153
34. Basileo M, Iorio A, Ferrante F, Marchesini E, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM2. THE GOOD USE OF PLASMA. A CRITICAL ANALYSIS OF FIVE INTERNATIONAL GUIDELINES. XX Siset National Meeting, Florence, September 25-28, 2008 P178
35. Iorio A, Barillari G, Gandini G, Molinari C, Rocino A, Santagostino E, Tagariello G, Targhetta R. THE HAEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HAEMOPHILIA CENTRES. XX Siset National Meeting, Florence, September 25-28, 2008 C102
36. Coppola A, Daniele F, Rocino A, Targhetta R, Santoro R, Giuffrida A, Zanon E, Iorio A, Mancuso G, Santagostino E for the Italian Association of Haemophilia Centres (AICE) PROFIT Study Group THE ITALIAN REGISTRY OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A WITH INHIBITORS: 2-YEAR UPDATE (PROGNOSTIC FACTORS IN IMMUNE TOLERANCE, THE PROFIT STUDY). XX Siset National Meeting, Florence, September 25-28, 2008 C100
37. A Iorio, S Halimeh, C Bidlingmaier, C Escuriola Ettingshausen, A Gringeri, S Holzhauer, R Knöfler, W Kreuz, K Kurnik, D Manner, E Santagostino, PM Mannucci, U Nowak-Göttl. Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review. III EAHAD meeting, Edimburg February 3-5, 2010
38. A Iorio, G Fabbriciani, M Marcucci, M Brozzetti, M Luciani, P Filipponi. Bone mineral density in hemophilia patients. A meta-analysis. III EAHAD meeting, Edimburg February 3-5, 2010
39. Alfonso Iorio, Suzanne Holzhauer, Christoph Bidlingmaier, Carmen Escuriola-Ettingshausen, Susan Halimeh, Gili Kenet, Brigitte Pautard, Ulrike Nowak-Göttl. Predictive model to assess the risk of inhibitor development in children with severe and moderate hemophilia A - Results of a multicenter cohort study. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011
40. Alfonso Iorio, and Ulrike Nowak-Göttl on behalf of the EAHAD ad hoc working party. Predictors of inhibitor development in Hemophilia A previously untreated patients: the role of factor concentrate type. An individual patient data meta-analysis. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011
41. Nugent D, Guelcher C, Forsyth A, Frick N, Iorio A, and Cooper DL. Hemophilia

- Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis on Career and Lifestyle Decisions. National Hemophilia Foundation, NHF's 64th Annual Meeting, 8-10 November 2012 Orlando, Florida, USA
42. Guelcher C, Rice M, Forsyth A, Nugent D, Iorio A, and Cooper DL. Hemophilia Impacts Interpersonal Relationships, Intimacy and Family Dynamics: US Results from the Hemophilia Experiences, Results and Opportunities (HERO) Study. National Hemophilia Foundation, NHF's 64th Annual Meeting, 8-10 November 2012 Orlando, Florida, USA
43. Nugent D, Guelcher C, Rice M, Forsyth A, Iorio A, and Cooper DL. US Results from the Hemophilia Experiences, Results and Opportunities (HERO) Study Affirm Hemophilia Treatment Centers (HTCs) are Central to Hemophilia Care, Yet Financial Concerns and Distance May Limit Access to Treatment for Some Patients. National Hemophilia Foundation, NHF's 64th Annual Meeting, 8-10 November 2012 Orlando, Florida, USA
44. Forsyth A, Guelcher C, Nugent D, Frick N, Wisniewski T, Iorio A, and Cooper DL. Hemophilia Impacts Quality of Life (QoL) in Adult PWH at an Early Age, with Pain a Contributing Factor: US Results from the Hemophilia Experiences, Results and Opportunities (HERO) Study. National Hemophilia Foundation, NHF's 64th Annual Meeting, 8-10 November 2012 Orlando, Florida, USA
45. A Forsyth, C Guelcher, A Buzzi, T Wisniewski, DL Cooper, A Iorio. Associations of Quality of Life, Pain, and Self-Reported Arthritis with Bleed Rate and Hemophilia Treatment Center and Healthcare Practitioner Utilization: Global Results from the HERO study. 13th Musculoskeletal Congress of the World Federation of Hemophilia, April 18-21, Chicago, US.
46. A Forsyth, F Querol; AM Stain, L Pericleous, DL Cooper, A Iorio. Associations Between Physical Activity Risk Level, Treatment Regimen, and Hemophilia Treatment Center and Healthcare Professional Utilization: Results from the HERO Study. 13th Musculoskeletal Congress of the World Federation of Hemophilia, April 18-21, Chicago, US.
47. K. Strike, T. Almonte, A. Chan, K. Decker, R. Goldsmith, A. Iorio, N. Matsui, F. Smith, I. Walker, L. Waterhouse. Interdisciplinary musculoskeletal clinic for persons with inherited bleeding disorders (PWBD). 13th Musculoskeletal Congress of the World Federation of Hemophilia, April 18-21, Chicago, US.
48. Forsyth A, Witkop M, Lambing A, Dunn S, Cooper DL, Nugent D Relationship of Quality of Life, Pain, Self-Reported Arthritis With Age, Employment, Bleed Rate, and Utilization of Hemophilia Treatment Center and Healthcare Provider Services: US Results From Adult Patients With Hemophilia in the HERO Study. National Hemophilia Foundation, NHF's 65th Annual Meeting, 3-5 October 2013 Anaheim California, USA

49. Stain AM, Iorio A. Canadian Social Worker and Nurse Perspectives on the Haemophilia, Experiences, Results and Opportunities (HERO) Study Results From Canada. 13th Musculoskeletal Congress of the World Federation of Hemophilia, April 18-21, Chicago, US.
50. Nugent D, Stain AM, Gregory M, Pericleous L, Cooper DL, Iorio A. Associations between Negative Impact on Employment or Relationships and Hemophilia Treatment Centre and Healthcare Practitioner Utilisation: Global Results from the HERO Study. International Society for Pharmacoeconomics and Outcomes Research. 18th Annual International Meeting, Louisiana, New Orleans. May 2013. ID 32057.
51. Associations between Inhibitors, Treatment Regimen, and Bleed Frequency and Healthcare Practitioner Utilisation in the Hemophilia Treatment Centre: Global Results from the HERO Study. International Society for Pharmacoeconomics and Outcomes Research. 18th Annual International Meeting, Louisiana, New Orleans. May 2013. ID 32056.
52. A. Iorio Study design: A critical aspect of research. 14th Musculoskeletal Congress of the World Federation of Hemophilia, May 2015, Dublin, IR.

Not Peer Reviewed

- Books
 - Contribution to books
1. Iorio A, Nenci GG. Manifestazioni Gastroenteriche delle Malattie Internistiche. In Gasbarrini A. Trattato di Gastroenterologia. Piccin, 2010, Italia
 2. Paciaroni M, Iorio A. Subarachnoid hemorrhage. In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. e-Essential Evidence. 1st ed. Hoboken, NJ: John Wiley and Sons. 01-01-2010 <http://www.essentialevidenceplus.com/content/eee/51>
 3. Makris M, Iorio A. Hemophilia. In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. e-Essential Evidence. 1st ed. Hoboken, NJ: John Wiley and Sons. 04-02-2010 <http://www.essentialevidenceplus.com/content/eee/264>
 4. Iorio A, Paciaroni M. Intracranial hemorrhage In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. e-Essential Evidence. 1st ed. Hoboken, NJ: John Wiley and Sons. 02-11-2009. <http://www.essentialevidenceplus.com/content/eee/38>

5. Iorio A. (collaborator) in J. Hirsh, G. Agnelli Tromboembolismo venoso - Guida alla diagnosi, profilassi e terapia. Il Pensiero Scientifico Editore, Roma 1993.
6. IorioA, Agnelli G: Warfarin. (Update of the Italian Medical Enciclopedia item, volume IV)
7. Book chapter: A. Iorio and G. Agnelli. Antipyretic analgesics. In: Dukes, Annual 18. Aronson J.K. and van Boxtel C.J. eds., Elsevier Science B.V., Amsterdam 1995.
8. Iorio A. The Epidemiology of Inhibitors in Hemophilia. In Textbook of Hemophilia, 3rd Edition Christine A. Lee, Erik E. Berntorp, W. Keith Hoots. May 2014, Wiley-Blackwell.

- Journal articles

9. Iorio A. Le trombofilie acquisite. Ann Med. Perugia 2001 92, suppl. 1: 38-41
10. Iorio A., Filippucci E. L'organizzazione del centro per il monitoraggio della terapia anticoagulante orale. Ann Med. Perugia 2002 suppl. 1, 93: 44-47
11. Conti S., Iorio A. I disordini congeniti ed acquisiti dell'emostasi e della fibrinolisi. Ann Med. Perugia 2003 suppl.1, 94, 108-13
12. E.Filippucci – A. Iorio. I coagulometri portatili. EsaDia, Rivista di attualità Diagnostiche, Anno 11, numero 31, pagine 30-37 2008
13. M Basileo – A: Iorio. Il processo di validazione clinica di un algoritmo computerizzato per il monitoraggio della TAO. EsaDia, Rivista di attualità Diagnostiche, Anno 11, numero 38, pagine 4-9 2011

- Journal abstracts

14. Iorio A., Filippucci E. Il monitoraggio della terapia anticoagulante orale. Atti del 53° Congresso Nazionale A.I.Pa.C., Pesaro , 13 - 16 maggio 2003, 2003, 32-37

- Proceedings of Meetings

1. Iorio, G. Agnelli, C. Renga, G.G. Nenci, E. Young, J. Hirsh. Comparison of the non specific binding of unfractionated and low molecular weight heparins to plasma proteins after administration in healthy volunteers. Atti del First International Winter Meeting on Coagulation: basic laboratory and clinical aspects of venous thromboembolism. Cortina, 9 - 12 marzo 1994.

2. Iorio, P. Parise, J. Hauert, G. Agnelli. Streptokinase and rt-PA activate platelets by a different way: implication on the rethrombosis rate after their administration in myocardial infarction. Atti del Congresso Internazionale "Mechanisms of coronary thrombosis in unstable angina and acute infarction" Roma, Università Cattolica del Sacro Cuore, 18-19 maggio 1994.
3. R. Mozzi, V. Andreoli, S. Buratta, A. Iorio, S. Pelli. Biosynthesis of phosphatidylserine by base-exchange in cerebrocortical membranes. Atti del Symposium on Progress in Neurochemistry, held on May 4-6 May 1995 in Villa S. Giovanni (RC).
4. M. Berrettini, P. Parise, S. Ricotta, M. Malaspina, A. Iorio, G.G. Nenci. Effetto degli acidi grassi polinsaturi sui livelli plasmatici di inibitore della via estrinseca in pazienti con malattia aterotrombotica cronica. Atti della riunione annuale della Sezione Tosco-Umbra della Società Italiana di Patologia Vascolare. Firenze, 30 marzo 1996, p 21.
5. P. Parise, C. Renga, M. Leone, P. Melelli, A. Iorio, G. Agnelli per il gruppo BAPE. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. Atti della riunione annuale della Sezione Tosco-Umbra della Società Italiana di Patologia Vascolare. Firenze, 30 marzo 1996, p 21.
6. Iorio A., Tascedda T., Ghirarduzzi A., Tortorella G., Casali B., Farnetti E., Bellesia E., Silingardi M., Morini L., Guiducci U., Iori I. 2001 Genima study: genetic polymorphisms and myocardial infarction among italian young adults. International Symposium "Advances in vascular pathology 2001". Monte-Carlo, 4-6 marzo
7. Iorio A., Tascedda T., Ghirarduzzi A., Cattabiani L., Brini M., Iori I. 2001 Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. International Symposium "Advances in vascular pathology 2001", Monte-Carlo, 4-6 marzo
8. Iorio A., Silingardi M., Ghirarduzzi A., Salvarani C., Bellesia E., Tascedda T., Cantini F., Govoni M., Salvi F., Iori I. 2001 Factor V Leiden and G20210A prothrombin allele are not associated with thrombosis in Behcet's disease. International Symposium "Advances in vascular pathology 2001". , Monte-Carlo, 4-6 marzo 2001
9. Iorio A., Agnelli G., Nenci G.G. 2001 Profilassi della trombosi venosa profonda in neurochirurgia. "Trombosi in Medicina Interna", Castiglione della Pescaia, aprile 2001
10. Salviato R., Belvini D., Mancuso G., Scaraggi A., Musso R., Muleo G., Iorio A., Tamponi G., Baudo F., Landolfi R., Perugini L., Tagariello G. 2002 Identificazione del difetto genico in pazienti affetti da emofilia A grave con

inibitore anti fattore VIII. XI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia, Milano, 2002, 44

11. Baudo F., Gaidano G., a nome del RIEA (Registro Italiano Emofilia Acquisita) - ., 2002 Terapia dell'emorragia da inibitore acquisito del fattore VIII (FVIII) con fattore VIIa ricombinante (rFVIIa). Abstract book del XI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia , Milano, 4, Iorio A. è elencato come membro del RIEA
12. Belvini D., Salviato R., Radossi P., Tagariello G., e A., 2002 Caratterizzazione del difetto molecolare nei pazienti italiani con emofilia B. Abstract book del XI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia , Milano, 40, Iorio A. è elencato come membro dell'AICE
13. Gringeri A., NEPTARE cooperative group -, 2002 Neptare: studio di farmacoutilizzazione di novoseven a livello domiciliare e per interventi chirurgici. Abstract book del XI Convegno Triennale sui Problemi Clinici e Sociali dell'Emofilia, Milano, 68, Iorio A. è elencato come membro del NEPTARE cooperative group
14. Minciotti A., Paccamiccio E., Trottini S., Rosafalco M., Filippucci E., Duca E., Vecchioli M., Nenci G.G., Iorio A. 2003 Terapia anticoagulante orale con l'impiego di tecnologia POC e monitoraggio via web nell'ambito del Sistema Sanitario Nazionale Italiano. 53° Congresso Nazionale A.I.Pa.C., Pesaro, 13 - 16 maggio 2003, A3-26
15. Iorio A.[Correspondent Author], Filippucci E., Testa S., Parisoli A., Alatri A., Franzoni M., Trottini S., Rinaldi G., Ghirarduzzi A. 2003 Programma per la valutazione della qualità clinica nei Centri di Sorveglianza degli Anticoagulati. Risultati preliminari di un' esercizio multicentrico italiano. 53° Congresso Nazionale A.I.Pa.C., Pesaro, 13 - 16 maggio 2003, A3-25
16. Gruppo Italiano E., 2003 Studio ECAPS (emorragie cerebrali in Pronto Soccorso in pazienti in terapia anticoagulante od antiaggregante):dati preliminari a metà del progetto. Atti del Congresso SIMEU , Roma, Roma, Iorio A. è elencato come membro del Gruppo Italiano ECAPS
17. Iorio A., Morfini M., a nome dell'Associazione Italiana Centri Emofilia -. 2005 Verso il nuovo registro nazionale dell'emofilia: metodologia di lavoro e risultati preliminari. XII Convegno Triennale sui problemi clinici e sociali dell'emofilia, Milano, 17-20 Novembre , 73
18. Mancuso M., Santagostino E., Rumi M., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolini R., Colombo M., Mannucci P. 2005 Eradicazione del virus C dell'epatite (HCV) dopo terapia combinata con Interferone Pegilato (PEG-INF) e Rivabirina in pazienti emofilici HIV negativi. XII Convegno Triennale sui problemi clinici e sociali dell'emofilia, Milano, 17-20 Novembre, 92

19. Camilloni B., Iorio A.M., Neri M., Lepri E., Ferrante F., Guercini F., Iaboni S., Paccamiccio E., Iorio A. 2006 6th National Congress of the Italian Society of Virology a joint meeting with the Virus Group of the Society for General Microbiology (UK). Orvieto (TR), 18-20 september 2006, 79 tris; 78
20. Bauleo F.A., Cavalletti P., Puccetti M., Basigliani I., Iaboni S., Iorio A., Paccamiccio E., Cordiano R., Tacchio A.R. Miglioramento nella gestione di patologie croniche: una esperienza distrettuale sul monitoraggio TAO. Atti del XVI Congresso della SiQuas-VRQ, tenutosi ad Assisi il 16-17 novembre 2006
21. Iorio A, Basileo M, Marchesi M, Rocchetti L, Esposito A; Palazzesi GP, Materazzi M, Pellegrini L, Marchesini E, Silvani C. Audit clinico sull'impiego di plasma fresco congelato (PFC) in Umbria: disegno dello studio e risultati preliminari. Atti del Convegno dei Servizi trasfusionali (SIMTI), Stresa 24-26 settembre 2007
22. Iorio A, Basileo M, Marchesi M, Rocchetti L, Esposito A; Palazzesi GP, Materazzi M, Pellegrini L, Marchesini E, Silvani C. Utilizzo di AGREE per l'analisi delle linee guida internazionali sul buon uso del plasma. Atti del Convegno dei Servizi trasfusionali (SIMTI), Stresa 24-26 settembre 2007
23. Dragani, E. Marchesini, M. Carloni, E. Olioecchio, F. Ferrante, O. Iuliani, G. Agnelli, A. Iorio. HAEMOPHILIA MANAGEMENT THROUGH AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. Atti della XX° Conferenza dell'European Haemophilia Consortium (EHC), Parma 15-17 maggio 2007
24. Iorio, A. Gringeri, J. Hassan, P. Iannaccaro, M. Morfini, G. Rossetti, A. Scaraggi, M. Schiavoni, P. Schinco, A. Tagliaferri. THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES. . Atti della XX° Conferenza dell'European Haemophilia Consortium (EHC), Parma 15-17 maggio 2007
25. Iorio A, Barbara AM, Barthy R, Vasilic L, Liu Y, Iserman E, Crowther M, Cotoi C, Taggart K, Cameron S, Haynes B, Heddle N. MASCOT: Linkage at McMaster Health Sciences of ACCESSSS, Clinical Clustering Information, OSCAR and the Ad-Hoc Developed TRUST-XT Database: Proof of Concept of a Knowledge Translation Need and Impact Assessment Strategy. Ontario Innovation Fund Showcase: From Innovation To Practice. Metro Toronto Convention Centre, Toronto, November 2013. Poster.

i
i Accepted for Publication (in final form)
i
i
i

1. Holger Schünemann, Matthew Ventresca, Mark Crowther, Matthias Briel, Qi Zhou, David Garcia, Gary Lyman, Simon Noble, Fergus Macbeth, Gareth Griffiths, Marcello DiNisio, Alfonso Iorio, Joseph Beyene, Lawrance Mbuagbaw,

Ignacio Neumann, Nick Van Es, Melissa Brouwers, Jan Brozek, Gordon Guyatt, Mark Levine, Stephan Moll, Nancy Santesso, Michael Streiff, Tejan Baldeh, Ivan Florez, Ozlem Gurunlu Alma, Ziad Solh, Walter Ageno, Maura Marcucci, George Bozas, Gilbert Zulian, Anthony Maraveyas, Bernard Lebeau, Harry Buller, Jessica Evans, Robert McBane, Suzanne Bleker, Uwe Pelzer, Elie A. Akl, and the IPDMA heparin use in cancer patients research group. Use of heparins in patients with cancer: Individual participant data meta-analysis of randomized trials study protocol. BMJ open, accepted for publication.

i Submitted for Publication

1. Chatree Chai-Adisaksopha, Alfonso Iorio, Said Y AlKindi, Matthew Cheah, Mark A Crowther, and Lori-Ann Linkins Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumors. BLOOD/2015/689927
2. Iosief Abrahama, Francesco Cozzolino, Massimiliano Orso, Mauro Marchesi, Antonella Germani, Guido Lombardo, Paolo Eusebia, Rita De Florio, Maria Laura Luchetta, Alessandro Montedori, Alfonso Iorio. The Epidemiology and Characteristics of Randomized Trials Based on the Intention-to-Treat Reporting in Systematic Reviews. BMJ open, submitted.

j Unpublished Documents

- a) technical report series
- b) other

• e-publications

- 1) Iorio A, E. Olivoecchio. Pagine pubbliche del Registro Nazionale delle Coagulopatie Congenite. <http://www.aiceonline.it/PublicPages.htm>
- 2) Cartabellotta A e Iorio A. Metodologia di produzione delle LG Siset. <http://www.siset.org/lineeguida/metodologia.pdf>
- 3) Iorio A, Bucciarelli P, Coccheri S, De Caterina R, Di Pasquale G, Marino P, Pengo V, Prisco D, Santini M. Profili anti-trombotici nel paziente con fibrillazione o flutter atriale sottoposto a cardioversione. <http://www.siset.org/lineeguida/LG6.pdf>
- 4) M Morfini, G Calizzani, HJ Hassan A, A Iorio, C Molinari, G Muleo, E Santagostino, AR Tagliaferri. Improve AICE. <http://www.improveaice.it/>

q. Presentations at Meetings

- i) Invited

- 1) Third Symposium on Glycosaminoglycans, blood cells and endothelium - Results and perspectives of bilateral collaboration on novel approaches to pharmacokinetics and metabolism. Como, May 3-5, 1993.
- 2) Up-to-date course "Heparin therapy in the '90" organized in Milan by the Instrumentation Laboratory on June 16-17 1994, lecture on "New antithrombotic agents".
- 3) Fourth Symposium on Glycosaminoglycans. Non-anticoagulant actions of Glycosaminoglycans - Results and perspectives of the German-Italian collaboration. Como October 6 – 9, 1994.
- 4) "Clinical pharmacology of antithrombotic and thrombolytic agents", at the 3^o meeting of the course 'Thrombosis in cardiovascular diseases' organized by the Hearth Foundation 'Myriam Zito Sacco' and the Azienda U.S.L. of Rimini, held in Rimini on June 24, 1995.
- 5) "Treatment of thromboembolic disease". "Venous and arterial Thrombosis: New acquisitions". Cuneo, November, 1996.
- 6) "Anticoagulant therapy after peripheral vascular surgery." IV Residential Course in "Antithrombotic Prophylaxis and Therapy" Parma, April 10, 1997. (keynote speaker)
- 7) "Anticoagulant therapy after peripheral vascular surgery." V Residential Course in "Antithrombotic Prophylaxis and Therapy" Parma, October 16, 1997. (keynote speaker)
- 8) "The laboratory diagnosis of platelet function disorders." "Ematologia 1999". Istituto di Ematologia e Oncologia Medica "L. e A. Seragnoli". Università degli Studi di Bologna. Reggio Emilia, January 16, 1999.
- 9) "Laboratory diagnosis and molecular genetics", at the XL National Congress of the Società dei Neurologi, Neurochirurghi e Neuroradiologi Ospedalieri. Otranto June 3, 2000.
- 10) "Acquired Thrombophilia": Post-degree Course in Vascular Medicine. University of Perugia. Perugia, June 11-15, 2001.
- 11) "Information technology in the clinical laboratory" – Lecture at the "Scuola di Specializzazione in Igiene e Medicina Preventiva" of the University of Modena and Reggio Emilia, held in Modena on May 25, 2001. (keynote speaker)
- 12) "Quality, efficacy and appropriateness of health care activities". Lecture in courses organized in Roma by the Moccia Group and sponsored by Merck Sharp & Dohme under the auspices of the Aziende Sanitarie Locali Roma B (Sandro Pertini Hospital), Roma E (S.Spirito Hospital), Roma G (Roccapriore Hospital), 2001. (keynote speaker)

- 13) "Oral anticoagulant therapy management": 9th Post-degree Course in Vascular Medicine. University of Perugia. Perugia, June 10-14, 2002.
- 14) "Physiopathology of the hemostatic system" 4th Residential Course in Laboratory Medicine – Thrombophilia – SIMEL Orvieto September 25 and 30, October 9, 2002, Orvieto
- 15) "Acquired Thrombophilia". Course "Venous Thromboembolic Disease" Centro per la formazione permanente e l'aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. (keynote speaker)
- 16) "The laboratory of Hyperhomocyst(e)inemia". Course "Venous Thromboembolic Disease" Centro per la formazione permanente e l'aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. (keynote speaker)
- 17) "Use of diagnostic test for DVT". Course "Venous Thromboembolic Disease" Centro per la formazione permanente e l'aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. (keynote speaker)
- 18) Chairman of the session "Thrombophilia I" at the 17th International Congress on Thrombosis of the Mediterranean League against Thromboembolic Diseases. Bologna, October 26-30, 2002.
- 19) The management of oral anticoagulant therapy, at the 35° National Meeting of the A.I.Pa.C., held in Pesaro on May 13-16, 2003
- 20) ITT in severe Haemophilia A patient with high level inhibitor. Course "Inhibitor and immunotolerance in haemophilia: State of the Art from the clinical practice to the scientific aspects". Held in Rosia on May 16, 2003
- 21) Automation for the laboratory diagnostics of haemorrhagic diseases. 5° Residenzial Course in Laboratory Medicine "laboratory Diagnosis of Haemorrhagic diseases. Held in Orvieto, on May 26, 2003 (keynote speaker)
- 22) The management of bleeding patients with liver deficiency. Course: Nursing of high risk patients for thromboembolic and haemorrhagic diseases. CEFPAS, Held in Caltanissetta, on October 14 and 15 2003
- 23) The management of gastrointestinal and urinary tract bleeding. Course: Nursing of high risk patients for thromboembolic and haemorrhagic diseases. CEFPAS, Held in Caltanissetta, on October 14 and 15 2003
- 24) Haemophilia: the future has begun", at the 1° National Professional Training Course: "Global Mangement of the haemophilia patient", held in Perugia on June 20 and 21 2003

- 25) "Randomization, data management and data analysis". Workshop "Venous Thromboembolism recurrences and the Prolong Study, held in Bologna on June 24, 2003.
- 26) Congenital and acquired disorders of haemostasis and fibrinolysis. 10° Course in Vascular Medicine: Cerebrovascular Diseases – Haemorrhagic Coagulopathies, held in Perugia on June 16 to 20, 2003
- 27) Prevention and treatment of thromboembolic events in the medical patient. ECM Course "Home treatment of the patient at risk for thromboembolic diseases, held in Cortona, on May 24, 2003. (keynote speaker)
- 28) Diagnosis and classification of von Willebrand Disease. First Interregional Meeting on Haemorrhagic Diseases, held in Macerata on May 31 2003
- 29) Quality control of oral anticoagulant treatment, at the 2003 National Meeting of the FCSA, held in Abano on March 20 and 21 2003.
- 30) Distributed oral anticoagulant treatment at the 2003 National Meeting of the FCSA, held in Abano on March 20 and 21 2003
- 31) State of the art regarding the National Haemophilia Registry, at the II 2003 AICE meeting; held in Turin on November 21 2003 (keynote speaker)
- 32) Administrative and management issues in the oral anticoagulant management centre. - Annual meeting of the Italian Association of Anticoagulation Clinics (FCSA), March 11-12 2004, Milan.
- 33) Hemophilia A: pathogenesis and clinical presentations, at the meeting "Update in congenital coagulopathies: the role for prophylaxis", held on March 27, 2004, Cagliari
- 34) Annual Training Course of the Italian Association of Dentistry (AIO), "Internal Medicine Course for Dentists", held on April 3, 2004, Perugia (keynote speaker)
- 35) "Current activities of the Hemophilia Centre in Perugia" at the Annual Meeting of the AUAFE (Umbria associations friends of the Hemophilia Foundation), held on April 17, 2004, Bastia Umbria
- 36) Telemonitoring of patients on chronic oral anticoagulant therapy, at the Meeting "Internet to extend action in various activity fields" held at the Trade Organization, April 27th, 2004, Milan
- 37) Update of the analysis of the National Haemophilia Registry, at the I 2004 AICE meeting; held on May 26-28 2004, Parma (keynote speaker)
- 38) "Molecular diagnosis" at the Meeting "Clinics and diagnostics of thrombophilic states", held on June 24th, 2004, Amatrice.

- 39) Chairman of the Oral Communication Session “Prevention and Treatment of Venous Thromboembolism” at the XVIII National Meeting of the Italian Society for Thrombosis and Haemostasis, held on September 30 to October 3, 2004, Rome.
- 40) “Approach to the patients on oral anticoagulants who needs to undergo surgery, at the L’ approccio terapeutico nel paziente anticoagulato che deve sottoporsi ad interventi chirurgici, at the meeting Oral pathologies in hemophilic and anticoagulant-treated patients” held on October 30th, 2004, Macerata
- 41) Telemonitoring systems for patients on chronic oral anticoagulant therapy, at the Annual Training course of the Italian Federation of anticoagulation clinics (FCSA), held on November 12-14, 2004, Cagliari
- 42) Update of the analysis of the National Haemophilia Registry, at the II 2004 AICE meeting; held on November 18-20 2004, Palermo (keynote speaker)
- 43) New antithrombotic treatments”: at the meeting on “Oral anticoagulant treatment” held on December 11th 2004, Sondrio
- 44) “von Willebrand Disease” at the IV Course in Pediatric Haematology and immunohematology, held on January 28-29 2005, Rome
- 45) “Quality control in the coagulation laboratory: the role for the Italian Association of Hemophilia Centres (AICE), held on March 18-19, 2005, Bari
- 46) “Sports and bleeding disorders” at the Specialization Course in Sports Medicine, University of Rome, April 18th, 2005, Rome (keynote speaker)
- 47) Interim analysis of the Prolong Study” at the Workshop on collaborative italian studies on venous thromboembolism held by the Italian Federation of Anticoagulation Clinics (FCSA), held on May 18th, 2005, Bologna (keynote speaker)
- 48) “Does new evidence let us agree new recommendations for the management of venous thromboembolism in the Emergency Department?” at the meeting “Update on the management of deep vein thrombosis and pulmonary embolism. Siset workshop on new pathways on management on venous thromboembolism in the emergency department” May 27-28, 2005 Palermo
- 49) “Evidence Based Medicine, levels of evidence and recommendations” at the meeting “Update on the management of deep vein thrombosis and pulmonary embolism. Siset workshop on new pathways on management on venous thromboembolism in the emergency department” May 27-28, 2005 Palermo
- 50) “Emocard, a case report form to improve the quality of hemophilia treatment” at the launching meeting of the Hemophilia Centre of L’Aquila, held on June 18th, 2005 L’Aquila.
- 51) Update of the analysis of the National Haemophilia Registry, at the I 2005 AICE meeting; held on June 24 2005, Pisa (keynote speaker)

- 52) Automated D-dimer for the diagnosis of DVT and DIC. Annual Meeting of the Chinese Society of Haematology, September 11th, 2005, Chengdu, China (keynote speaker)
- 53) Automated D-dimer for the diagnosis of DVT and DIC. Workshop on new advances in the coagulation laboratory, September 13th, Beijing, China (keynote speaker)
- 54) “Role of the laboratory in the diagnosis of venous thromboembolism” at the VII Educational Course of the Italian Society of Thrombosis and Haemostasis (SISIT) – Approach to the diagnosis of haemorrhagic and thrombotic disorders, September 16-17, 2005, Brescia
- 55) Antiphospholipid antibodies Syndrome. VII Educational Course of the Italian Society of Thrombosis and Haemostasis (SISIT) – Approach to the diagnosis of haemorrhagic and thrombotic disorders, September 16-17, 2005, Brescia (keynote speaker)
- 56) Oral anticoagulant therapy and telemedicine at the National Training course of the Italian Society for Thrombosis and Haemostasis, held on September 22-24, 2005 Campobasso
- 57) Hormonal cancer therapy and thrombotic risk at the 1st Italian Meeting about Thrombosis and Haemostasis in the woman and in the child, Held on October 6-8 2005, Padua (keynote speaker)
- 58) Annual Training Course of the Italian Association of Dentistry (AIO), “Internal Medicine Course for Dentists”, held on October 21st, 2005, Perugia (keynote speaker)
- 59) Update of the analysis of the National Haemophilia Registry, at the II 2005 AICE meeting; held on November 17-18 2005, Milano (keynote speaker)
- 60) “Toward an interregional network” at the Annual Meeting of the AUAFE (Umbria associations friends of the Hemophilia Foundation), held on November 26th, 2005, Bastia Umbria
- 61) Update of the analysis of the National Haemophilia Registry, at the I 2006 AICE meeting; held on March 30-31 2006, Florence (keynote speaker)
- 62) Hormonal cancer therapy and thrombotic risk at the National Meeting Cancer and Thrombosis: up to date of medical knowledge, held on May 13th 2006, Piacenza
- 63) Physiopathology of Thrombosis and Haemostasis, at the Meeting “Thrombophilia and thrombosis: risk factors and laboratory workup”, held on May 19th, 2005 in Nottola di Montelpuciano by the Italian Society for Laboratory Medicine (SIMeL)
- 64) “New and old drugs” at the IV^o Interregional Meeting “Update in Laboratory Medicine: Deep Venous Thrombosis in Internal Medicine” held on June 8, 2006 in Rieti

- 65) Update of the analysis of the National Haemophilia Registry, at the II 2006 AICE meeting; held on September 13 2006, Florence (keynote speaker)
- 66) “The methodology for the SISET guidelines program” at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan (keynote speaker)
- 67) “Antithrombotic prophylaxis for patients with atrial fibrillation undergoing electrical cardioversion” at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan
- 68) “Telemedicine applications for oral anticoagulants management: a health service based model” at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan
- 69) “Intracerebral haemorrhage treatment in the patient on oral anticoagulants” at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan
- 70) “Prophylactic treatment in haemophilia” at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan (keynote speaker)
- 71) “Iatrogenic causes of an ICH: OAT therapy” at the NovoSeven Working Day – Decennial Rome 27-29 September 2006
- 72) “The Interregional EmoWeb Database for hemophilia patients: facilities for patients and physicians, at the I Meeting “The union of three regions for scientific research and health care promotion”, held on September 30th, 2006, S.Benedetto del Tronto
- 73) “Telemedicine applications for oral anticoagulants management: a health service based model” at the XXXVII National Meeting of the Italian Transfusion Society (SIMITI) – held on October 4-7 2006, Paestum
- 74) “Intracerebral Haemorrhage treatment” at the Meeting “Critical bleeding and bleeding deficiencies” held on October 13th, 2006 in Florence (keynote speaker)
- 75) Oral anticoagulant treatment management: role for the general medical practitioner at the meeting “Prophylaxis and treatment of venous thromboembolism in general medicine” held on October 14, 2006 in Perugia
- 76) Proposal of Intersociety guidelines about anticoagulant therapy in the Emergency Department, at the V National Meeting of the SIMEU/ACEP, held in Turin, November 9 to 11, 2006 (keynote speaker)
- 77) Abnormalities of platelet function: which clinical role? at the training course “Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events”, held in Palermo, November 27 to 28, 2006.

- 78) Clinical suspicion of Deep Vein Thrombosis and/or Pulmonary Embolism: pre-test clinical probability and choice of diagnostic tests, at the training course “Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events”, held in Palermo, November 27 to 28, 2006.
- 79) Management of the patient with congenital or acquired disorders of haemostasis, at the training course “Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events”, held in Palermo, November 27 to 28, 2006.
- 80) Treatment of thromboembolic events in presence of heparin induced thrombocytopenia, at the training course on “Diagnosi, treatment and follow up venous thromboembolism. Results and perspectives of the Prolong studies, held in Bologna on January 15, 2007.
- 81) Update on the Italian National Registry of Congenital Coagulopathies, at the AICE meeting in Copanello, April 28 to 29, 2007. (keynote speaker)
- 82) Anticoagulant therapy, at the Brescia Intensive Care Neuroscience meeting, held in Brescia on May 9 to 11, 2007
- 83) Telemedicine Systems: applications to monitoring of oral anticoagulant therapy and to self-testing, at the SIMeL training course “Quality, efficiency, clinical laboratory automation”, held in Francavilla al Mare on May 31, 2007.
- 84) Management of ITI in the hemophilic patient with inhibitor: importance of the anamnestic reponse and of therapy duration, at the meeting “Scientific update on Coagulopathies, held in Pisa on June 30, 2007.
- 85) Long term treatment of venous thromboembolism, at the XIV post-doctoral course in Vascular Medicine, held in Perugia on September 13 to 15, 2007.
- 86) National Hemophilia Registry - Emocard – State of the Art, at the AIEC Meeting: Organization of Hemophilia Health Care, held in Bari on September 19, 2007 (keynote speaker)
- 87) Methodology of the SISET Guidelines, at the National SISET course, held in Bari on September 20 to 21, 2007 (keynote speaker)
- 88) Antithrombotic prophylaxis in the patients with atrial fibrillation or atrial flutter undergoing cardioversion, at the National SISET course, held in Bari on September 20 to 21, 2007
- 89) Clinical indication to factor VIIa use, at the National SISET course, held in Bari on September 20 to 21, 2007
- 90) “Open issues in oral anticoagulant therapy”, during the training course “Home prophylaxis. Prophylaxis of venous thromboembolism in the medical patient: new evidence” held in Città di Castello on September 29, 2007

- 91) Oral anticoagulant therapy management. Role of decentralized systems in peripheral health care units, at the XXXIX National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, held in Rimini on October 2 to 5, 2007
- 92) The coagulation laboratory in the monitoring of coagulation active treatments, at the SIMeL training course “Sinergisms between clinics and the laboratory for haemorrhagic and thrombotic disorders”, held in Umbertide on January 16, 2008
- 93) Management of the adult haemophilic patient, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 94) Management of the haemophilic patient with inhibitor, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 95) Management of surgery in the haemophilic patient, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 96) Rare haemorrhagic disorders, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 97) Acquired hemophilia, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 98) Assessment of factor recovery and half-life, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 99) Quality control in the coagulation laboratory: the AICE experience, at the training course “Management of congenital and acquired disorders”, held in Florence on January 24 to 26, 2008. (keynote speaker)
- 100) The SISET guidelines, at the Meeting “News about prophylaxis and treatment of venous thromboembolism”, held in Cremona on February 15, 2008.
- 101) Open issues in the management of VKA therapy, at the training course on venous thromboembolism organized by the Umbra School of General Medicine held in Bastia Umbra on February 23, 2008.
- 102) Moderazione della sessione la Malattia di Von Willebrand, nell’ambito del convegno “Malattie rare emorragiche e congenite: La profilassi, tenutosi a Verona il 28-29 febbraio 2008
- 103) “I fattori di rischio nello sviluppo degli inibitori: i vaccini” nell’ambito del workshop “Dall’esperienza clinica alle raccomandazioni internazionali: 20 anni di terapia dell’emofilia A con concentrati ricombinanti”, tenutosi a Roma il 14-15 marzo 2008

- 104) Emorragia Cerebrale, nell'ambito del Corso di Aggiornamento "Il paziente emorragico e l'emorragia critica", tenutosi a Castelfranco Veneto il 3 aprile 2008
- 105) Moderazione della sessione Bleeding disorders, nell'ambito dell'8th International Winter Meeting on Coagulation: "Basic, Laboratory and Clinical Aspects of Venous and arterial Thromboembolic diseases", tenutosi a Bormio dal 6 al 12 aprile 2008.
- 106) Update sul Registro nazionale dell'emofilia, nell'ambito del Convegno AICE "Il trattamento dell'emofilia e delle sue complicanze nel terzo millennio", tenutosi a Milano il 9 aprile 2008. (keynote speaker)
- 107) Indicazioni cliniche all'uso del fattore VII attivato, nell'ambito del Convegno "Aggiornamento in Emostasi e Trombosi" tenutosi ad Ancona il 18 aprile 2008
- 108) Il fattore VII attivato nell'emorragia intracranica spontanea o traumatica del paziente in TAO: quali evidenze? Quali indicazioni?, nell'ambito del Congresso Regionale SIMEU Emilia Romagna "Urgenze trombotiche ed emorragiche in Medicina d'Urgenza, tenutosi a Ravenna il 14 maggio 2008
- 109) Antivitamin K management: the future?, nell'ambito del 12° European Vascular Course, tenutosi ad Amsterdam dal 15 al 17 maggio 2008 (keynote speaker)
- 110) SISET guidelines about antithrombotic treatment for cardioversion, at the X training course "Antithrombotic treatment in cardiology", held in Florence on May 25 to 27, 2008. (keynote speaker)
- 111) Chairman of the round table "Oral contraceptive and hormonal replacement therapy and thrombosis: advice for the woman, at the 2° Italian Congress on Thrombosis and Haemostasis in women and children, held in Padua on May 22 to 24, 2008.
- 112) Pharmacological prevention of deep vein thrombosis, at the XI educational course of the SISET "The mediterranean sea and prevention in haemostasis and thrombosis, 2° day, held in Lecce on July 11-12, 2008.
- 113) The SISET guideline methodology: general and special issues, at the XX National Congress of the SISET, held in Bari, September 25-28, 2008.
- 114) Clinical epidemiology about the clinical use of rFVIIa: evidences from registries and survey. XX National Congress of the SISET September 25 to 28, 2008
- 115) Haemorrhagic complications caused by overdose of antithrombotic therapy, at the XX National Congress of the SISET, September 25-28, 2008
- 116) Bridging therapy" during oral anticoagulant therapy: Cons". XV Course on Vascular Medicine and Stroke, held in Perugia on October 16 to 18, 2008.
- 117) The Italian Registry of Hemophilia and related syndromes: a tool for health care planning of a rare disease at the XIII National Meeting of Clinical and Social Aspects of Hemophilia, held in Milan on October 14 to 16, 2008

- 118) An emerging pathology: acquired inhibitor of coagulation and their laboratory workup, at the training course “Management of bleeding emergency”, held in Rieti on November 18, 2008.
- 119) VKA antagonists treatment: a treatment tool to be better understood. When to use it? at the 25^o National Meeting of the SIMG, held in Florence, November 20 to 22, 2008
- 120) The Good use of Plasma: Guidelines, at the Symposium: “From Blood collection to pharmacoeconomy: a trip through hemophilia and hemorrhagic emergency” held in Castelfranco Veneto on November 21, 2008
- 121) Decentralized management of VKA therapy, at the training course on oral anticoagulant therapy, held in Perugia on November 15, 22 and 29, 2008
- 122) Venous thromboembolism recurrence after a first thrombotic event due to a removable risk factor, at the training course on: follow up after venous thromboembolism and the Dulcis Study, held in Bologna on December 9, 2008.
- 123) International clinical trials are the best way to improve global haemophilia care: No. 2nd Congress in Munich. European Association for Haemophilia and Allied Disorders. Thursday 26th February 2009.
- 124) NovoSeven® and rare bleeding disorders: laboratory assays, clinical aspects and registries. Factor VII deficiency, at the “NovoSeven Working Day, between experience and innovation, a likely future” held in Rome on March 5 to 6, 2009.
- 125) Update on the National Hemophilia Registry, at the AICE meeting “Hemophilia treatment and related side effects in the third millennium, held in Milan on March 18, 2009
- 126) Heparin monitoring: a patient centered view. Innovative solution for health care, held in Vibo Valentia on April 1, 2009.
- 127) Efficacy and safety results about Moroctocog alpha: studies 310-311. Refacto AF launching symposium, Lisbona, Portugal, April 24th, 2009
- 128) Management of bleeding emergencies in the adult patient. XIV National Meeting of the Italian Federation of Internal Medicine Directors, Cenobbio (Como), May 13-16 2009
- 129) New antiemophilic factors: registrative studies. Symposium: A new generation of anti-hemophilic factors. Rome, June 19th 2009
- 130) A metanalysis of the available cohort studies. At the SIPPET SYMPOSIUM Boston – July, 14th 2009
- 131) New Recombinant Derivatives of Factor VIII, Moroctocog alfa (AF-CC): Pharmacokinetics. At the Refacto AF launching symposium, Syros, Greece, September 13th, 2009.

- 132) Interactive review of six case Interactive Sessions: Bridging from Theory to Practice. Bayer-Schering-Plug European Hematology Meeting, Riga, Latvia, September 17-19, 2009.
- 133) News about oral anticoagulant management in the new version of the ACCP guidelines. Oral anticoagulant treatment: up to date. Macerata, September 25th, 2009.
- 134) Management of bleeding in patients on oral anticoagulant treatment. National Course of the Italian Society of Thrombosis and Haemostasis. Varese, September 25-27 2009.
- 135) Epidemiology of von Willebrand Disease: data from the AICE registry. Treatment of von Willebrand Disease: from DDAVP to purified factor VIII concentrates. Milan, October 14, 2009.
- 136) Update on the National Hemophilia Registry, at the AICE meeting, held in Milan on October 15, 2009.
- 137) The Sixty plus Prospective Hemophilia Registry and Assessment, at the AICE meeting held in Milan on March 18, 2009.
- 138) Chair of the opening session of the 16th Master Course in Vascular Medicine, University of Perugia, Perugia October 22 to 24, 2009.
- 139) Prophylaxis: Is it a right for all patients? NO. During the symposium Hemophilia principles of care. The clinical decision, held in Rome on November 13th, 2009.
- 140) Update on the National Hemophilia Registry, at the AICE meeting, held in Milan on March 11, 2010.
- 141) Moroctocog alfa: Clinical Evidence and Experience, at the educational program "Treating hemophilia" at the Annual meeting of the ISTH subcommittees, held in Il Cairo on May 21-24, 2010.
- 142) Managing hemophilia in the elderly: a multimedial approach through the virtual case of Patrizio, held in Padua on April 19-20, May 5-6 and 9-10.
- 143) "Il problema degli inibitori nell'emofilia: i dati nazionali e internazionali", at the Continuing Education Course: Affrontare I problemi psicologici dell'emofiliai", held in Naples on July the 2nd, 2010.
- 144) Chairman of the session on "Pulmonary Embolism" at the 21st International Thrombosis Congress of the Mediterranean League against Thromboembolic diseases, held in Milan on July 6-9, 2010.
- 145) "Evaluation of enhanced on-demand treatment in inhibitor patients", Symposium "Securing and maintain joint health in inhibitor patients" at the Hemophilia World

- Congress of the World Federation of Hemophilia, held in Buenos Aires, July 9-14 2010
- 146) Chairman and teacher of the preceptorship course “Optimizing recombinant therapy in Hemophilia B in Japan” at the Hemophilia World Congress of the World Federation of Hemophilia, held in Buenos Aires, July 9-14 2010.
- 147) How to become a better researcher: Tools to overcome the hurdles. At the NovoNordisk Global Hemophilia Network Meeting “Changing possibilities in Haemophilia” held in London on September 12-14 2010.
- 148) Indicazioni CLiniche all’uso del fattore VII. Al Congresso 2010 della Federazione degli Aiuti e Direttori Ospedalieri Internisti, sezione triveneto, Riva del Garda, 7-9 ottobre 2010.
- 149) The Italian Registry of Congenital Coagulopathies, at the XXI Congress of the Italian Society for Thrombosis and Haemostasis,, held in Bologna, October 27-30, 2010. (keynote speaker)
- 150) The Italian Registry of Congenital Coagulopathies, at the First Italian Course for Emerging Physicians in Hemophilia, held in Florance, November 2-5, 2010.
- 151) Chairman of the Educational Advisory Board about Hemophilia Treatment guidelines and opportunities, held in Beirut, Lebanon, on November 4 and 6 2010. (keynote speaker)
- 152) Optimizing therapy in hemophilia B. Interactive workshop at the Pfizer sponsored global summit “Managing Hemophilia for Life”, held in Rome on November 26 to 28th, 2010.
- 153) Is there still a role for Warfarin in low risk patients with Atrial Fibrillation? At the preceptorship in cardiological hot issues organized by the Population Health Research Institute, held in Hamilton on April 14th, 2011 (keynote speaker)
- 154) Update on The Italian Registry of Congenital Coagulopathies, at the 7th Bari International Conference (BIC)- 21-23 Maggio 2011.
- 155) Interventions to reduce inhibitors: Product choice at the Canadian Hemophilia Physician Update, Toronto, June 10-12, 2011. (keynote speaker)
- 156) Guida alla lettura di un trial clinico and Gli aspetti psico-sociali nell'emofilia at the meeting LE COAGULOPATIE CONGENITE: COME VIVERE UNA VITA “NORMALE”, Perugia 23-24 Settembre 2011
- 157) A. Iorio. Profilassi nell'emofilia. La nuova COCHRANE at the XIV Convegno sui problemi clinici e sociali dell'emofilia 4 . 6 novembre 2011 Firenze.
- 158) Update on The Italian Registry of Congenital Coagulopathies, at the XIV Convegno sui problemi clinici e sociali dell'emofilia 4 . 6 novembre 2011 Firenze.

- 159) Interpreting inhibitor rates in haemophilia A at the international meeting: Managing Haemophilia for Life, Global Summit held on November 18-20, 2011 in Madrid. (keynote speaker)
- 160) Current Evidence of Immunogenicity of Factor Products at the ASH satellite Symposium New Technologies in the Treatment of Hemophilia: Impact on Clinical Practice *December 10, 2011* San Diego, California. (keynote speaker)
- 161) Hemophilia outside the realm of the hematologist. Chair Grand Round, Department of Medicine, McMaster University, Hamilton, February 1st, 2012. (keynote speaker)
- 162) Inibitori nei PTP. Hemophilia Care, a lifelong commitment. April 19-20, 2012. Rome, Italy.
- 163) Medical Update on EAHAD Data. Hemophilia Advisory Board Meeting. Quebec City, QC. April 28, 2012.
- 164) Iorio A. The use of the clinical trial design in hemophilia: methodological considerations. Plenary Lecture. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1. (keynote speaker)
- 165) A. Iorio. Inhibitors in PTPs. Hemophilia Care: A Lifelong Commitment. Rome, Italy April 19-20, 2012.
- 166) A. Iorio. Practical approaches to assessing the risk and management of inhibitors: The state of the art. 1st AfME Hemophilia Forum Managing Hemophilia for Life May 18-19th 2012, Dubai. (keynote speaker)
- 167) A. Iorio. Managing inhibitor development in hemophilia: a case study. 1st AfME Hemophilia Forum Managing Hemophilia for Life May 18-19th 2012, Dubai. (keynote speaker)
- 168) Dr Lou Aledort and Dr Alfonso Iorio. Immunogenicity of rBDD FVIII and rFL FVIII: A Debate. Canadian Hemophilia Physician Update. Halifax, June 16, 2012. (keynote speaker)
- 169) A. Iorio. Pearl and pitfalls in evaluating inhibitor data. Biogen satellite symposium. XXX International Congress of the World Federation of Hemophilia, July 8-12, 2012 Paris, France. (keynote speaker)
- 170) A. Iorio. HERO – a multi-stakeholder approach to better haemophilia care Novo Nordisk Satellite Symposium. XXX International Congress of the World Federation of Hemophilia, July 8-12, 2012 Paris, France. (keynote speaker)
- 171) A. Iorio. Risk factors for Inhibitors: state of the art and epidemiological considerations. Invited Lecture at the Meet the expert session – Auckland, New Zealand. September 27, 2012. (keynote speaker)

- 172) A. Iorio. Factor VII treatment of hemophilia – Facting the development and treatment of inhibitors. 3rd Biotest European Haemophilia Forum Naples/Italy, October 10 – 13, 2012.
- 173) A. Iorio. A Physician's Perspective on aging with a Bleeding Disorder. Hemophilia Ontario CWOR: Aging with a bleeding disorder. Hamilton, ON, November 3rd, 2012.
- 174) A. Iorio and V. Jimenez-Juste. Debate: The majority of inhibitors will resolve with routine low-dose prophylaxis. Global Summit: Managing Haemophilia for Life, Windsor, UK, 16–18 November 2012 (keynote speaker)
- 175) A. Iorio Approaches to assessment of inhibitor development in clinical trials. Global Summit: Managing Haemophilia for Life, Windsor, UK, 16–18 November 2012 (keynote speaker)
- 176) A. Iorio. Acquired Hemophilia: An Elusive but Important Diagnosis for the Internists. University of Calgary, Department of Medicine Rounds. Calgary, Alberta. January 15, 2013. (keynote speaker)
- 177) A. Iorio. Recombinant vs. Plasma derived factors. Pfizer satellite symposium, Franco-Argentinean Symposium of Academia Nacional de Medicina in Buenos Aires, April 18, 2013. (keynote speaker)
- 178) A. Iorio. HERO – a multi-stakeholder approach to better hemophilia care. 10th Annual National Hemophilia Congress. Novo Nordisk Satellite Symposium. Izmir, Turkey. April 15, 2013. (keynote speaker)
- 179) A. Iorio. Comparing immunogenicity of factor concentrates through meta-analysis of published studies: strengths and limitations. 10th Annual National Hemophilia Congress. Novo Nordisk Satellite Symposium. Izmir, Turkey. April 15, 2013. (keynote speaker)
- 180) A. Iorio. Epidemiology lessons learned by study of hemophilia and its treatment. The Centre for Blood Research. University of British Columbia. April 26, 2013. (keynote speaker)
- 181) A. Iorio. The use of ice in the management of acute joint bleeds. Canadian Hemophilia Society. Rendez-vous 2013. Winnipeg, Manitoba. May, 25, 2013.
- 182) Practical Approaches to Assessing inhibitor development in clinical trials. Pfizer Latin America Hemophilia Forum (educational forum). Cartagena, Columbia. June 2, 2013. (keynote speaker)
- 183) A. Iorio. Clinical cases in inhibitor assessment. Pfizer Latin America Hemophilia Forum (educational forum). Cartagena, Columbia. June 2, 2013.
- 184) A. Iorio. The value of meta-analysis in hemostasis thrombosis. Sick Kids Hospital Grand Rounds. Toronto, Ontario. June 13, 2013. (keynote speaker)

- 185) A. Iorio. Improving the efficiency of updating Cochrane Reviews: a joint pilot project of the McMaster PLUS database team and the Musculoskeletal Review Group. 21st Cochrane Colloquium. Quebec City, Quebec. September 18-23, 2013.
- 186) A. Iorio. Improving the retrieval and uptake of high quality clinical evidence from the published literature. American Medical Informatics Association Annual Meeting San Francisco (CA), 2013 Mar 18. (keynote speaker)
- 187) A. Iorio. Switching products and risk of inhibitors in hemophilia: A real world examination. Hot Topics in the Epidemiology of Inhibitor Development in People with Hemophilia. An ASH Ancillary Meeting, New Orleans, Louisiana, Saturday, December 7, 2013 (Symposium chair and keynote speaker)
- 188) Alfonso Iorio. Building evidence based optimal treatment in hemophilia: where are we at? An epidemiologic perspective. The 7th regional meeting of the Lebanese Society of Hematology and Blood Transfusion. Beirut, October 3-5 2013, Lebanon (keynote speaker)
- 189) Alfonso Iorio. The 7th regional meeting of the Lebanese Society of Hematology and Blood Transfusion. Beirut, October 3-5 2013, Lebanon (keynote speaker)
- 190) Alfonso Iorio. Prevention of recurrent VTE: optimal duration or personalized treatment? The 7th regional meeting of the Lebanese Society of Hematology and Blood Transfusion. Beirut, October 3-5 2013, Lebanon (keynote speaker)
- 191) Alfonso Iorio. Prophylaxis: the Canadian experience. NovoNordisk South America Summit. Buenos Aires, Argentina, April 5th 2013
- 192) Alfonso Iorio. Rate of inhibitor development in patients treated with plasma derived or recombinant factor concentrates. NovoNordisk South America Summit. Buenos Aires, Argentina, April 4th 2013 (keynote speaker)
- 193) Alfonso Iorio. Insight and hope in hemophilia HERO: An initiative for a wider understanding of psychosocial issues in hemophilia. NovoNordisk South America Summit. Buenos Aires, Argentina, April 4th 2013 (keynote speaker)
- 194) Alfonso Iorio. Inhibitors in hemophilia. An evidence based approach. Pfizer satellite Symposium – French Hematology Days. Buenos Aires, Argentina, April 4th 2013 (keynote speaker)
- 195) Alfonso Iorio. Rate of inhibitor development in patients treated with plasma derived or recombinant factor concentrates. Pfizer satellite Symposium – French Hematology Days. Buenos Aires, Argentina, April 4th 2013 (keynote speaker)
- 196) A. Iorio and J. Van den Bom. Debate: To be resolved: 2nd generation rFVIII is more immunogenic than 3rd generation rFVIII. Canadian Hemophilia Physician Update (CHPU) 2013 Saturday, June 15, 2013, Vancouver, British Columbia. (keynote speaker)

- 197) Improving Access to Expert Care (Further research on assessment of outcomes). HERO (Haemophilia Experiences, Research and Outcomes) Summit 2013, 27-28 June 2013, The Hague, Netherlands (Chair and keynote speaker)
- 198) A Iorio. Moving toward evidence based hemophilia care in the surgical and not surgical settings. Hematology Grand Round, November 21st, 2013. (keynote speaker)
- 199) A Iorio. Evidence Based Medicine and rare diseases: a few lessons learned from clinical research in Hemophilia. Hematology Grand Round. USC, Los Angeles, November 19th 2013 (keynote speaker)
- 200) A Iorio. 10 good reasons to go Bayesian (beginning from rare disorders). Hemophilia Clinic Rounds. USC, Los Angeles, November 20th 2013 (keynote speaker)
- 201) A Iorio. Effects of switching factor VIII products. Therapy-related risk factors in inhibitor formation. Nijmegen, The Netherlands, March 7th, 2013
- 202) A Iorio. Clinical Cases in Inhibitor Assessment. Pfizer Latin America Hemophilia Forum, 1–2 June 2013, Cartagena, Colombia (keynote speaker)
- 203) A Iorio. Practical Approaches to Assessing inhibitor Development in Clinical Trials Pfizer Latin America Hemophilia Forum, 1–2 June 2013, Cartagena, Colombia (keynote speaker)
- 204) A Iorio. Plenary: Practical approaches to assessing inhibitor development – risk factors, clinical trials and management (09:10–09:55). AfME/EURIT Summit Istanbul 11–12 May 2013. (keynote speaker)
- 205) A Iorio. Masterclass: Case studies in the management of inhibitor development in hemophilia. AfME/EURIT Summit Istanbul 11–12 May 2013. (keynote speaker)
- 206) A Iorio. Practical approach to the management of inhibitor. Satellite symposium at The Korean Society on Thrombosis and Hemostasis meeting, May 9th 2013, Daejeon, South Korea. (keynote speaker)
- 207) A Iorio. Practical approach to the management of inhibitor. Satellite symposium at The Korean Hemophilia Foundation, May 10th 2013, Seoul, South Korea. (keynote speaker)
- 208) A Iorio. Making Recommendations using the GRADE approach. International Summer School Clinical Practice Guidelines on Rare Diseases, Rome July 8-12, 2013.
- 209) A Iorio. The GRADE approach to evidence appraisal. International Summer School Clinical Practice Guidelines on Rare Diseases, Rome July 8-12, 2013.
- 210) A. Iorio. Registry based medicine (REM)*: dream or reality? At the meeting: History of Comprehensive Hemophilia Care in Canada. A Tribute To the St Michael's Hospital Program On Its 30th Anniversary. Toronto, September 23rd, 2013. (keynote speaker)

- 211) A Iorio. “Epidemiology lessons learned by study hemophilia and its treatment” The Centre for Blood Research Seminar Series. April 26th, 2013, Vancouver, BC. (keynote speaker)
- 212) A Iorio. The Future of Care. British Columbia Education Day. Organized by the Canadian Hemophilia Society. April 27th, 2013, Vancouver, BC. (keynote speaker)
- 213) A Iorio. Discussion of the impact of new technologies and research on care. Rendez Vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. 23-26 May 2013, Winnipeg, Manitoba.
- 214) A Iorio. Less frequent infusions or higher trough levels? Rendez Vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. 23-26 May 2013, Winnipeg, Manitoba.
- 215) A Iorio. The next 10 year of hemophilia care. Rendez Vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. 23-26 May 2013, Winnipeg, Manitoba. (keynote speaker)
- 216) A Iorio. Does product type influence the development on inhibitor in PTPs and PUPS? Plenary Lecture at the 7th Annual Congress of the European Association for haemophilia and Allied Disorders. Brussels, Belgium. February 26-28, 2014. (keynote speaker)
- 217) A. Iorio. Non-adherence and its impact on treatment efficacy. WHF 2014 World Congress. Melbourne, Australia. May 11-15, 2014.
- 218) A. Iorio. Assessment of long term safety and efficacy of clotting factor concentrates. WHF 2014 World Congress. Melbourne, Australia. May 11-15, 2014. (keynote speaker)
- 219) A Iorio. Real-World Prophylaxis Experience: Perspectives from Clinical Practice. WHF 2014 World Congress. Melbourne, Australia. May 11-15, 2014.
- 220) A Iorio. ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience. WHF 2014 World Congress. Melbourne, Australia. May 11-15, 2014.
- 221) A Iorio. An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness. WHF 2014 World Congress. Melbourne, Australia. May 11-15, 2014.
- 222) A Iorio. New SSC Project: IRS-PTPs: Inhibitor Reporting Standardization in Previously Treated Patient. International Society on Thrombosis and Haemostasis, Inc. Milwaukee, Wisconsin. June 23-26, 2014.
- 223) A Iorio. Guidelines and Priorities for safe switching between plasma derived and recombinant Factor VIII. Iranian Ministry of Health. October 23, 2014. Tehran, Iran. (keynote speaker)

- 224)A Iorio. Comparison studies on safety and efficacy different generations of recombinant products. Iranian Ministry of Health. October 23, 2014. Tehran, Iran. (keynote speaker)
- 225)A Iorio. WAPPS - Web-based Application for a Population Pharmacokinetic Service. Convegno Triennale AICE at Florence, Italy. November 4, 2014. (keynote speaker)
- 226) A Iorio. Linkage at McMaster Hamilton Health Sciences of ACCESSSS, Clinical Clustering Information, OSCAR and the ad-hoc developed TRUST-XT database. Hamilton Health Sciences. Council of Chiefs. Hamilton, June 10, 2014 (keynote speaker)
- 227)A Iorio. Advate PASS meta-analysis. XXIV HRSU, March 13-16, 2014, Washington, DC (keynote speaker)
- 228)A Iorio. B-domain – is this an issue? London 2014 Goring Workshop: 12-14 January 2014 (keynote speaker)
- 229)A Iorio. DDAVP: indications and use. CHANC meeting, Toronto, January 11, 2014 (keynote speaker)
- 230)A Iorio. Population Pharmacokinetics for busy clinicians and active patients: how to get the most out of it? 8th Annual Congress of European Association of Haemophilia and Allied Disorders. Helsinki, Finland. February 11-13, 2015.
- 231)A Iorio. Inhibitor developments according to FVIII concentrate in PUPs: how to interpret current evidence? 8th Annual Congress of European Association of Haemophilia and Allied Disorders. Helsinki, Finland. February 11-13, 2015. (keynote speaker)
- 232)A Iorio. Advances in Technology: How can we assess the potential, and then confirm the reality? 8th Annual Congress of European Association of Haemophilia and Allied Disorders. Helsinki, Finland. February 11-13, 2015. (keynote speaker)
- 233)A Iorio. Critical Appraisal of inhibitors in PUP data. EHC Round Table on Factor Concentrate-related Inhibitor Risk in Haemophilia A. The European Community Parliament. Brussels, Belgium. March 2, 2015.
- 234)A Iorio. Balancing risk factors for inhibitor development in clinical practice. Hemophilia Research Study Update. Berlin, Germany. March 12-14, 2015. (keynote speaker)
- 235)A Iorio. Implementation of a population pharmacokinetic approach to individual PK estimation to tailor treatment in haemophilia patients. Internal seminar given at FDA, Washington, DC. April 27, 2015. (keynote speaker)
- 236)A Iorio. Study design: A Critical Aspect of Research. XIV International Musculoskeletal Meeting, World Federation of Hemophilia. Belfast, Ireland. May 7-9, 2015.

- 237) A Iorio. Launch of the Canadian Bleeding Disorder Registry. Canadian Hemophilia Society (CHS) Rendez-vous 2015. Halifax, Nova Scotia. May 29, 2015.
- 238) A Iorio. The EUHASS/CHESS approach to adverse event surveillance. New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins Public Workshop. National Institute of Health, Bethesda, Maryland, September 17-18, 2015
- 239) A Iorio. Inhibitor reporting standardization in previously treated patients. SSC of the ISTH, 2015 Congress Toronto, Canada. June 20-25, 2015.
- 240) A Iorio. WAPPS project (Web Accessible Population Pharmacokinetics Service) SSC of the ISTH, 2015 Congress Toronto, Canada. June 20-25, 2015.
- 241) A Iorio. Risk factors for inhibitor development: any clinical role? Hemophilia Federation of Australia, XVII meeting, Gold Coast, Australia. October 1-2, 2015. (keynote speaker)
- 242) A Iorio. GRADE for prognostic evidence. Special Session #10: GRADE: the past 15 and next...years. Cochrane Colloquium October 3-7, 2015, Vienna, Austria.
- 243) A. Iorio (presenting), J. Stonebraker, M. Brooker, M. Soucie. How to measure progress in the provision of care for hemophilia. The 9th WFH Global Forum on Research and Treatment Products for Bleeding Disorders, Montreal, Quebec. October 22-23, 2015.
- 244) A Iorio. Balancing risk factors for inhibitor development in clinical practice: what meta analysis mean⁴⁶. Hämophilie Symposion. 13 - 14. November 2015, Hamburg, Germany. (keynote speaker)
- 245) A Iorio. Clinical Practice Guideline: Care Models for the Management of Hemophilia. National Hemophilia Foundation Annual Meeting, Dallas, August 15, 2015
- 246) A Iorio. A Canadian registry for Acquired Hemophilia: a starter for a critical discussion. AHCDC Annual Meeting, Halifax, June 15-17 2015.
- 247) A Iorio. Using Evidence For Hematology Laboratory Practice. XXVIIIth International Symposium on Technological Innovations in Laboratory Hematology, May 19-21 2015, Chicago, Illinois. (keynote speaker)
- 248) A Iorio. Critical Evaluation of New Therapies For Hemophilia A: An Evidenced Based Approach for Nurses. CANHC Research and Best Practice Series. November 6th, 2015
- 249) A Iorio. Building an opportunity for data-driven clinical reflections at HHS: exploring the usage of iv iron supplementation. Mickey Zeller and Alfonso Iorio. Hematology Grand Round, Hamilton, Friday, Sept 4th, 2015

ii) Contributed

- Peer reviewed (oral communications)

- 1) G.Agnelli, A.Iorio, A.Alatri, E.Boschetti, L.Mazzolai, G.G.Nenci, F.Ofosu, J.Hirsh: Plasma half-life of the anti-IIa activity of low molecular weight heparins assessed with a sensitive test (PTNA). *Thrombosis and Haemostasis* 1993, 69(6), 768.
- 2) Iorio A, Agnelli G, Leone M, Boschetti E, Nenci GG, Hirsh J. Enoxaparine shows a prolonged plasma half-life of its anti-IIa activity assessed with PTNA. *Annals of Haematology* 1993; 66 (suppl 1): A24
- 3) Iorio A, Agnelli G, Alatri A, Boschetti E, Nenci GG, Hirsh J: Prolonged plasma half-life of the anti-IIa activity of Enoxaparine assessed with a sensitive test (PTNA). *Thrombosis Research* 1993, 70(suppl 1), S14.
- 4) A.Iorio, G.Agnelli, G.G.Nenci, A.Mele, R.Bürge, J.Heim: Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). *Thrombosis Research* 1993, 70(suppl 1), S91.
- 5) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators: role of fibrinogen degradation products. *Thrombosis and Haemostasis* 1993, 69(6), 1337.
- 6) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators: role of fibrinogen degradation products. *Annals of Haematology* 1993; 66 (suppl 1): A31.
- 7) Parise P, Hauert J, Iorio A, Callegari P, Nenci GG: Fibrinogen degradation products (FgDP) generation is the major determinant of platelet inhibition induced by plasminogen activators (PA). *Thrombosis Research* 1993, 70(suppl 1), S112.
- 8) G Agnelli, C Renga, M Leone, P Melelli, P Parise, A. Iorio, GG Nenci. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin twice a day. *Thrombosis and Haemostasis* 1993, 69(6), 857.
- 9) Iorio A, Agnelli G, Renga C, Leone M, Melelli P, Parise P, Nenci GG. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin b.i.d. *Annals of Haematology* 1993; 66 (suppl 1): A25.
- 10) G Agnelli, M Leone, P Melelli, C Renga, A. Iorio, GG Nenci Inhibition of fluid phase and clot-bound thrombin: effects of heparin, hirudin and a thrombin-inhibiting decapeptide (LU 58463). *Thrombosis and Haemostasis* 1993, 69(6), 1301.

- 11) Iorio A, Agnelli G, Leone M, Melelli P, Renga C, Nenci GG. Hirudin and PEG-Hirudin inhibit clot-bound thrombin more efficiently than heparin. *Annals of Haematology* 1993; 66 (suppl 1) A19
- 12) G.Agnelli, A.Iorio, E.Boschetti, G.G.Nenci, F.Ofosu, J.Hirsh. Low molecular weight heparins show prolonged anti-IIa plasma half-life. *Circulation* 1993; 88,4(2), 1200.
- 13) Iorio, F. Nucciarelli, M. Leone, G. Agnelli. Effects of dermatan sulfate on activated partial thromboplastin time determined with five different reagents. *Thromb Haemostas* 1995; 73: 1353.
- 14) Mozzi R, Andreoli V, Buratta S, Iorio A, Horrocks LA. Regulation of phosphatidylserine synthesis in rat cerebral cortex. *J Neurochem* 1994; 63(1): S23B.
- 15) A Iorio, G. Agnelli, S. Goldhaber, M. Levine. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. *Cardiologia* 1994; 39(2): 51.
- 16) G. Agnelli, C. Pascucci, A.M. Mezzasoma, A. Iorio. The displacement of non-specifically bound unfractionated heparin from plasma proteins produces an antithrombotic effect. *Thromb Haemostas* 1995; 73: 963.
- 17) S. Ricotta, A. Iorio, P. Parise, G. Agnelli. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Thromb Haemostas* 1995; 73: 1095.
- 18) S.Buratta, S.Porcellati, A. Iorio and R.Mozzi. Base exchange enzyme activity in porcine liophylized platelets and the effect of heparin on PS synthesis by base exchange. *Italian Biochemical Society Transactions (IBST)* 1994; 5: 182.
- 19) Iorio, S. Ricotta, P. Parise, G. Agnelli. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Inter Angio* 1996; 15: 30.
- 20) Iorio, P. Parise, S.Z. Goldhaber, G. Agnelli for the BAPE Investigators. Fibrinogenolysis and thrombin activation after accelerated weight adjusted or conventional administration of rt-PA for pulmonary embolism. *Inter Angio* 1996; 15:31.
- 21) Iorio, A. Alatri, V. Ranucci, S. Falconi, V. Pasqualucci, G. Agnelli. Prophylaxis for venous thromboembolism and spinal anaesthesia: results of a national survey. *Inter Angio* 1996; 15: 32.
- 22) G. Agnelli, A. Iorio, F. Abbadessa, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with AMI treated with a double rt-PA bolus and randomised to two different heparin regimens. *Haemostasis* 1996; 26(Suppl 3):39A.

- 23) Ascani, A. Iorio, A.M. Stabile, G. Agnelli. Withdrawal of warfarin therapy after deep vein thrombosis: a randomized study on the effects of a very low fixed dose regimen. *Thromb Haemost* 1997;78(Suppl 1):335A.
- 24) G. Agnelli, F. Piovella, P. Buoncristiani, P. Severi, M. Pini, L. Crippa, G. Brambilla, M. Damiani, G. Andrioli, E. Giugni, S. Pasetti, G. Ghetti, C. Beltrametti, R. Pugliese, A. Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: a randomised double blind venography study. *Thromb Haemost* 1997;78(Suppl 1):1576A.
- 25) G. Agnelli, A. Iorio, F. Abbadessa, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Haemost* 1997;78(Suppl 1):2050A.
- 26) G. Agnelli, A. Iorio, F. Abbadessa, F. Guarraggi, M. Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Res* 1998;91(Suppl 1):89A
- 27) G. Agnelli, F. Piovella, P. Buoncristiani, P. Severi, M. Pini, L. Crippa, G. Brambilla, M. Damiani, G. Andrioli, E. Giugni, S. Pasetti, G. Ghetti, C. Beltrametti, R. Pugliese, A. Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients: a randomised double blind venography study. *Thromb Res* 1998;91(Suppl 1):106A
- 28) M. Berrettini, G. Tagariello, G. Castaman, F.A. Scaraggi, A. Tagliaferri, M.G. Mazzucconi, F. Baudo, V. Trapani Lombardo, A. Iorio, G. Lucarelli, A. Sergi. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. *Thromb Res* 1998;91(Suppl 1):107A
- 29) D. Guidetti, E. Bellesia, G. Rinaldi, A. Iorio, A. Pilia, M. Brini. Hemocoagulative and molecular biology parameters in 100 cerebrovascular patients. *Thromb Res* 1998;91(Suppl 1):129A
- 30) Iorio, A. Pilia, G. Rinaldi, M. Silingardi, A. Ghirarduzzi, I. Iori, M. Brini. Antiphospholipid antibodies: economic evaluation of an automated screening protocol. *Thromb Res* 1998;91(Suppl 1):131A
- 31) G. Rinaldi, E. Bellesia, A. Iorio, A. Pilia, A. Ghirarduzzi, M. Silingardi, C.A. Zotti, A. Fanti. Factor V Leiden in young patients with retinal vein occlusion. *Thromb Res* 1998;91(Suppl 1):132A
- 32) G. Rinaldi, E. Bellesia, A. Iorio, A. Pilia, A. Ghirarduzzi. Factor V Leiden and G26210A variation of the prothrombin gene identification by the use of one-step

- multiplex PCR mediated site-directed mutagenesis. *Thromb Res* 1998;91(Suppl 1):133A
- 33) Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Ascani A., Bazzan M., Alatri A., Guazzaloca G., Bertoldi A., Tomasi C., Scannapieco G., Ageno W., Iorio A. 1999 Three months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: the warfarin optimal duration italian trial (WODIT). *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2164
- 34) Iorio A., Agnelli G. 1999 Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery: a metanalysis. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2059
- 35) Buratta S., Iorio A., Andreoli V., Mambrini R., Porcellati S., Mozzi R. 1999 Serine base-exchange enzyme in commercially available porcine lyophilized platelets: different effect of unfractionated and low molecular weight heparin. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2137
- 36) Schiatti C., Iorio A., Rinaldi G., Silingardi M., Ghirarduzzi A., Guidetti D., Iori I., Brini M. 1999 Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2440
- 37) Silingardi M., Salvarani C., Rinaldi G., Ghirarduzzi A., Boiardi L., Iorio A., D'Inca M., Cantini F., Govoni M., Salvi F. 1999 Prothrombin 202120A mutation in Behcet's disease. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2112
- 38) Ghirarduzzi A., Iorio A., Silingardi M., D'Inca M., Rinaldi G., Iori I. 1999 Different management of oral anticoagulant therapy in patients with mechanical prosthetic heart valves: prospective cohort study. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2147
- 39) Ghirarduzzi A., Iorio A., Silingardi M., D'Inca M., Tincani E., Galimberti D., Rinaldi G., Iori I. 1999 Elderly patients treated with oral anticoagulant: a prospective cohort study. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 2148
- 40) Berrettini M., Bura A., Lucarelli G., Tagariello G., Castaman G., Scaraggi F., Tagliaferri A., Mazzucconi M., Baudo F., Trapani Lombardo V., Iorio A. 1999 . The role of thrombophilic states in the bleeding tendency of patients with hemophilia. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 1544
- 41) Agnelli G., Airolidi G., Brambilla G., Buoncristiani P., Severi P., Pasetti S., Giugni E., Iorio A. 1999 Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. *Thrombosis And Haemostasis* (0340-6245), Supplemento 1, 81, 16
- 42) Iorio A., Silingardi M., Tascetta T., Ghirarduzzi A., Guidetti D., Iori I., Brini M. 2000 Plasma homocysteine measurement: comparison of three different assay

- methods in plasma from vascular patients. *Haematologica* (0390-6078), Supplemento 5, 85, 57, PO-126
- 43) Silingardi M., Iorio A., Ghirarduzzi A., D'Inca M., Galimberti D., Tincani E., Iori I. 2000 Hyperhomocysteinemia and retinal vein occlusion. *Haematologica* (0390-6078), Supplemento 5, 85, 58, PO-127
- 44) Agnelli G., Airolidi G., Brambilla G., Buoncristiani P., Severi P., Pasetti S., Giugni E., Iorio A. 2000 Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. *Haematologica* (0390-6078), Supplemento 5, 85, 88, CO-194
- 45) M. Silingardi, A. Ghirarduzzi, A. Iorio, G. Rinaldi, C.A. Zotti, A. Fanti. Central retinal vein occlusion in homozygous factor V Leiden. *Thromb Res* 1998;91(Suppl 1):134°
- 46) Ghirarduzzi, A. Iorio, M. Silingardi, G. Rinaldi, D. Galimberti, I. Iori. Different management of oral anticoagulant therapy: a prospective cohort study. *Thromb Res* 1998;91(Suppl 1):135A
- 47) Iorio A., Agnelli G. 2000 Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Haematologica* (0390-6078), Supplemento 5, 85, 128, PO-286
- 48) Filippucci E., Agnelli G., Leone M., Iorio A., Nenci G.G. 2000 Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor. *Haematologica* (0390-6078), Supplemento 5, 85, 139 PO-309
- 49) Buratta S., Iorio A., Tascetta T., Andreoli V., Mambrini R., Porcellati S., Mozzi R. 2000 Serine base exchange enzyme in commercially available porcine lyophilised platelets: different effect of unfractionated and low molecular weight heparins. *Haematologica* (0390-6078), suppl. 5, 85, 120, PO-267
- 50) Ghirarduzzi A., Tascetta T., Silingardi M., Galimberti D., D'Inca M., Nicolini A., Cattabiani L., Brini M., Iorio A. 2001 Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P2944
- 51) Tascetta T., Silingardi M., Ghirarduzzi A., Iori I., Brini M., Iorio A. 2001 APTT evaluation in the presurgery screening: survey of 5000 patients. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, CD3324
- 52) Silingardi M., Ghirarduzzi A., Iori I., Salvarani C., Boiardi L., Bellesia E., Tascetta T., Morini L., Galimberti D., Cantini F., Govoni M., Salvi F., Iorio A. 2001 Factor V Leiden and G20210A prothrombin allele are not associated with thrombosis in Behcet's disease. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P2519

- 53) Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Farnetti E., Bellesia E., Tascetta T., Silingardi M., Morini L., Guiducci U., Iori I. 2001 Genima study: genetic polymorphisms and myocardial infarction among italian young adults. *Thrombosis And Haemostasis* (0340-6245), Supplement July 2001, P1571
- 54) Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Tascetta T., Silingardi M., Guiducci U., Iori I. 2001 Studio GEMINA: ruolo dei polimorfismi genetici e dell'omocisteinemia nell'infarto del miocardico in giovani-adulti italiani. *Italian Heart Journal* (1129-471X), suppl.6, 2, 67
- 55) Iorio A., Guercini F., Pini M. 2002 Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparison with oral anticoagulant. *Haematologica* (0390-6078), suppl.5, 87, 31
- 56) Ghirarduzzi A., Tortorella G., Iorio A., Casali B., Bellesia E., Silingardi M., Nicolini A., Guiducci U., Iori I. 2002 Gemina study: genetic polymorphisms and myocardial infarction among italian young adults. *Haematologica* (0390-6078), suppl.5, 87, 69
- 57) Iorio A., Accardo P., Bellesia E., Tascetta T., Tonelli L., Brini M. 2002 Feasibility of the use of filtered plasma in the automated screening test for activated protein C resistance. *Haematologica* (0390-6078), suppl.5, 87, 93
- 58) Ghirarduzzi A., Silingardi M., Cattabiani L., Nicolini A., Tonelli L., Iorio A. 2002 Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Haematologica* (0390-6078), suppl.5, 87, 94
- 59) Guercini F., Pini M., Iorio A. 2002 Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months. *Haematologica* (0390-6078), suppl.5, 87, 127
- 60) Nicolini A., Ghirarduzzi A., Silingardi M., Iorio A., Baldi G. 2002 Intracranial bleeding in Reggio Emilia: epidemiology and relationships with antithrombotic treatment. *Haematologica* (0390-6078), suppl.5, 87, 128
- 61) Conti S., Guercini F., Pini M., Iorio A. 2002 Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature. *Pathophysiology Of Haemostasis And Thrombosis* (1424-8832), suppl.2, 32, 51
- 62) Iorio A., Guercini F., Pini M. 2002 Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulant. *Pathophysiology Of Haemostasis And Thrombosis* (1424-8832), suppl.2, 32, 71
- 63) Massi Benedetti M., Brunetti P., Iorio A., Ferolla P., Stabile A., Akwe J., Canonico V., Celleno R., Timi A. 2003 Acute ketoacidosis in continuous subcutaneous insulin

- infusion treated Type 1 diabetics impairs the fibrinolytic capacity. *Diabetes & Metabolism* (1262-3636), 29, 4S361 (2738)
- 64) Ghirarduzzi A., Iorio A., Nicolini A., Silingardi M., Cattabiani L., Belloni L., Iori I. 2003 1286 Prospective consecutive cases of venous thromboembolic diseases at the single Venous thromboembolic Unit of Reggio Emilia. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, 1286a, P1444
- 65) Iorio A., Testa S., Parisoli A., Alatri A., Franzoni M., Trottini S., Cinotti R., Rinaldi G., Ghirarduzzi A. 2003 Clinical quality assessment program for the oral anticoagulant clinic. Preliminary report of a multicentric italian exercise. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1965
- 66) Paccamiccio E., Trottini S., Rosafalco M., Filippucci E., Duca E., Vecchioli M., Nenci G.G., Iorio A. 2003 Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS). *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1956
- 67) Accardo P., Ghirarduzzi A., Silingardi M., Franzoni M., Iorio A. 2003 Clinical and laboratoristic performance evaluation of three point-of-care devices for INR determination (Coagucheck, ProTime, Harmony). *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1966
- 68) Iorio A., Guercini F., Conti S., Pini M. 2003 Low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism: metanalysis of the randomized comparisons with oral anticoagulants. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P1873
- 69) Silingardi M., Fornaciari G., Beltrami M., Iorio A., Ghirarduzzi A., D'Inca M., Negri E., Nicolini A., Morini L., Iori I. 2003 Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0463
- 70) Iorio A., Ferolla P., Orsini Federici M., Celleno R., Stabile A., Canonico V., Massi Benedetti M. 2003 Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0957
- 71) Mancuso M., Santagostino E., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolini R., Rumi M., De Filippi F., Colombo M., Mannucci P. 2004 Sustained suppression of hepatitis C by pegylated Interferon (PEG-INF) and Ribavirin in hemophilic patients. *Haematologica* (0390-6078), September, 8, 89, 30
- 72) Iorio A., Ferrante F., Conti S., Nenci G.G. 2004 LMWH or Ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials. *Haematologica* (0390-6078), 89, 37

- 73) Castori L., Depunzio I., Servettini I., Ferrante F., Carloni D., Iorio A. 2004 Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications. *Haematologica* (0390-6078), September, 8, 89, 58
- 74) Ghirarduzzi A., Nicolini A., Iotti M., Iorio A., Baldi G. 2004 Intracranial bleeding: relationship with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. *Haematologica* (0390-6078), September, 8, 89, 61
- 75) Ferrante F., Ghirarduzzi A., Silingardi M., Franzoni C., Iorio A. 2004 Clinical and laboratory performance evaluation of three point-of-care devices for INR determination (Coagucheck, Prottime, Harmony). *Haematologica* (0390-6078), September, 8, 89, 62
- 76) Iorio A., Minciotti A., Ferrante F., Nenci G.G. 2004 Pharmacoeconomic evaluation of the management of oral anticoagulant treatment with point-of-care devices in the Italian national health care system. *Haematologica* (0390-6078), 89, 63,
- 77) Ferrante F., Bifarini B., Tesoro S., Peduto F., Iorio A. 2004 Coagulation screening for otorhinolaryngoiatric surgery: a pharmacoeconomic appraisal in the setting of the Italian national health system. *Haematologica* (0390-6078), September, 8, 89, 81
- 78) Iorio A., Orsini Federici M., Ferrante F., Stabile A., Galli F., Massi Benedetti M. 2004 Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients. *Haematologica* (0390-6078), September, 8, 89, 119
- 79) Guercini F., Conti S., Iorio A. 2004 Low-molecular-weight heparin and cancer survival: pooled analysis of 1726 patients treated for three months. *Haematologica* (0390-6078), September, 8, 89, 133
- 80) Altomonte F., Altomonte M., Iorio A., Ghirarduzzi A., Ricciardi A., Remollino V., Spinsi L., Saporito A., Caiazza A., Musso G., Cervellin G., Lamberti S., Buzzalino M., De Giorgi F., Del Prato C., Golinelli M., Gai V., Monsù R., Giofrè M., Giovanari D., Cattaneo S., Frumento F., Caporrella A., Re G., De Iaco F., Bologna G., Nocenti F., Lorenzi C., Zoratti R., Sciolla A., Tiscione V., Pastorello M., Vandelli A., Villa A., Zanna M., De Palma A. 2004 Ecaps study: multicentric evaluation of cerebral hemorrhage in anticoagulated/antiaggregated patients in the italian emergency rooms. *Haematologica* (0390-6078), September, 8, 89, 152
- 81) Ghirarduzzi A., Iotti M., Cattabiani L., Ieran M., Iorio A., Silingardi M., Iori I. 2004 Venous thromboembolic disease: clinical features of 1282 prospective consecutive cases at angiology unit of Reggio Emilia. *Haematologica* (0390-6078), September, 8, 89, 161
- 82) Paccamiccio E., Ferrante F., Trottini S., Rosafalco M., Duca E., Vecchioli M., Nenci G.G., Iorio A. 2004 OAT with POC devices and remote computer monitoring in the

- setting of the Italian NHS: a controlled clinical trial. *Haematologica* (0390-6078), 89, 180-1
- 83) Ferrante F., Paccamiccio E., Servettini I., Iorio A. 2004 Quality control programs for POC devices to measure INR. Results of a pilot exercise. *Haematologica* (0390-6078), September, 8, 89, 181
- 84) Mackensen S., Gringeri A., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A., Molinari C. 2004 Development of disease-specific quality of life questionnaire for adult patients with hemophilia (HAEM-A-QOL). *Haematologica* (0390-6078), September, 8, 89, 186
- 85) Mackensen S., Gringeri A., Mantovani I., Skovlund S., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A. 2004 Development and validation of the first treatment satisfaction scale for adult hemophiliacs (HEMO-SAT). *Haematologica* (0390-6078), September, 8, 89, 191
- 86) Iorio A., La Torre D., Conti S., Gambelunghe G. 2004 Successful treatment of spontaneous intracerebral haemorrhage in a patient with prosthetic mechanical heart valves. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 9
- 87) Iorio A., Chantarangkul V., Ferrante F., Tripodi A. 2004 Hemo Web, a web-based tool to handle the external quality control program for the hemophilia center coagulation laboratory. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 17
- 88) Mancuso M., Santagostino E., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolin R., Rumi M., De Filippi F., Colombo M., Mannucci P. 2004 Sustained suppression of hepatitis C by pegylated interferon (pegINF) and ribavirin in hemophilic patients. *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 48
- 89) Von Mackensen S., Gringeri A., Mantovani L., Skovlund S., Santoni L., Tagliaferri A., Tagariello G., Ciavarella N., Iorio A. 2004 Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo0-SatA). *Haemophilia* (1351-8216), October 2004, Supplement 3, 10, 126
- 90) Baudo F., Gaidano G., Carloni M., Coppola A., Iorio A., Marietta M., Marongiu F., Mazzucconi M., Miraglia E., Schiavoni M., Schinco P., Fariciotti A. 2004 Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor. *Journal Of Thrombosis And Haemostasis* (1538-7933), July, 1, P0596
- 91) Stobart K., Iorio A. 2005 Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia. *Blood* (0006-4971), November 16, issue 11, 106, abstract 3114, Session Type: Poster Session 365-III
- 92) Mancuso M., Santagostino E., Rumi M., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolin R., Colombo M., Mannucci P. 2005

- High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. *Blood* (0006-4971), November 16, issue 11, 106, abstract 3219
- 93) Giuliano V., Castellani D., Clerici C., Morelli O., Iorio A., Sabatino G., Baldoni M., Palmerini F., Asciutti S., Morelli A. 2005 Oral Anticoagulants and small intestinal bacterial overgrowth. *Canadian journal of gastroenterology* (0835-7900), September, Suppl B, 19
- 94) Baldi G., Altomonte F., Altomonte M., Ghirarduzzi A., Brusasco C., Parodi R., Conti S., Iorio A. 2005 Determinants of Mortality in Cerebral Hemorrhage Patients on Antithrombotic Treatment: Prospective Evaluation in the Italian Emergency Departments of a Multicentric Cohort of 1071 Patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl 1, 3, P0257
- 95) Iorio A., Guercini F., Ferrante F., Nenci G.G. 2005 Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P1613
- 96) Ferrante F., Fattorini L., Bifarini B., Tesoro S., Depunzio I., Peduto V., Iorio A. 2005 Coagulation Screening for Otorhinolaryngoiatric Surgery: A Pharmacoeconomic Appraisal in the Setting of the Italian National Health System. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P0249
- 97) Ferrante F., Paccamiccio E., Iaboni S., Iorio A. 2005 Validation of Laboratory Reference Standard for Clinical Use of INR-POC Devices: A Randomized Multicentre Exercise. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P1733
- 98) Giuliano V., Iorio A., Castellani D., Gizzi S., Palmerini F., Sabatino G., Morelli O., Clerici C., Filippucci E., Baldoni M., Nenci G.G., Morelli A. 2005 Host-Drug Interaction: The Influence of Small Intestinal Bacterial Overgrowth on Oral Anticoagulant Dose Requirement. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl 1, 3, P2219
- 99) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A., Iorio A. 2005 Absence of Interaction Between Influenza Vaccination and Oral Anticoagulant Therapy: A Randomized Blinded Clinical Trial. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P1027
- 100) Mancuso M., Santagostino E., Rumi M., De Filippi F., Linari S., Coppola A., Rocino A., Iorio A., Dragani A., Barillari G., Tagariello G., Nicolin R., Colombo M., Mannucci P. 2005 Pegylated Interferon and Ribavirin Anti-hepatitis C Therapy in Patients with Hemophilia Is as Effective and Safe as in Non-hemophilic Patients. *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, P0218

- 101) Palareti G., Tosetto A., Cosmi B., Legnani C., Brusi C., Pengo V., Ghirarduzzi A., Pattacini A., Testa S., Iorio A., Tripodi A. 2005 The D-dimer (DD) Test to Establish the Duration of Anticoagulation after a First Unprovoked Episode of Venous Thromboembolism (VTE); the Prospective Randomized 'Prolong' Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, Suppl 1, 3, H02
- 102) Mantovani L., Monzini M., Mannucci P., Scalone L., Villa M., Gringeri A., for the Conan Study Group -, 2005 Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia* (Oxford. Print) (1351-8216), 11, 589-597, Iorio A è elencato tra All contributors participating in patients' enrollment and in collecting data
- 103) Belvini D., Salviato R., Radossi P., Pierobon F., Mori P., Castaldo G., Tagariello G., AICE HB study group -, 2005 Molecular genotyping of the Italian cohort of patients with hemophilia B. *Haematologica* (0390-6078), 90, 635-642, Iorio A è elencato in Appendice come responsabile del Centro Emofilia di Perugia
- 104) v Mackensen S., Gringeri A., Ravera S., the HAEM-A-QoL G., 2005 Validation of the Haemophilia-specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL). 10th Anniversary Congress of the European Hematology Association (EHA), Stockholm, Sweden, June 2-5, Iorio A. è elencato come membro del HAEM-A-QoL Group
- 105) v Mackensen S., Gringeri A., the HAEM-A-QoL Group -, 2005 Health-related Quality of Life in Adult Patients with Haemophilia-Assessment with a New Disease-specific Questionnaire (Haem-A-QoL). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl.1, vol.3, P0813, Iorio A. è elencato come membro del Ham-A-QoL Study Group
- 106) v Mackensen S., Gringeri A., Skovlund S., Hemo-Sat Study Group -, 2005 Assessment of Treatment Satisfaction in Patients with Haemophilia-Development and Validation of the First Disease-Specific Questionnaire (Hemo-SatA). *Journal Of Thrombosis And Haemostasis* (1538-7933), August, suppl.1, vol.3, P1999, Iorio A. è elencato come membro del Hemo -Sat Study Group
- 107) Iorio A., Camilloni B., Basileo M., Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Iorio A. 2005 Influenza vaccination in patients on long-term anticoagulant therapy. The Second European Influenza Conference , Malta, 11-14 september
- 108) Camilloni B., Iorio A.M., Neri M., Lepri E., Ferrante F., Guercini F., Iaboni S., Paccamiccio E., Iorio A. 6th National Congress of the Italian Society of Virology a joint meeting with the Virus Group of the Society for General Microbiology (UK). Orvieto (TR), 18-20 september 2006, 79 tris; 78 2006

- 109) Iorio A., Giuliano V., Bassotti G., Castellani D., Filippucci E., Palmerini F., Morelli O., Clerici C., Baldoni M., Gizzi S., Agnelli G., Morelli A. Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica* (0390-6078), September, suppl 2, 91, (C036) 11 2006
- 110) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A.M., Iorio A. The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica* (0390-6078), September, suppl 2, 91, (C038) 11 2006
- 111) Iorio A., Gringeri A., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica* (0390-6078), September, suppl 2, 91, (C074) 22 2006
- 112) Iorio A., Stobart K. Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica* (0390-6078), September, suppl 2, 91, (C075) 23 2006
- 113) Guercini F., Ferrante F., Nenci G.G., Iorio A. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica* (0390-6078), September, suppl 2, 91, (P041) 56 2006
- 114) Iorio A., Giuliano V., Bassotti G., Castellani D., Filippucci E., Palmerini F., Morelli O., Clerici C., Baldoni M., Gizzi S., Agnelli G., Morelli A. 2006 Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica* (0390-6078), September, suppl 2, 91, September, (C036) 11
- 115) Guercini F., Conti S., Ferrante F., Paccamiccio E., Iaboni S., Vecchioli M., De Punzio I., Basileo M., Camilloni B., Iorio A.M., Iorio A. 2006 The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica* (0390-6078), September, suppl 2, 91, (C038) 11
- 116) Iorio A., Gringeri A., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. 2006 The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica* (0390-6078), September, suppl 2, 91, (C074) 22
- 117) Iorio A., Stobart K. 2006 Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica* (0390-6078), September, suppl 2, 91, (C075) 23
- 118) Guercini F., Ferrante F., Nenci G.G., Iorio A. 2006 Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica* (0390-6078), September, suppl 2, 91, (P041) 56

- 119) Iorio A.[Correspondent Author], Gringeri A., Iannaccaro P., Morfini M., Scaraggi A., Schiavoni M. 2006 The Haemophilia Registry of the Italian association of haemophilia centres: methodology and preliminary analysis. *Haemophilia* (1351-8216), (suppl 2), 12, 33
- 120) Dragani A., Marchesini E., Carloni M., Oliovecchio E., Ferrante F., Iuliani O., Agnelli G., Iorio A. 2007 HAEMOPHILIA MANAGEMENT THROUGH AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12 , P-M-127
- 121) Iorio A.[Correspondent Author], Stobart K. 2007 SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS OF PROPHYLACTIC CLOTTING FACTOR CONCENTRATE IN HEMOPHILIA. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva , 2007, July 6–12 , P-M-128
- 122) Iorio A.[Correspondent Author], Gringeri A., Hassan J., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. 2007 THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva , 2007, July 6–12 , P-M-129
- 123) Iorio A.[Correspondent Author], Marchesini E., Agnelli G. 2007 ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-M-147
- 124) Iorio A.[Correspondent Author], Marchesini E., Falco A., Caso M., Pastorello M., Tiscione V., Ballarino P., Altomonte F., Baldi G., Agnelli G., Toni D. 2007 RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-T-162
- 125) Santagostino E., Coppola A., Tagliaferri A., Mancuso M., Scaraggi F., Biasoli C., Schinco P., Iorio A., Latella C., Di Minno G. 2007 IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS: THE ITALIAN RETROSPECTIVE-PROSPECTIVE REGISTRY - THE PROFIT STUDY. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis , Geneva, 2007, July 6–12 , P-W-128
- 126) Santoro C., Iorio A., Pignoloni P., Rago A., Biondo F., Ferrante F., Agnelli G., Mazzucconi M. 2007 OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII (BDD-RFVIII) CONCENTRATE USING

- CHROMOGENIC AND ONE-STAGE ASSAYS WITH POOLED NORMAL PLASMA (PNP) AND REFACTO LABORATORY STANDARD (RLS). Proceedings of the XXist Congress of the International Society on Thrombosis and Haemostasis , Geneva , 2007, July 6–12 , P-W-129
- 127) Santoro, F . Ferrante, A. Iorio, F. Biondo, P. Pignoloni and M. Mazzucconi. Pharmacokinetics of reformulated B-domain deleted recombinant factor VIII (BDD-rFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). Haemophilia (2008), 14 (Suppl. 2), 1–120 (03 PO 08)
 - 128) Iorio, S . Pizzinelli and F . Ferrante. Replacement therapy with recombinant FIX – multicentre evaluation of current dosing practice in Italy. Haemophilia (2008), 14 (Suppl. 2), 1–120 (03 PO 26)
 - 129) Iorio, E. Oliovecchio,* E. Zanon, M. Mazzucconi, A. Accorsi and M. Luciani. The haemophilia registry of the Italian Association of Haemophilia Centres. Haemophilia (2008), 14 (Suppl. 2), 1–120 (03 PO 26)
 - 130) E. Zanon, A. Coppola, A. Tagliaferri , G. Rossetti, M. Lapecorella, A. Dragani, F. Peyvandii, E. Santagostino, A. Iorio and R. Santoro. Haemophilia A and B and other rare bleeding disorders: an Italian retrospective survey on the intracranial haemorrhagic episodes. Haemophilia (2008), 14 (Suppl. 2), 1–120 (05 PO 16)
 - 131) Iorio, E. Marchesini, F. Ferrante, E. Oliovecchio and L. Lotte Gluud. Antiviral therapy for chronic hepatitis C in haemophilia patients with human immunodeficiency virus. Haemophilia (2008), 14 (Suppl. 2), 1–120 (07 PO 08)
 - 132) F. Ferrante, A. Iorio, B. Camilloni, M. Basileo, G. Tagariello and A. Iorio. Inhibitor development in mild/moderate haemophilia: could influenza vaccination have been the trigger? Haemophilia (2008), 14 (Suppl. 2), 1–120 (08 PO 17)
 - 133) G. Tagariello, E. Santagostino, M. Morfini, A. Iorio, M. Innocenti, M. Mancuso, G. Pasta, P. Radosi, G. Rodrigo, C. Santoro, R. Sartori, A. Scaraggi and L. Solimeno. Lower than expected frequency of prosthetic surgery in patients with haemophilia B and chronic arthropathy: data from the Italian registry for surgery in haemophilia. Haemophilia (2008), 14 (Suppl. 2), 1–120 (12 PO 89)
 - 134) Iorio, M. Basileo, E. Marchesini, L. Rocchetti, M. Marchesi and C. Silvani. Critical appraisal of five international guidelines on fresh frozen plasma clinical use. Haemophilia (2008), 14 (Suppl. 2), 1–120 (13 PO 25)
 - 135) Iorio A. THE ITALIAN REGISTRY OF HEMOPHILIA AND ALLIED DISORDERS: A TOOL TO HELP HEALTH CARE PLANNING FOR A RARE DISEASE. 13^o Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008 (1) s3
 - 136) Tagliaferri A., Franchini M., Rivolta G.F., Iorio A., Mannucci P.M., AICE. FINAL RESULTS FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTERS (AICE)

- SURVEY ON THE CAUSES OF DEATH AMONG ITALIAN HEMOPHILIACS. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO023
- 137) Tagariello G., Iorio A., Santagostino E., Morfini M., Innocenti M., Mancuso M.E., Pasta P.L., Radossi P., Rodorigo G., Santoro C., Sartori R., Scaraggi A., Solimeno L.P. HEMOPHILIA B PATIENTS HAVE A LOWER RISK TO UNDERGO ORTHOPAEDIC SURGERY THAN HEMOPHILIA A PATIENTS: RESULTS FROM AN ITALIAN COHORT STUDY AND REVIEW OF THE LITERATURE. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO032
- 138) Zanon E., Spiezia L., Santagostino E., Peyvandi F., Coppola A., Tagliaferri A., Rossetti G., Iorio A., Santoro R., Lapecorella M., Mazzucconi G., Dragani A., Giuffrida A., Gamba G., Giancarlo C. INTRACRANIAL HAEMORRHAGE IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. CO120
- 139) Basileo M., Camilloni B., Ferrante F., Iorio A.M., Tagariello G., Agnelli G., Iorio A. INHIBITOR DEVELOPMENT IN MILD HAEMOPHILIA A: COULD INFLUENZA VACCINATION HAVE BEEN THE TRIGGER?. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO003
- 140) Siboni S.M., Zanon E., Mikovic D., Iorio A., Castaman G., Mazzucconi M.G., Peyvandi F. CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PATIENTS WITH RARE BLEEDING DISORDERS (RBDS). 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO005
- 141) Iorio A., Marchesini E., Ferrante F., Agnelli G. ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN HEMOPHILIA PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008 PO007
- 142) Iorio A., Biasoli C., Coppola A., D'Inca M., Federici A., Ferrante F., Girotto M., Landolfi R., Mancuso G., Musso R. 2007 ANNUAL UPDATE OF THE HAEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HAEMOPHILIA CENTRES. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO008
- 143) Santoro C., Iorio A., Ferrante F., Marchesini E., Pignoloni P., Rago A., Biondo F., Agnelli G., Mazzucconi M.G. PHARMACOKINETICS EVALUATION OF THE RECALIBRATED REFAC TO LABORATORY STANDARD IN THE ASSESSMENT OF POST-INFUSION PLASMA LEVELS OF B-DOMAIN DELETED RECOMBINANT FACTOR VIII CONCENTRATE. 13° Triennial Meeting on Clinical and Social issues

- in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO009
- 144) Oliovecchio E., Ferrante F., Marchesini E., Carloni M.T., Dragani A., Iuliani O., Agnelli G., Iorio A. WEB BASED SUPPORT FOR HAEMOPHILIA MANAGEMENT: AN INTER-REGIONAL NETWORK IN MIDDLE ITALY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO010
- 145) Basileo M., Iorio A., Ferrante F., Marchesini E., Materazzi M., Marchesi M., Esposito A., Pellegrini L., Rocchetti L., Agnelli G., Silvani C.M. INTERNATIONAL GUIDELINES ABOUT CLINICAL USE OF FRESH FROZEN PLASMA: A CRITICAL APPRAISAL. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO011
- 146) Basileo M., Iorio A., Marchesini E., Iaboni S., Palazzesi G., Marchesi M., Esposito A., Pellegrini L., Rocchetti L., Agnelli G., Silvani C.M. CLINICAL AUDIT OF THE USE OF FRESH FROZEN PLASMA IN UMBRIA. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO012
- 147) Iorio A., Ferrante F., Rocca A., Accorsi A., Barillari G., Biasoli C., Carloni M.T., Castaman G., Ciavarella N, Contino L., D'Incà M., Coppola A., Dragani A., Grandini G., Luciani M., Mariani G., Mazzucconi M.G., Molinari C., Morfini M., Muleo G., Rocino A., Rodorigo G., Rossetti G., Santagostino E., Schiavulli M., Schinco P.C., Scaraggi F., Siboni S., Tagariello G., Tagliaferri A.R., Targhetta R., Zanon E. REPLACEMENT THERAPY WITH RECOMBINANT FIX. MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE IN ITALY. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO013
- 148) Coppola A., Biasoli C., Iorio A., Castaman G., Messina M., Mansueto F., Feola G., Santoro R., Sartori R., Schinco P., Santagostino E. MANAGING INCOMPLETE OR LACK OF RESPONSE TO THE FIRST IMMUNE TOLERANCE INDUCTION (ITI) COURSE: STRATEGIES FROM THE ITALIAN ITI REGISTRY (THE PROFIT STUDY). 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO064
- 149) Iorio A., Marchesini E., Falco A., Caso V., Pastorello M., Tiscione V., Ballarino P., Altomonte F., Baldi G., Agnelli G., Toni D. RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO070

- 150) Alfonso Iorio, Esmeralda Filippucci, Maura Marcucci, Clive Kearon, and Gualtiero Palareti. Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3029.
- 151) A. Iorio. International clinical trials are the best way to improve global haemophilia care? No. Haemophilia 2009; 15: 22. DOI: 10.1111/j.1365-2516.2009.1979.x
- 152) A Iorio, J. Douketis, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto D-DIMER TO PREDICT THROMBOSIS RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: EFFECT OF PATIENT- AND D-DIMER-RELATED FACTORS ON RECURRENCE PREDICTION. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1 OC-TH-002
- 153) Tosetto, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, J. Douketis CLINICAL PREDICTION GUIDE TO PREDICT THROMBOSIS RECURRENCE AFTER A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. OC-TH-004
- 154) Iorio, C. Kearon, E. Filippucci, M. Marcucci, V. Pengo, G. Agnelli, G. Palareti VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-MO-282
- 155) . Douketis, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto DOES THE CLINICAL PRESENTATION OF VENOUS THROMBOEMBOLISM PREDICT THE RISK FOR AND TYPE OF THROMBOSIS RECURRENCE? Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-WE-286
- 156) . Douketis, A. Iorio, M. Marcucci, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto DOES PATIENT SEX AND PRIOR HORMONAL THERAPY PREDICT RISK FOR THROMBOSIS RECURRENCE AFTER A FIRST VENOUS THROMBOEMBOLISM? Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. AS-TH-005
- 157) M. Marcucci, A. Iorio, J. Douketis, T. Baglin, M. Cushman, S. Eichinger, G. Palareti, D. Poli, C. Tait, A. Tosetto D-DIMER TO PREDICT THROMBOSIS RECURRENCE: COMPARISON OF AGGREGATE DATA AND INDIVIDUAL PATIENT DATA META-ANALYSES. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-TH-412
- 158) M. Basileo, E. Filippucci, S. Iaboni, P. Grilli, M. Vecchioli, G. Agnelli, A. Iorio COMPUTER ASSISTED VKA MONITORING WITH POINT OF CARE DEVICE BY GENERAL PRACTITIONERS. Journal of Thrombosis and Haemostasis, 2007: 9: Suppl 1. PP-MO-457

- 159) Iorio, E. Filippucci, M. Basileo, S. Iaboni, E. Paccamiccio, M. Vecchioli, G. Agnelli PROSPECTIVE ASSESSMENT OF CLINICAL ENDPOINTS OF VKA TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-MO-458
- 160) . Zanon, L. Spiezia, E. Santagostino, A. Coppola, A. Tagliaferri, G. Rossetti, A. Iorio, R. Santoro, A. Dragani, A. Giuffrida, R. Musso, G. Mancuso, G. Castaman, G. Gamba, G. Mazzucconi, M. Lapecorella INTRACRANIAL HAEMORRHAGE IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. AS-TU-032
- 161) Iorio, M. Marcucci, E. Marchesini, P. Mannucci PLASMA DERIVED (PD) AND RECOMBINANT (R) FACTOR VIII (FVIII) CONCENTRATES INDUCE A DIFFERENT RATE OF INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS. A SYSTEMATIC REVIEW OF THE LITERATURE. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. OC-MO-035
- 162) G. Tagariello, A. Iorio, E. Santagostino, M. Morfini, R. Bisson, M. Innocenti, M. Mancuso, M. Mazzucconi, G. Pasta, P. Radossi, G. Rodorigo, C. Santoro, R. Sartori, A. Scaraggi, L. Solimeno, P. Mannucci COMPARISON OF THE RATES OF JOINT ARTHROPLASTY IN PATIENTS WITH SEVERE FACTOR VIII AND IX DEFICIENCY: AN INDEX OF DIFFERENT CLINICAL SEVERITY OF THE TWO COAGULATION DISORDERS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-MO-542
- 163) M. Marcucci, G. Fabbriani, M. Brozzetti, A. Iorio BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSIS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-WE-529
- 164) Coppola, M. Margaglione, E. Santagostino, A. Rocino, F. Scaraggi, A. Tagliaferri, G. Castaman, M. Messina, M. E. Mancuso, A. Iorio, P. Schinco, E. Zanon, R. Musso, G. Mancuso, G. Di Minno, P. Mannucci FACTOR VIII GENE (F8) MUTATIONS AS A PREDICTOR OF OUTCOME IN IMMUNE TOLERANCE INDUCTION (ITI) IN HEMOPHILIA A PATIENTS WITH HIGH-RESPONDING INHIBITORS. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. OC-TU-075
- 165) S. M. Siboni, E. Zanon, G. Sottilotto, D. Mikovic, A. Iorio, G. Castaman, M. Mazzucconi, P. M. Mannucci, F. Peyvandi CENTRAL NERVOUS SYSTEM (CNS) BLEEDING IN PATIENTS WITH RARE BLEEDING DISORDERS (RBDS) . *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. AS-TU-033
- 166) Iorio, A. Rocca, S. Pizzinelli MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE OF RECOMBINANT FIX IN ITALY. *Journal of Thrombosis and Haemostasis*, 2007: 9: Suppl 1. PP-TH-654
- 167) M. Basileo, M. Marchesi, E. Marchesini, M. Materazzi, A. Germani, L. Rocchetti, C. Silvani, A. Iorio AUDIT OF THE CLINICAL USE OF FRESH-FROZEN PLASMA IN

- UMBRIA: STUDY DESIGN AND RESULTS. *Journal of Thrombosis and Haemostasis*, 2007; 9: Suppl 1. PP-WE-688
- 168) Iaboni S, Filippucci E, Ferrante F, Grilli P, Vecchioli M, Agnelli G, Iorio A. ANTICOAGULATION MANAGEMENT BY POINT OF CARE DEVICES AND COMPUTER MONITORING BY GENERAL PRACTITIONERS. XX Siset National Meeting, Florence, September 25-28, 2008 C076
- 169) Marchesini E, Ferrante F, Filippucci E, Iaboni S, Agnelli G, Iorio A. ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS IN PATIENTS HIV-INFECTED. XX Siset National Meeting, Florence, September 25-28, 2008 P177
- 170) Basileo M, Iorio A, Marchesini E, Iaboni S, Palazzesi GP, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. CLINICAL AUDIT OF THE USE OF FRESH FROZEN PLASMA IN UMBRIA: STUDY DESIGN AND RESULTS OF THE PILOT PHASE. XX Siset National Meeting, Florence, September 25-28, 2008 P182
- 171) Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Alatri A, Guazzaloca G, Palareti G for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). D-DIMER TO DETERMINE DURATION OF ANTICOAGULATION AFTER A FIRST EPISODE OF IDIOPATHIC VENOUS THROMBOEMBOLISM: EXTENDED FOLLOW-UP OF THE PROLONG STUDY. XX Siset National Meeting, Florence, September 25-28, 2008 C066
- 172) Ferrante F, Camilloni B, Iorio AM, Tagariello G, Agnelli G, Iorio A. INHIBITOR DEVELOPMENT IN MILD HAEMOPHILIA A: COULD INFLUENZA VACCINATION HAVE BEEN THE TRIGGER? XX Siset National Meeting, Florence, September 25-28, 2008 P196
- 173) Ferrante F, Carloni M, Marchesini E, Dragani A, Oliovecchio E, Iuliani O, Agnelli G, Iorio A. MANAGEMENT OF PATIENTS WITH HEMOPHILIA IN AN INTER-REGIONAL NETWORK IN CENTRAL ITALY. XX Siset National Meeting, Florence, September 25-28, 2008 P193
- 174) Ghirarduzzi A, Landini F, Pengo V, Corradini S, Iorio A, Prandoni P. NEW ONSET OF CANCER AND RECURRENT VENOUS THROMBOEMBOLISM AFTER DISCONTINUING ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLIC EVENT. A PROSPECTIVE COHORT STUDY IN 1,919 PATIENTS. XX Siset National Meeting, Florence, September 25-28, 2008 C053
- 175) Santoro C, Iorio A, Ferrante F, Marchesini E, Pignoloni P, Rago A, Biondo F, Agnelli G, Mazzucconi M. PHARMACOKINETICS OF THE REFORMULATED B-DOMAIN DELETED RECOMBINANT FACTOR VIII CONCENTRATE USING CHROMOGENIC AND ONE-STAGE CLOTTING ASSAYS WITH POOLED NORMAL PLASMA AND REFAC TO LABORATORY STANDARD. XX Siset National Meeting, Florence, September 25-28, 2008 P190

- 176) Filippucci E, Iaboni S, Ferrante F, Paccamiccio E, Vecchioli M, Agnelli G, Iorio A. PROSPECTIVE EVALUATION OF THE CLINICAL QUALITY OF ORAL ANTICOAGULANT TREATMENT IN A PRIMARY CARE COMPUTER ASSISTED MANAGEMENT MODEL. XX Siset National Meeting, Florence, September 25-28, 2008 C077
- 177) Ferrante F, Iaboni S, Filippucci E, Marchesini E, Vecchioli M, Agnelli G, Iorio A. QUALITY ASSURANCE SCHEME BASED ON LEVEY JENNINGS ANALYSIS AND WESTGARD RULES APPLICATION FOR POC-INR MONITORING. XX Siset National Meeting, Florence, September 25-28, 2008 P124
- 178) Iorio A, Marchesini E, Falco A, Caso V, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. XX Siset National Meeting, Florence, September 25-28, 2008 P174
- 179) Iorio A, Ferrante F, Pizzinelli S on behalf of the Italian ad hoc study group. REPLACEMENT THERAPY WITH RECOMBINANT FIX. MULTICENTRIC EVALUATION OF CURRENT DOSING PRACTICE IN ITALY. XX Siset National Meeting, Florence, September 25-28, 2008 P192
- 180) Filippucci E, Vedovati MC, Iorio A, Agnelli G. SAFETY OF R-HIRUDIN USE FOR HEPARIN-INDUCED THROMBOCYTOPENIA TREATMENT IN A CEREBRAL VEIN THROMBOSIS PATIENT: A CASE REPORT. XX Siset National Meeting, Florence, September 25-28, 2008 P153
- 181) Basileo M, Iorio A, Ferrante F, Marchesini E, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM2. THE GOOD USE OF PLASMA. A CRITICAL ANALYSIS OF FIVE INTERNATIONAL GUIDELINES. XX Siset National Meeting, Florence, September 25-28, 2008 P178
- 182) Iorio A, Barillari G, Gandini G, Molinari C, Rocino A, Santagostino E, Tagariello G, Targhetta R. THE HAEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HAEMOPHILIA CENTRES. XX Siset National Meeting, Florence, September 25-28, 2008 C102
- 183) Coppola A, Daniele F, Rocino A, Targhetta R, Santoro R, Giuffrida A, Zanon E, Iorio A, Mancuso G, Santagostino E for the Italian Association of Haemophilia Centres (AICE) PROFIT Study Group THE ITALIAN REGISTRY OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A WITH INHIBITORS: 2-YEAR UPDATE (PROGNOSTIC FACTORS IN IMMUNE TOLERANCE, THE PROFIT STUDY). XX Siset National Meeting, Florence, September 25-28, 2008 C100
- 184) M Marcucci, A Iorio, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci a nome dei partecipanti al progetto Registro Politerapie SIMI. Somministrazione di FANS

- in pazienti in trattamento anticoagulante orale ed eventi emorragici correlati in una cohorte di anziani ricoverati in reparti di medicina interna. *Internal and Emergency Medicine*, 2009; 4: S11
- 185) A Iorio, M Marcucci, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci a nome dei partecipanti al progetto Registro Politerapie SIMI. Terapia antitrombotica combinata e correlati eventi emorragici e tromboembolici in una coorte di anziani ricoverati in reparti di Medicina Interna. *Internal and Emergency Medicine*, 2009; 4: S14
- 186) A Iorio, PM Mannucci, L Pasina, M Marcucci, J Bonazzi, G Agnelli, F Salerno, S Corrao, A Nobili, a nome dei partecipanti al progetto Registro Politerapie SIMI. La profilassi antitrombotica in pazienti con fibrillazione o flutter atriale (FFA) preesistente ricoverati in reparti di Medicina Interna: adesione alle linee guida. *Internal and Emergency Medicine*, 2009; 4: S26
- 187) Lisa K Lütkehoff, Manuela Albisetti, Timothy J. Bernard, Mariana Bonduel, Leonardo R. Brandao, Stephane Chabrier, Anthony Chan, Barbara Fiedler, Heather J. Fullerton, Vijeja Ganesan, Neil A Goldenberg, Meredith Golomb, Eric F. Grabowski, Christine Heller, Susanne Holzhauer, Alfonso Iorio, Janna Journeycake, Gili Kenet, Fenella J Kirkham, Karin Kurnik, John K Lynch, Christoph Male, Marilyn J. Manco-Johnson, Rolf Mesters, Paul Monagle, Heleen C van Ommen, Leslie Raffini, Paolo Simioni, Ronald Straeter, Guy Young, and Ulrike Nowak-Göttl. Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 3993.
- 188) Alfonso Iorio, Susan Halimeh, Christoph Bidlingmaier, Leonardo R. Brandao, Carmen Escuriola-Ettingshausen, Neil A Goldenberg, Alessandro Gringeri, Susanne Holzhauer, Gili Kenet, Ralf Knoefler, Wolfhart Kreuz, Karin Kurnik, Daniela Manner, Emanuela Marchesini, Maura Marcucci, Elena Santagostino, Guy Young, Pier Mannuccio Mannucci, and Ulrike Nowak-Göttl. Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 3154.
- 189) Augusto B. Federici, Paolo Bucciarelli, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, and Pier M. Mannucci. Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 3494
- 190) A Iorio, S Halimeh, C Bidlingmaier, C Escuriola Ettingshausen, A Gringeri, S Holzhauer, R Knöfler, W Kreuz, K Kurnik, D Manner, E Santagostino, PM Mannucci, U Nowak-Göttl. Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review. III EAHAD meeting, Edimburg February 3-5, 2010

- 191) A Iorio, G Fabbriani, M Marcucci, M Brozzetti, M Luciani, P Filipponi. Bone mineral density in hemophilia patients. A meta-analysis. III EAHAD meeting, Edimburg February 3-5, 2010
- 192) Matino D, Makris M, D'Amico R; Iorio A. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Haemophilia (2010), 16 (Suppl. 4), 1–158, 06P24
- 193) Morfini M, Iorio A; Mazzucconi M, Cinotti S, Zanon E; Paladino E. Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. Haemophilia (2010), 16 (Suppl. 4), 1–158, 08P28
- 194) Iorio A, Halimeh S, Goldenberg N, Kenet G, Young G, Brandao L. Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review. Haemophilia (2010), 16 (Suppl. 4), 1–158, 17P40
- 195) Marcucci M, Fabbriani G, Brozzetti M, Luciani M, Iorio A. Bone mineral density in hemophilia patients: a meta-analysis. Haemophilia (2010), 16 (Suppl. 4), 1–158, 22FP09
- 196) Iorio A, Marchesini E, Marcucci M, Stobart K. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Haemophilia (2010), 16 (Suppl. 4), 1–158, 29P15
- 197) Olioecchio E, Marchesini E, Matino D, Contino L, Alatri A, Carloni M. Transition to a web-based architecture of the Italian hemophilia registry network. Haemophilia (2010), 16 (Suppl. 4), 1–158, 10F15
- 198) Federici A.B.), Bucciarelli P., Iorio A., Castaman G., Mazzucconi M.G., Morfini M., Rocino A., Schiavoni M., Rodeghiero F., Mannucci P.M. PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS. Blood Transfus 2010; 8 (Suppl 4) OC007
- 199) Iorio A., Douketis J., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Tosetto A. D-DIMER TO DETERMINE RISK FOR DISEASE RECURRENCE AFTER UNPROVOKED VENOUS THROMBOEMBOLISM: ADDRESSING UNANSWERED QUESTIONS WITH A LARGE INDIVIDUAL PATIENT META-ANALYSIS. Blood Transfus 2010; 8 (Suppl 4) OC025
- 200) Marcucci M., Tosetto A., Douketis J., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Iorio A. ARE MEN AT HIGHER RISK FOR DISEASE RECURRENCE THAN WOMEN? Blood Transfus 2010; 8 (Suppl 4) OC033
- 201) Morfini M., Iorio A), Mazzucconi M.G., Cinotti S., Zanon E., Paladino E., Marchesini E. BIOEQUIVALENCE OF B-DOMAIN DELETED AND PLASMA DERIVED FVIII CONCENTRATES Blood Transfus 2010; 8 (Suppl 4) OC046

- 202) Iorio A., Halimeh S., Goldenberg N., Kenet G., Young G., Brandao L.R., Marchesini E., Marcucci M., Mannucci P.M., Nowak-Gottl U. EFFECT OF PLASMA-DERIVED OR RECOMBINANT FACTOR VIII ON INHIBITOR DEVELOPMENT. A SYSTEMATIC REVIEW Blood Transfus 2010; 8 (Suppl 4) OC047
- 203) Zanon E., Santagostino E., Rocino A., Mazzucconi M.G., Messina M., Tagliaferri A., Giuffrida A.C., Coppola A., Santoro R., Iorio A., Valdrè L., Musso R. INTRACRANIAL HAEMORRHAGE (ICH) IN HAEMOPHILIA A AND B: AN ITALIAN RETROSPECTIVE SURVEY Blood Transfus 2010; 8 (Suppl 4) OC104
- 204) Tositto A., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait R.C., Douketis J. CLINICAL PREDICTION OF VTE RECURRENCE IN PATIENTS WITH PREVIOUS UNPROVOKED VENOUS THROMBOEMBOLISM. RESULTS FROM AN INDIVIDUAL-LEVEL META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) OC114
- 205) Filippucci E., Kearon C., Marcucci M., Pengo V., Siragusa S., Palareti G., Iorio A. VENOUS THROMBOEMBOLISM RECURRENCE AFTER A FIRST EPISODE OF PROVOKED VENOUS THROMBOSIS DUE TO A TRANSIENT RISK FACTOR. A SYSTEMATIC REVIEW OF THE LITERATURE Blood Transfus 2010; 8 (Suppl 4) OC115
- 206) Iorio A., Marcucci M., Pasina L., Marengoni A., Salerno F., Corrao S., Nobili A., Mannucci P.M on behalf of the REPOSI investigators. ANTITHROMBOTIC PROPHYLAXIS IN ELDERLY PATIENTS ATRIAL FIBRILLATION ADMITTED TO INTERNAL MEDICINE WARDS IN ITALY: ADHERENCE TO GUIDELINES Blood Transfus 2010; 8 (Suppl 4) P021
- 207) Marcucci M., Tositto A., Baglin T., Douketis J., Cushman M., Eichinger S., Palareti G., Poli D., Tait C., Iorio A. DOES THE CLINICAL PRESENTATION AND EXTENT OF VENOUS THROMBOSIS PREDICT LIKELIHOOD AND TYPE OF RECURRENCE? A PATIENT LEVEL META-ANALYSIS OF 2,554 UNSELECTED PATIENTS AFTER A FIRST THROMBOSIS Blood Transfus 2010; 8 (Suppl 4) P043
- 208) Marcucci M., Douketis J., Tositto A., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait C.(9), Iorio A., D-DIMER TO PREDICT RECURRENCE AFTER A FIRST EPISODE OF UNPROVOKED VENOUS THROMBOEMBOLISM: COMPARISON OF AGGREGATE AND INDIVIDUAL PATIENT DATA META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) P046
- 209) Marchesini E., Marcucci M., Stobart K., Chan A., Iorio A. CLOTTING FACTOR CONCENTRATES GIVEN TO PREVENT BLEEDING AND BLEEDING-RELATED COMPLICATIONS IN PEOPLE WITH HAEMOPHILIA A OR B Blood Transfus 2010; 8 (Suppl 4) P052
- 210) Marcucci M., Marchesini E., Fabbriani G.L., Brozzetti B., Luciani M., Iorio A. BONE MINERAL DENSITY IN HEMOPHILIA PATIENTS: A META-ANALYSIS Blood Transfus 2010; 8 (Suppl 4) P057

- 211) Matino D., Makris M., D'Amico R., Iorio A. RECOMBINANT FACTOR VIIA CONCENTRATE VERSUS PLASMA DERIVED CONCENTRATES FOR THE TREATMENT OF ACUTE BLEEDING EPISODES IN PEOPLE WITH HAEMOPHILIA AND INHIBITORS. *Blood Transfus* 2010; 8 (Suppl 4) P061
- 212) Oliovecchio E., Marchesini E., Rodorigo G., Marietta M., Di Minno G., Perricone C., Macchi S., Castaman G., Morfini M., Iorio A. TRANSITION TO A WEB-BASED ARCHITECTURE OF THE ITALIAN HEMOPHILIA REGISTRY NETWORK *Blood Transfus* 2010; 8 (Suppl 4) P065
- 213) Augusto B. Federici, Alfonso Iorio, and Giancarlo Castaman. Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients *Blood (ASH Annual Meeting Abstracts)*, Nov 2010; 116: 238
- 214) Gili Kenet, Mariana Bonduel, Anthony Chan, Neil Goldenberg, Suzanne Holtzhauer, Alfonso Iorio, Janna M. Journeykake, Ralf Junker, Christoph Male, Mary Patricia Massicotte, Rolf M. Mesters, Paul Monagle, Heleen Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young, and Ulrike Nowak-Göttl. Impact of Persistent Antiphospholipid Antibodies on Symptomatic Thromboembolism In Children: A Systematic Review & Meta-Analysis [Observational Studies] *Blood (ASH Annual Meeting Abstracts)*, Nov 2010; 116: 3169
- 215) Susanne Holtzhauer, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Susan Halimeh, Alfonso Iorio, Gili Kenet, Brigitte Pautard, and Ulrike Nowak-Göttl. A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. *Blood (ASH Annual Meeting Abstracts)*, Nov 2010; 116: 710.
- 216) Alfonso Iorio, Suzanne Holtzhauer, Christoph Bidlingmaier, Carmen Escuriola-Ettingshausen, Susan Halimeh, Gili Kenet, Brigitte Pautard, Ulrike Nowak-Göttl. Predictive model to assess the risk of inhibitor development in children with severe and moderate hemophilia A - Results of a multicenter cohort study. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011
- 217) Alfonso Iorio, and Ulrike Nowak-Göttl on behalf of the EAHAD ad hoc working party. Predictors of inhibitor development in Hemophilia A previously untreated patients: the role of factor concentrate type. An individual patient data meta-analysis. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011
- 218) U Nowak-Götti, G Kenet, M Bonduel, A Chan, N Goldenberg, S Holtzhauer, A Iorio, J Journeykake, R Junker, C Male, P Masicotte, P Monagle, H Van Ommen, L Raffini, P Simioni, G Young. Impact of Persistent Antiphospholipid antibodies on symptomatic thromboembolism in children: A systematic review & meta-analysis (observational studies). XXIII Congress – The International Society on

- Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (O-WE-032).
- 219) A Federici, P Bucciarelli, G Castaman, E Olievecchio, A Iorio, P Mannucci. Heterogeneity of the clinical, laboratory and molecular markers of VWD Type 3: Results from the retrospective/prospective studies on 122/52 Italian patients. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-461)
 - 220) A Iorio, F Querol, A Forsyth, F Cassis. HERO, An international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-491)
 - 221) A Iorio, F Cassis, F Querol, A Forsyth. HERO – An International initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in 7 countries. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-492)
 - 222) A Iorio, A Forsyth, F Cassis, F Querol. Psychological Aspects of Living with Haemophilia: The HERO project and narrative review of the published literature. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-493)
 - 223) M Morfini, A Iorio, M Gabriella Mazzucconi, S Cinotti, E Zanon, E Paladino, E Marchesini, C Santoro. Bioequivalence of a B-Domain deleted and plasma derived FVIII concentrates. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-515)
 - 224) Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Irfan A, Solà I, Dahm P, Glujovsky D, Johnston B, Martinez L, Ramirez-Morera A, Sun X, Vandvik PO, Akl E, Tikkinen KA, Iorio A, Santesso N, Brozek J, Schünemann H, Guyatt. Risk difference estimation and reporting in systematic reviews. Cochrane Colloquium 2011 Madrid, Spain (19-22 October)
 - 225) Catrin Tudur-Smith, James Oyee, Maura Marcucci, Maroeska Rovers, Alfonso Iorio, Richard Riley, Paula Williamson, Mike Clarke. Individual participant data meta-analyses compared with meta-analyses based on aggregate data Cochrane Colloquium 2011 Madrid, Spain (19-22 October)

- 226) Tosetto A, Iorio, A, Marcucci M, Baglin T, Cushman M, Sabine E, Palareti G, Poli D, Tait CR, Douketis, JD. Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Oral Presentation, Session 322. 53rd ASH Annual Meeting and Exposition. San Diego, California. December 10-13, 2011
- 227) Matino D, Iorio A, Gargaro M, Tagariello G, Luciani M, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor XIII: A Multi-Centre Pilot Study. Oral Presentation, Session 322. 53rd ASH Annual Meeting and Exposition. San Diego, California. December 10-13, 2011
- 228) Iorio A. IPD meta-analysis to investigate the risk factor for inhibitor development. . Perugia Hemophilia Centre, University of Perugia, Italy; Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. Invited talk. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1 Haemophilia (2012), 18 (Suppl. 1), 1–10
- 229) Iorio A. The use of the clinical trial design in Hemophilia: methodological considerations. Hemophilia Centre, University of Perugia, Italy; Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. Invited talk. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 18, page 8 Haemophilia (2012), 18 (Suppl. 1), 1–10. M. Marcucci, G. Kenet, S. Holzhauer, C. Bidlingmaier, C. Escuriola Ettinghausen, A. Iorio, U. Nowak-Gottl. Concentrate type and dose in hemophilia A patients: is there an independent effect on risk of inhibitor formation? Oral communication. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1 Haemophilia 2012, 18 (Suppl. 1), 11–51
- 230) W. KALNINS, F. QUEROL, M. GREGORY and A. IORIO. Clinical presentation and management of adult patients responding to the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-MO-04.4-1. Haemophilia 2012, 18 (Suppl. 3), 1–208
- 231) W. KALNINS, F. QUEROL, K. HALTER and A. IORIO. Clinical presentation and management of pediatric hemophilia patients as reported by parents surveyed in the Haemophilia Experiences Results Opportunities (HERO) survey. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-022. Haemophilia 2012, 18 (Suppl. 3), 1–208
- 232) C. BOS, A. CHAN, S. ATKINSON, K. BANDOSZ, K. NAGEL, K. STRIKE, C. WEBBER, K. WEBERT, A. IORIO and I. WALKER. Nutritional intake and bone mineral density in boys with severe hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-047. Haemophilia 2012, 18 (Suppl. 3), 1–208

- 233) C. BOS, A. CHAN, C. WEBBER, A. IORIO, K. NAGEL, I. WALKER and K. WEBERT. Low bone mineral density and increased fat mass in boys with severe Hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-048. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 234) A. STAIN,* E. SANDOVAL, K. HALTER, and A. IORIO. Hemophilia knowledge and frequently used and valued information sources: Patient/parent perceptions from the Hero study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-088. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 235) F. CASSIS, A. BUZZI, A. FORSYTH, M. GREGORY and A. IORIO. Impact of hemophilia on relationships with partners, family, and friends: Assessment of adult patient respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-087. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 236) D. NUGENT, C. GARRIDO, K. HALTER, A. BUZZI and A. IORIO. Impact of hemophilia on interpersonal relationships: Assessment of parent/caregiver respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-2. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 237) A. COPPOLA, M. MARGAGLIONE, E. SANTAGOSTINO, A. ROCINO, A. TAGLIAFERRI, M. MESSINA, E. ZANON, S. LINARI, A. IORIO, L. VALDRE, M. MANCUSO and G. DI MINNO. Predictors of success of immune tolerance induction in hemophilia A patients with high-responding inhibitors: A score from the Italian registry. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 238) M. MARCUCCI, G. KENET, S. HOLZHAUER, C. BIDLINGMAIER, C. ESCURIOLA ETTINGSHAUSEN, A. IORIO and U. NOWAK-GOTTL. Assessment of treatment-related risk factors for inhibitor development in previously untreated hemophilia A patients: Different statistical approaches. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-3. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 239) K. STRIKE, A. CHAN, K. ROSS, C. BOS, T. ALMONTE, K. DECKER, R. GOLDSMITH, A. IORIO, I. WALKER, K. WEBERT and L. WATERHOUSE. Osteochondral Lesions of the Ankle Joint in Patients with Hemophilia A: A Retrospective Case Series. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-212. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 240) F. CASSIS, A. FORSYTH, M. GREGORY and A. IORIO. Qualitative and quantitative assessment of sexual intimacy in adult patients in the hemophilia experiences

- results opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-148. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 241) A. FORSYTH, M. GREGORY and A. IORIO. Demographic characteristics of adult patient respondents in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-199. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 242) D. NUGENT, C. GARRIDO, K. HALTER and A. IORIO. Demographic characteristics of parents of children/adolescents with hemophilia responding in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-200. Haemophilia 2012, 18 (Suppl. 3), 1-208
- 243) C. GARRIDO, S. RAMIREZ, A. FORSYTH and A. IORIO. Quality of life (QOL) and well-being of hemophilia patients and parents managing hemophilia: Hero study analysis. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-218. Haemophilia 2012, 18 (Suppl. 3), 1-208.
- 244) Guyatt G, Spencer F, Iorio A, Vandvik P, You J. Uncertainty in baseline risk can reduce confidence in estimates of effect. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 245) Sun X, Brignardello-Petersen R, Carrasco-Labra A, Neumann I, Alonso-Coello P, Akl E, Johnston B, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Subgroup analyses in systematic reviews: a survey of Cochrane and non-Cochrane reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 246) Johnston B, Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Sun X, Akl E, Briel M, Busse J, Dahm P, Glujovsky D, Granados C, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Reporting of absolute estimates of effect of patient important benefits and harms in abstract of systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 247) Akl E, Alonso-Coello P, Neumann I, Brignardello-Petersen R, Carrasco-Labra A, Johnston B, Sun X, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. reporting, handling and judging risk of bias associated with missing participant data in systematic reviews. Abstracts of the 2012 Cochrane

- Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
- 248) Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl E, Sun X, Johnston B, Busse J, Dahm P, Glujovsky D, Iorio A, Irfan A, Martinez L, , Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Briel M, Granados C, Mustafa R, Guyatt G. Risk difference estimation and reporting in systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200
 - 249) Iorio, A. Effect of switching FVIII products on inhibitor development in Hemophilia A. Abstract of the 5th Nijmegen Symposium on Factor VIII Inhibitors. March 27, 2013, Nijmegen, The Netherlands.
 - 250) Forsyth A, Guelcher C, Buzzi A, Wisniewski T, Cooper D, Iorio A. Associations of Quality of Life, Pain and Self-Reported Arthritis with Bleed Rate and Hemophilia Treatment Centre and Healthcare Practitioner Utilization: Global Results from Hero Study. World Federation of Hemophilia, 13th International Musculoskeletal Congress. April 20, 2013. B4.4.
 - 251) Nugent D, Stain AM, Gregory M, Pericleous L, Cooper DL, Iorio A. Association between inhibitors, treatment regimen, and bleed frequency and health care practitioner utilisation in the haemophilia treatment center (HTC): global results from the haemophilia experiences, results and opportunities (HERO) study. Value in Health 2013, 16: A1-A298. PSY86
 - 252) Cassis F, Gregory M, Kalnins W, Wisniewski T, Cooper DL, Iorio A. Associations between negative impact on employment or relationships and haemophilia treatment centre (HTC) and health care practitioner utilisation: global results from the Haemophilia Experiences, Results and Opportunities (HERO) study. Value in Health 2013, 16: A1-A298. PSY87
 - 253) Iorio, A. Inhibitor development in previously untreated patients. Xperience Symposium. Pfizer Hemophilia Meeting. May 10, 2013. South Korea.
 - 254) Iorio, A. Case Studies in the management of inhibitor development in hemophilia. Master Class – Managing Hemophilia for Life: Pfizer AfME / EURIT Hemophilia Forum. 12 May 2013. Istanbul, Turkey.
 - 255) Iorio, A. Practical approaches to assessing inhibitor development – risk factors, clinical trials and management. Plenary Session - Managing Hemophilia for Life: Pfizer AfME / EURIT Hemophilia Forum. 12 May 2013. Istanbul, Turkey.
 - 256) Iorio, A. Inhibitor development in PTP: available registries and harmonisation. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. SC01-4.05. June 29, 2013-July 4, 2013.
 - 257) Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: First results of an individual patient data meta-analytic project.

- Maura Marcucci, Maria Elisa Mancuso, Elena Santagostino, Gili Kenet, Mohssen Elalfy, Susanne Holzhauser, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Alfonso Iorio, Ulrike Nowak-Gottl. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. AS 22.2. June 29, 2013 – July 4, 2013.
- 258) Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. Davide Matino, Alfonso Iorio, Marco Gargaro, Elena Santagostino Christina Santoro, Giovanni Di Minno, Massimo Morfini, Paolo Puccetti, Francesca Fallarino. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. AS 22.3. June 29, 2013 – July 4, 2013.
- 259) Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. Augusto Federici, Giancarlo Caastaman, Alfonso Iorio, Mariana Bonduel, Elbio D'Amico, Emiliy Olivoecchio, Christina Santoro, Simona Siboni, Barbara Zieger, Pier Mannucci. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PA 2.08-1. June 29, 2013 – July 4, 2013.
- 260) Do inhibitors, treatment regimen and bleed frequency impact hemophilia treatment centre and provider utilisation: An analysis of adults with hemophilia in the HERO study. Alfonso Iorio, Diane Nugent, Ann Marie Stain, Matt Gregory, Louisa Pericleous, David Cooper. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.36-6. June 29, 2013 – July 4, 2013.
- 261) External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. Maura Marcucci, Sabine Eichinger, Alfonso Iorio, James Douketis, Alberto Toso, Trevor Baglin, Mary Cushman, Gualtiero Palareti, Daniela Poli, Tait Campbell, Paul Kyrle. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.70-3. June 29, 2013 – July 4, 2013.
- 262) Barbara AM, Mathew P, Mauser-Bunschoten EP, Rivolta GF, Romanov V, Roussel-Robert V, Tagliaferri A, Windyga J, Iorio A. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. Annual Congress of the European Association for Hemophilia and Allied Disorders (EAHAD), Square Brussels Meeting Centre, Brussels, Belgium, February 2014. Poster.
- 263) Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate shared decision making in hemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. American Society of Hematology (ASH) Annual Meeting and Exposition, Ernest N. Morial Convention Center, New Orleans, Louisiana, USA, December 2013. Poster.

- 264) Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate evidence-based practice and shared decision making in haemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. Faculty of Health Sciences Research Plenary. McMaster University, Hamilton, May 2013. Poster.
- 265) Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate evidence-based practice and shared decision making in haemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. McMaster University's Clinical Epidemiology & Biostatistics (CE&B) Annual Research Day. Sheraton Hotel, Hamilton, March 2013. Poster.
- 266) Xi M, Navarro-Ruan T, Mammen S, Blanchette V, Hermans C, Morfini M, Collins P, Fischer K, Neufeld EJ, Young G, Kavakli K, Radossi P, Dunn A, Thabane L and Iorio A. for the WAPPS study group Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates. American Society of Hematology Annual Meeting. San Francisco, California. December 6-9, 2014.
- 267) Chatree Chai-Adisaksopha, Alfonso Iorio, Mark Crowther, Javier de Miguel, Estuardo Salgado, Marija Zdraveska, Manuel Monreal and the RIETE investigators. Switching to warfarin after 6-month completion of anticoagulant treatment of cancer-associated thrombosis. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
- 268) Chatree Chai-Adisaksopha, Said Al Kindi, Matthew Cheah, Alfonso Iorio, Mark Crowther, and Lori-Ann Linkins. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumors. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
- 269) Chatree Chai-Adisaksopha, Matthew Cheah, Said Al Kindi, Alfonso Iorio, Mark Crowther, and Lori Ann Linkins. Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer Associated Thrombosis. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
- 270) Augusto Bramante Federici, Giancarlo Castaman, Alfonso Iorio, Emily Oliovecchio, and Prodeswil Investigators. 759 Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis in the Prodeswil Study. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
- 271) Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stafan Lethagan, Nora McCormick, Paul Karner. Modeling the Impact of Potential Improvements in Real-World Adherence with Extended-Half Life versus Conventional Factor VIII and IX on Bleeding. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.

- 272) Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stafan Lethagen, Nora McCormick, Paul Karner. Comparisons of Efficacy and Factor Consumption During Treatment with Recombinant Factor VIII Fc Fusion Protein and Conventional Factor VIII. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.
- 273) Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner. Factor Consumption and Efficacy: Recombinant Factor IX Fc Fusion Protein Compared with Conventional Recombinant Factor IX. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.

- Not peer reviewed

- 1) R.Mozzi, V.Andreoli, A.Iorio, F.Pierini. Phosphatidylserine (PS) synthesis by base exchange is inhibited by GTP and activated by heparin in rat brain membranes. Abstract at the 2nd International Union of Biochemistry and Molecular Biology Conference: Biochemistry of Cell Membranes.
- 2) Iorio A, Hauert J, Agnelli G, Parise P. Streptochinasi ed rt-P attivano le piastrine con meccanismi diversi: implicazioni sull'incidenza di retrombosi dopo terapia trombolitica nell'infarto del miocardio. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A35.
- 3) Iorio A, Agnelli G, Alatri A, Melelli P, Boschetti E, Nenci GG. Cinetica dell'attività anti-IIa della nadroparina in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A117.
- 4) Iorio A, Renga C, Leone M, Melelli P, Parise P and Agnelli G per il gruppo BAPE. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A316.
- 5) Renga C, Agnelli G, Iorio A, Nenci GG, Young E, Hirsh J. Legame non specifico alle proteine plasmatiche dell'eparina non frazionata e delle eparine a basso peso molecolare dopo somministrazione in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A118.
- 6) Agnelli G, Renga C, Iorio A, Melelli P, Leone M, Lormeau JC. Correlazione tra la lunghezza delle catene saccaridiche e l'attività anti-IIa di frazioni epariniche valutata con il plasma thrombin neutralization assay. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A339.
- 7) Leone M, Melelli P, Renga C, Iorio A, Nenci GG, Agnelli G. Inibizione della trombina libera e legata alla fibrina: confronto tra eprina e LU 58463, un inibitore puro della trombina. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A340.

- 8) Renga C, Nucciarelli F, Leone M, Iorio A, Agnelli G. Effetti del dermatan solfato sul tempo di tromboplastina parziale attivato determinato con cinque diversi reagenti. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A342.
- 9) S.Buratta, A.Iorio, S.Porcellati, V.Andreoli, R.Mozzi. Effect of heparin on phosphatidylserine synthesis in rat cerebral cortex and porcine platelets. Proceedings of the 35th International Conference on the Biochemistry of Lipids. IV, P24.
- 10) Ascani, A. Iorio, A.M. Stabile, G. Agnelli. Sospensione della terapia anticoagulante orale in pazienti con trombosi con trombosi venosa profonda: effetti di una bassa dose fissa di warfarin sui parametri emocoagulativi. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 88.
- 11) M.R. Taliani, A. Iorio, F. Gianese, G.G. Nenci, G. Agnelli. Impiego compassionevole del dermatan solfato in pazienti con controindicazioni all'impiego di eparina. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 98.
- 12) Alatri, A. Iorio, F. Gianese, G. Agnelli. Lo "spiazzamento" dell'eparina non frazionata dal legame non specifico con le proteine plasmatiche determina un incremento del suo effetto antitrombotico. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 103.
- 13) Iorio, S. Ricotta, P. Parise, G. Agnelli. Bassa incidenza del tromboembolismo venoso sintomatico in pazienti sottoposti ad intervento di chirurgia ortopedica con venografia negativa alla dimissione. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 344.
- 14) M. Silingardi, M. D'Inca, M. Ghirarduzzi, A. Iorio, G. Rinaldi, M. Brini, I. Iori. Positività per anticorpi antifosfolipidi (aPL) e prevalenza della sindrome da anticorpi antifosfolipidi (APS) primaria in soggetti con piastrinopenia, aborti ripetuti, trombosi venose o arteriose: analisi di 36 casi. Atti del 7° Convegno Nawioanle della FCSA, Bologna, 20-21 febbraio 1997.
- 15) Ghirarduzzi, M. D'Incà, M. Silingardi, F. Mazzali, A. Iorio, G. Rinaldi, I. Iori. Sindrome da anticorpi antifosfolipidi e autoanticorpi anti fattore VIII in corso di leucemia linfatica cronica. Atti del XCVIII Congresso Nazionale della Società italiana di Medicina Interna. Roma, 27-31 ottobre 1997.
- 16) M. Silingardi, A. Ghirarduzzi, C. Salvarani, G. Rinaldi, A. Iorio, D. Galimberti, M. Brini, I. Iori. Morbo di Behcet: sindrome "catastrofica" vasculitica associata a mutazione 20210A della protrombina. Atti del XCIX Congresso Nazionale della Società Italiana di Medicina Interna. Bari, 10-14 novembre 1998.

- 17) D. Guidetti, E. Bellesia, G. Rinaldi, A. Iorio. Ischemic stroke in young patients: hemocoagulative and molecular biology study. Atti dell'International Workshop "Stroke in the young". Genova, 11-12 dicembre 1998.
- 18) M. Berrettini, A. Iorio et al. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. Hemophilia 1998;vol:pag (Atti del XXIII International Congress of the World Federation of Hemophilia)
- 19) Ghirarduzzi A., Iorio A., D'Incà M., Silingardi M., Morini L., Salvarani C., Cerioli G., Iori I. 2000 Sindrome da anticorpi fosfolipidi. Descrizione di un caso clinico con trombosi atriale dx e revisione della casistica di Reggio Emilia. Atti del 101° Congresso Nazionale della Società Italiana di Medicina Interna, Torino, 18-22 novembre 2000, 431, abs310
- 20) Massi Benedetti M., Brunetti P., Iorio A., Ferolla P., Stabile A., Akwe J., Celleno R., Canonico V., Timi A. 2003 Alterazione della fibrinolisi durante chetoacidosi diabetica nel corso di sospensione di terapia insulinica infusione continua sottocutanea (CSII) in diabetici di tipo 1. XIV Congresso Nazionale, Catania (Italia)

r. Administrative Responsibilities

▪ Department

- 2014– present Chief, Health Information Research Unit, Clinical Epidemiology and Biostatistics, McMaster University
- 2013– 2014 Deputy Chief, Health Information Research Unit, Clinical Epidemiology and Biostatistics, McMaster University
- 2012– present - Departmental Education Coordinator, Clinical Epidemiology and Biostatistics, McMaster University
- 2011 – 2014 Member, HRM MSc Admissions Committee, Department of Clinical Epidemiology and Biostatistics, McMaster University

▪ Faculty

- 2014 – present Faculty of Health Sciences, Continuing Health Sciences Education Program Advisory Committee, McMaster University
- 2011 – 2014 Faculty of Health Sciences Scholarship Committee as the HRM program representative, Faculty of Health Sciences
- 2002 – 2010 Elected representative as Assistant Professor to the Faculty Council
- 2002 – 2010 Elected representative as Assistant Professor to the Faculty Council for Teaching

- University
- Hospital/Clinic

- 2013– present Director, Hamilton Niagara Regional Hemophilia Program
- 2006 – 2010 Member, Regional Committee for the Appropriateness of the use of plasma and plasma derived products, Umbria Region.
- 2003 – 2010 Chief of the Program “Health care management network for congenital and acquired bleeding disorders, with particular attention to the haemophilia and oral anticoagulant therapy”
Department of Internal Medicine, Azienda Ospedaliera di Perugia, Perugia(3 positive reviews)
- 1998 – 2001 coordinator of the Data Management Service of the Clinical Chemistry Department, Azienda S.Maria Nuova
- 1998 – 2001 MRP, coagulation section of the Clinical Chemistry Laboratory of Reggio Emilia
- 1999 – 2001 coordinator of the Departmental Service for Informatics in the Clinical Chemistry Department, Azienda S.Maria Nuova.


s. Biographical Listings

t. Other Responsibilities

- Meeting organization
- 1996 Scientific Secretary, course "Ricerca Clinica. Aspetti metodologici e regolatori ", Smith-Kline Foundation, held in Perugia on October 23 – 25,
- 1999 Chair and organizer, Meeting “Iperomocistemia: Aspetti clinici e di laboratorio”, held in Reggio Emilia.
- 1993 Scientific Secretary, course "Metodologia della Ricerca Clinica. Le norme di buon pratica clinica Smith-Kline Foundaton, held in Perugia on October 27 – 29.
- 2003 Chairman and Trainer and Scientific Secretary of the ECM course for physicians, nurses and laboratory technicians “ The quality systems for the surveillance centre for oral anticoagulant therapy”, held in Reggio Emilia on October 2003

- 2005 Chair and organizer, Meeting “Evidence Based Medicine. Report of a controlled clinical trial run in the AUSL 2 of the Umbria Region: Influenza vaccination in patients on oral anticoagulant therapy”, held in Perugia.
- 2006-15 Annual Interregional Meeting of the Emo Foundation, Perugia-Macerata-Pescara, held yearly from 2006 to 2015
- 2010 XXI National meeting of the Società Italiana per lo Studio dell’Emostasi e della Trombosi Bologna, 28 - 31 ottobre 2010
- 2012 1stAfME Hemophilia Forum “Managing Hemophilia for Life”, Dubai, May 18-19th 2012,
- 2013 HERO (Haemophilia Experiences, Research and Outcomes) Summit , The Hague, Netherlands 27-28 June 2013
- 2013 ASH Ancillary Meeting “Hot topics in the epidemiology of inhibitor development in people with hemophilia”. New Orleans, Louisiana, Saturday Dec 7, 2013
- 2013 RARE Best Practice Workshop, Freiburg, 11 and 12 October 2013
- 2013 Medical and Scientific Symposium Perspectives on personalization of care Winnipeg, Manitoba Friday, May 24, 2013
- 2014 Bayer HealthCare Hematology Conference, “Management of Bleeding Disorders: Aligning Evidence and Quality” Prague October 9-11 2014.
-

January 8, 2016



Alfonso Iorio, MD

[Health Information Research Unit](#)
CRL -140

[Clinical Epidemiology & Biostatistics](#)
McMaster University
1280 Main St West
Hamilton, ON L8S 4K1
Tel: +1 905 525 9140 ext 22421
Fax: +1 905-526-8447
e-mail: iorioa@mcmaster.ca